NCI Protocol #: 7627  
Local Protocol #: MC 057H  
NCI Version Date: April 15, 201 8 i 
 
  
 
   
 
 
MC057H – A Phase II Trial of GW786034 in Advanced Thyroid Cancer  
 
 
P2C Addendum 25 –  
 
CTEP R equest for Protocol Amendment dated February 14, 2018 : 
 
# Section  Comments  
1. 8.1 [COMPANY_001] supplies and the PMB, DCTD, NCI distributes commercially -
labeled 200 mg pazopanib tablets (as free base). Gray, film -coated 
tablets are debossed with “GS JT” on one side and packaged in bottles 
of 120 tablet s.   
 
Tablet excipi[INVESTIGATOR_414549], povidone, sodium 
starch glycolate, and magnesium stearate. The film -coat consists of 
titanium dioxide, hypromellose, iron oxide black, macrogol/polyethylene 
glycol 400 and polysorbate 80.  
 
[COMPANY_001]  supplies  and the PMB,  DCTD,  NCI distributes  pazopanib  as 
aqueous,  film-coated  tablets according  to the descriptions  and availability  
below.  
 
Streng
th Description  Bottle 
count  Availability  
200 mg  Oval -shaped, white tablets 
packaged in investigationally -
labeled HDPE induction - 
sealed bottles with white, 
plastic, child - resistant caps 34 Transitioning to 
commercially -
labeled supplies 
around March 
2017.  200 mg  Gray, tablets are debossed with 
“GS JT” on one side and 
packaged in commercially - 
labeled bottles  120 Transitioning 
from 
investigationally -
labeled supplies 
around March 
2017  

NCI Protocol #: 7627  
Local Protocol #: MC 057H  
NCI Version Date: April 15, 201 8 ii 
 
  
 
  # Section  Comments  
400 mg  Oval -shaped, white tablets 
packaged in investigationally -
labeled HDPE induction - 
sealed bottles with white, 
plastic, child - resistant caps 68 Not available  after 
March 31, 2018 
or when  existing 
supplies are 
exhausted   
Tablet excipi[INVESTIGATOR_910297], povidone, sodium starch glycolate, and magnesium 
stearate. The film-coat consists of titanium dioxide, hypromellose, 
macrogol/polyethylene  glycol  400 and polysorbate  80.  In addition,  the 
film-coat for commercially -labeled  200 mg tablets  contains  iron oxide  
black.  
 
 
 
 
 
 
 
NCI Protocol #: 7627  
Local Protocol #: MC 057H  
NCI Version Date: April 15, 201 8 1 
 
  
 
   
 
 
 
A Phase II Study of GW 786034  (Pazopanib)  in Advanced Thyroid Cancer  
 
Study Chair* : Keith C. Bible, M.D., Ph.D.  
Mayo Clinic Cancer Center  
[ADDRESS_1278202] SW  
[COMPANY_002]ster MN [ZIP_CODE]  
Telephone: 507 -284-2511  
Fax: 507 -284-5280  
[EMAIL_12035]  
  
Other Participating Institutions/Co -Investigators:
Robert Smallridge, M.D.  
Mayo Clinic Jacksonville  
[ADDRESS_1278203]  
Jacksonville FL [ZIP_CODE]  
Telephone: 904 -953-2224  
Fax: 904 -953-0272  
[EMAIL_17357]   Anne Traynor, M.D.  
University of Wisconsin  
Comprehensive Cancer Center  
[ADDRESS_1278204]  
Madison  WI [ZIP_CODE]  
Telephone: 608 -263-5389  
Fax: 608 -265-8133  
[EMAIL_17358]   Nina Karlin, M.D.  
Mayo Clinic Arizona  
[ADDRESS_1278205]  
Scottsdale, AZ [ZIP_CODE]  
Telephone: 480 -301-8335  
Fax: 480 -301-4675  
Karlin.nina@mayo.e du 
 
Statistician:  
Hui Tang , Ph.D.  
Mayo Clinic Cancer Center  
Telephone: 507 -538-4033  
[EMAIL_17359]     P2C Coordinating Center:  
Mayo Clinic Cancer Center  
[ADDRESS_1278206]  SW 
[COMPANY_002]ster MN [ZIP_CODE]  
Fax: 507 -284-5280  DCTD Supplied Investigational 
Agent(s):  
GW786034 (pazopanib; NSC 737754)  
Douglas W.  Ball, M.D.  
The Sidney Kimmel Comprehensive 
Cancer Center at Johns Hopkins  
[ADDRESS_1278207]. Room 553 
Baltimore, MD, [ZIP_CODE] -1000  
Telephone: 410 -955-8506  
Fax: 410 -614-9884  
[EMAIL_17360] u  Ammar Sukari, M.D.  
Barbara Ann Karmanos Cancer  
[ADDRESS_1278208]  
Detroit, MI [ZIP_CODE]  
Telephone: 313 -576-8778  
Fax: 313 -993-0559  
[EMAIL_7322]  Jeffrey  F. Moley, M.D.  
Washington University School of 
Medicine  
Campus Box [ADDRESS_1278209]. Louis, MO  [ZIP_CODE]  
Telephone: 314 -747-0954  
Fax 314 -747-1310  
[EMAIL_831]  
[CONTACT_910386] -Chi (Josh) Lin, M.D., Ph.D.   
National Taiwan University Hospi[INVESTIGATOR_307]  
[ADDRESS_1278210], Taipei 100, 
Taiwan  
Tel: +886 -2-23123456 ext [ZIP_CODE]  
Fax: +886 -2-23711174  
[EMAIL_10313]   PJ Flynn, M.D.  
Minnesota Oncology Hematology,  PA 
[ADDRESS_1278211] 
Minneapolis, MN  [ZIP_CODE]  
Tel: 612 -863-8585  
Fax: 612 -863-8586    
[EMAIL_612]  
 Boon Cher Goh  
Senior Consultant   
Department of Haematology -
Oncology   
National University Hospi[INVESTIGATOR_307]   
[ADDRESS_1278212]   
Singapore 119074   
Tel:  (65) 6772 4621   
Fax:  (65) 6777 5545   
[EMAIL_17361]   
Darren Wan Teck Lim 
Department of Medical Oncology   
National Cancer Center Singapore   
[ADDRESS_1278213]  
Singapore 169610    
Tel: (65) 6436 8174   
Fax: (65) [ADDRESS_1278214]  
Nedlands 6009  
Australia  
Phone: [PHONE_18903]  
Fax: [PHONE_18904]  Gilberto Lopes  
Johns Hopkins Singapore  
International Medical Center  
11 Jalan Tan Tock Seng  
Singapore 308433  
Tel: (65) 6880 -2222  
Fax: (65) 6880 -2155   

NCI Protocol #: 7627  
Local Protocol #: MC 057H  
NCI Version Date: April 15, 201 8 2 
 
  
 
 [EMAIL_17362]   [EMAIL_17363]    [EMAIL_17364] mi.edu   
   
Mohammed Milhem, MD  
University of Iowa Hospi[INVESTIGATOR_600] & Clinics  
[ADDRESS_1278215], C32 GH  
Iowa City, IA [ZIP_CODE]  
Phone:   [PHONE_18902]  
Fax:  [PHONE_11161]  
mohammed -[EMAIL_614]  
 Brigette Ma  
The Chinese University of Hong 
Kong  
Department of Clinical Oncology  
Prince of Wales Hospi[INVESTIGATOR_649300], Hong Kong  
Tel: (852) 2632 2118  
Fax: (852) 2648 7097  
[EMAIL_12350]  Bryan Haugen, M.D.  
University of Colorado Denver  
Anschutz Cancer Pavilion  
[ADDRESS_1278216], Mail Stop F704  
[PO_BOX]  
Aurora, CO 80 045 
Tel:  720 -848-0354  
Fax:  720 -848-0671  
[EMAIL_17365]   
   
   
* Investigator having NCI responsibility for this protocol.  
† Study contributor(s) not responsible for patient care.  
 
 
Document History  
NCI Submission: February 23, 2006  Addendum 9 - November 4, 2009  Addendum 19 - September 22, 2011  
Study Activation: February 22, 2008  Addendum 10 - March 10, 2010  Addendum 20 - November 30, 2011  
Addendum 1 - May 15, 2008  Addendum 11 - May 26, 2010  Addendum 21 – June 13, [ADDRESS_1278217] 30, 2010 Addendum 22 – September 6, [ADDRESS_1278218] 19, 2008  Addendum 13 - October 20, 2010  Addendum 23 - April 21, 2017  
Addendum 4 - December 9, 2008  Addendum 14 - February 9, 2011  Addendum 24 – April 11, 2018  
Addendum 5 - December 29, 2008  Addend um 15 - March 15, 2011  Addendum 2 5 –  
Addendum 6 - April 2, 2009  Addendum 16 - May 16, 2011   
Addendum 7 - May 22, 2009  Addendum 17 - June 16, 2011   
Addendum 8 - June 9, 2009  Addendum 18 - September 22, 2011   
  
NCI Protocol #: 7627  
Local Protocol #: MC 057H  
NCI Version Date: April 15, 201 8 3 
 
  
 
 SCHEMA  
 
 
 
Registration  
 
Advanced Thyroid Carcinoma  
(Separate cohorts for differentiated, medullary and anaplastic)  
 
 
 
 
 
 
 
 
Unacceptable toxicity  
PROG  
Patient Refusal  
Alternate therapy  
 
 
 
 
 
 
  GW786034 800 mg daily (orally), 28 day cycles  
Event Monitoring per Section 16  
Drug Names/Abbreviations  
P2C Name:  [CONTACT_31694]786034  
Generic Name: [CONTACT_910384]: 786034  
 
NCI Protocol #: 7627  
Local Protocol #: MC 057H  
NCI Version Date: April 15, 201 8 4 
 
  
 
 Table of Contents  
A PHASE II STUDY OF GW 786034 (PAZOPANIB ) IN ADVANCED THYROI D CANCER  1 
SCHEMA  ................................ ................................ ................................ ................................ ........  2 
TABLE OF CONTENTS  ................................ ................................ ................................ ................  4 
1. OBJECTIVES  ................................ ................................ ................................ ..........................  7 
1.1 Primary Objectives  ................................ ................................ ................................ ...........  7 
1.2 Correlative Objectives  ................................ ................................ ................................ ...... 7 
2. BACKGROUND  ................................ ................................ ................................ .....................  7 
2.1 Thyroid Cancer  ................................ ................................ ................................ .................  7 
2.2 GW7860 34 (pazopanib)  ................................ ................................ ................................ . 11 
2.3 Background and Rationale  ................................ ................................ .............................  18 
3. PATIENT SELECTION  ................................ ................................ ................................ ........  20 
3.1 Inclusion Criteria  ................................ ................................ ................................ ............  21 
3.2 Exclusion Criteria  ................................ ................................ ................................ ...........  22 
4. REGISTRATION PROC EDURES  ................................ ................................ ..........................  25 
4.1 Patient Registration  ................................ ................................ ................................ ........  25 
4.2 Required Regulatory Documents  ................................ ................................ ...................  26 
4.3 Required Registration Documents  ................................ ................................ .................  26 
4.4 Mandatory Translational Research  ................................ ................................ .................  26 
4.5 Treatment Allowed Only at P2C Member Institutions  ................................ ..................  26 
4.6 Timing of Treatment  ................................ ................................ ................................ ...... 27 
4.7  Pretreatment Tests  ................................ ................................ ................................ .........  27 
4.8 Baseline Symptoms  ................................ ................................ ................................ ........  27 
5. TREATMENT PLAN ................................ ................................ ................................ ............  27 
5.1 GW786034 (Pazopanib) Administration  ................................ ................................ ........  27 
5.2 General Concomitant Medication and Supportive Care Guidelines  ..............................  30 
5.3 Duration of Therapy  ................................ ................................ ................................ ....... 31 
5.4 Duration of Follow Up  ................................ ................................ ................................ ... 31 
6. DOSING DELAYS/DOSE M ODIFICATIONS  ................................ ................................ ... 32 
6.1 Management of Hypertension  ................................ ................................ ........................  32 
6.2 Management of Proteinuria  ................................ ................................ ............................  35 
6.3 Management of Other CTCAE Adverse Events  ................................ ............................  36 
NCI Protocol #: 7627  
Local Protocol #: MC 057H  
NCI Version Date: April 15, 201 8 5 
 
  
 
 6.4 Management of Other Clinically Significant Non -Hematologic Toxicities (not 
specifically addressed above)  ................................ ................................ ................................ ... 37 
6.5 Management of Potassium, Calcium, Phosphorus and Magnesium.  .............................  38 
7. ADVERSE EVENTS:  LIS T AND REPORTING REQU IREMENTS  ................................  39 
7.1 CAEPR for Pazopanib  ................................ ................................ ................................ .... 39 
7.2 Adverse Event Characteristics  ................................ ................................ .......................  42 
7.3 Expedited Adverse Event Reporting  ................................ ................................ ..............  43 
7.4 Routine Adverse Event Reporting  ................................ ................................ ..................  46 
7.5 Secondary AML/MDS  ................................ ................................ ................................ ... 46 
8. PHA RMACEUTICAL INFORMAT ION ................................ ................................ .............  46 
8.1 Nursing Guidelines  ................................ ................................ ................................ .........  50 
9. CORRELATIVE/SPECIAL STUDIES  ................................ ................................ .................  51 
9.1 Hypothesis 1  ................................ ................................ ................................ ...................  51 
9.2 Hypothesis 2:  ................................ ................................ ................................ ..................  51 
9.3 Sample Instructions for Hypothesis 1 & 2:  ................................ ................................ .... 51 
10. STUDY CALENDAR  ................................ ................................ ................................ ....... 53 
11. MEASUREMENT OF EFFEC T................................ ................................ ........................  54 
11.1 Schedule of Evaluations  ................................ ................................ .............................  54 
11.2  Treatment evaluation for patients (MTC or DTC) with measurable disease using 
RECIST1 Criteria  ................................ ................................ ................................ ......................  [ADDRESS_1278219]  ................................ ................................ ...............................  55 
11.4  Formal Statistical Definitions of Analysis Variables  ................................ .................  58 
12. DATA REPORTING / REG ULATORY CONSIDERATIONS  ................................ ....... 58 
12.1  Data Reporting  ................................ ................................ ................................ ............  58 
12.2  CTEP Multicenter Guidelines  ................................ ................................ ....................  58 
12.3  Cooperative Research and Development Agreement (CRA DA)/Clinical Trials 
Agreement (CTA)  ................................ ................................ ................................ .....................  59 
13. STATISTICAL CONSIDER ATIONS ................................ ................................ ...............  61 
13.1  Study Design/Endpoints  ................................ ................................ .............................  61 
13.2  Sample Size/Accrual Rate  ................................ ................................ ..........................  62 
13.3   Statistical Design to be used for the ATC, DTC, and MTC Patient Groups  ..............  63 
13.4  Analysis Plans  ................................ ................................ ................................ ............  66 
13.5  Monitoring  ................................ ................................ ................................ ..................  68 
NCI Protocol #: 7627  
Local Protocol #: MC 057H  
NCI Version Date: April 15, 201 8 6 
 
  
 
 13.6  Data Reporting  ................................ ................................ ................................ ............  68 
13.7  Subset Analyses for Minorities:  ................................ ................................ .................  68 
14.0  DESCRIPTIVE FACTORS  ................................ ................................ ...............................  69 
14.1    Baseline Calcitonin Levels  ................................ ................................ ............................  69 
15.0  PATHOLOGY CONSIDERAT IONS  ................................ ................................ ...............  69 
16. DATA SUBMISSION TO C OORDINATING CENTER  ................................ .................  69 
16.1  Data Collection  ................................ ................................ ................................ ...........  69 
16.2  Cancels ................................ ................................ ................................ ........................  69 
16.3  Ineligible  ................................ ................................ ................................ .....................  69 
16.4  Treatment Discontinuation  ................................ ................................ .........................  70 
16.5  Data Entry/Submission Timetable  ................................ ................................ ..............  71 
17.   FUNDING CONSIDERATIO NS ................................ ................................ ......................  72 
17.1  Costs Charged to Patient ................................ ................................ .............................  72 
17.2  Other Budget Concerns  ................................ ................................ ..............................  72 
17.3  Manufacturer to Supply Drug  ................................ ................................ .....................  72 
REFERENCES  ................................ ................................ ................................ .............................  72 
APPENDIX A: PERFORMA NCE STATUS CRITERIA  ................................ ............................  77 
APPENDIX B: DRUGS KN OWN TO BE METABOLIZE D BY [CONTACT_584383]450  
ISOENZYMES  ................................ ................................ ................................ .............................  78 
APPENDIX C: NEW YORK  HEART ASSOCIATION C LASSIFICATION OF CARDI AC 
DISEASE  ................................ ................................ ................................ ................................ ...... 83 
APPENDIX D: PATIENT’ S MEDICATION DIARY  ................................ ................................ . 84 
APPENDIX E: PATIENT’ S BLOOD PRESSURE DIA RY ................................ ........................  85 
APPENDIX F: BLOOD PR ESSURE – RECOMMENDAT IONSFOR DATA 
COLLECTION/RECORDING  AND EVENT MANAGEMEN T ................................ ...............  87 
APPENDIX G: MANAGE MENT OF GW786034 (PA ZOPANIB) -INDUCED 
HYPERTENSION*  ................................ ................................ ................................ ......................  88 
APPENDIX H: CTEP MUL TICENTER GUIDELINES  ................................ .............................  89 
APPENDIX I: MEDICATI ONS THAT MAY CAUSE Q TC PROLONGATION  .....................  91 
 
  
NCI Protocol #: 7627  
Local Protocol #: MC 057H  
NCI Version Date: April 15, 201 8 7 
  
 
 1. OBJECTIVES  
 
1.1 Primary Objectives  
 
1.11 The primary objectives of this trial are to establish the safety and efficacy 
of GW786034 (pazopanib) as a therapeutic in patients afflicted with 
differentiated, medullary and anaplastic  thyroid cancer s.  Efficacy will be 
assessed via the primary endpoint of the proportion of patients who incur 
clinical responses based upon RECIST criteria, and the secondary 
endpoint of progression free survival  (proportion of patients without 
progression  at 6 months for differentiated and medullary, 3 months for 
anaplastic). Tertiary  clinical endpoints include time to treatment failure, 
overall survival, duration of response, time to subsequent therapy, and 
biomarker -based measures of response and time to  progression.  
 
1.[ADDRESS_1278220] of 
therapy with GW786 034 on serum/plasma VEGF levels .  
 
1.[ADDRESS_1278221] common endocrine malignancy, with 
an estimated 25,000 new cases annually, accounting for approximately 1500 
deaths each year in the [LOCATION_002] (Jemal, Murray et al. 2005)  The disease is 
classified histologically into 5 major groups: Papi[INVESTIGATOR_1396] (PTC - representing 80 – 
85% of all differentiated  thyroid cancer); Follicular (FTC - 5 – 10%) and its 
Hurthle Cell variant (HCC - 3 – 5%); Medullary carcinoma (MTC - ~5%); and 
Anaplastic carcinoma (ATC - ~1%) (Hay, Bergstralh et al. 1993) .  
 
Papi[INVESTIGATOR_1396], Follicular and Hurthle cell carcinoma.  
These three major groups of tumors arise from the thyroid follicular cell, and 
typi[INVESTIGATOR_910298], including production of 
thyroglobulin and some capacity for iodine concentration (Kinder 2003) . 
Amongst older patients and those with more advanced disease at diagnosis, the 
capacity for iodine concentration is less pronounced and may be absent, which 
has import ant implications for treatment, as discussed below (Fernandes, Day et 
al. 2005) . Continued production of thyroglobulin provides a clinically useful 
marker for disease recurrence, correlating with disease burden, within an 
individual (Hay, Thompson et al. 2002) . 
NCI Protocol #: 7627  
Local Protocol #: MC 057H  
NCI Version Date: April 15, 201 8 8 
  
 
  
Overall survival for these cancer types is good, with a combined 5 -year survival 
of ~95% at 1 year and 85% at 5 years (Tseng, Lee et al. 1996) . However, non -
papi[INVESTIGATOR_910299] a less favorable prognosis that PTC.  Moreover, 
advanced stage of disease also impacts on survival, with overall 5 -year mortality 
for metastatic FTC and HCC about 50% (Chow, Law et al. 2003) .  Even amongst 
PTC patients, 10 year mortality is ~20% in stage III (node positive disease in 
patients over 45 years), and 5 -year mortality approaches  80% in stage IV disease 
(Hay, Thompson et al. 2002) . 
 
Treatment of differentiated thyroid carcinoma of all types relies on surgical 
resection of the disease along with the normal thyroid gland and any involved 
cervical lymph nodes, followed by [CONTACT_910349] e iodine therapy, administered both 
to eliminate the normal thyroid remnant and in an effort to eradicate residual or 
metastatic disease (D'Avanzo, Ituarte et al. 2004) . Postoperative suppression of 
thyrotropin (TSH) may also decrease the risk for recurrence and cause -specific 
mortality in high -risk p atients (Cooper, Speck er et al. 1998) .  
 
Radioactive iodine is an effective treatment for metastatic thyroid cancer, 
particularly amongst young patients, in whom control or effective cure, 
particularly of pulmonary metastases, can sometimes be achieved (Brink, van 
Heerden et al. 2000) . However, not all thyroid cancers concentrate iodine, making 
this group of tumors unresponsive to radioactive iodine treatment, while some 
tumors lose iodine avidity over time to become iodine -refractory (Caplan, Wickus 
et al. 2005) .  This problem of radioiodine refractory disease affects an estimated 
20% of PTC amongst young patients (<45 years), but as many as 70 – 80% of 
FTC, HCC and PTC amongst older patients. For patients experiencing locally 
recurrent disease in the neck, follow ing primary surgery and radioactive iodine 
treatment, external beam irradiation may provide effective control of the disease 
when further surgical exploration is not a suitable option (Kim, Yang et al. 2003) . 
 
Currently, no effec tive systemic treatment options are available for radioiodine 
refractory metastatic disease.  Palliative intervention may be used to treat 
symptomatic or pre -symptomatic metastases, including surgical resection and 
external beam irradiation. Response rates  of 10 – 20% have been reported in small 
series of chemotherapy trials, using doxorubicin and/or cisplatin (Gimm 2001) , 
but no responses were seen in a trial of etoposide treatment in differentiated 
thyroid cancer of all types (Leaf, Wolf et al. 2000) . Occasional patients may 
exhibit some inhibition of t umor growth in response to octreotide, though this 
may be restricted to the minority of patients with octreotide -avid disease, and the 
impact on tumor spread and on survival is, at best, marginal (Alhamarneh, 
Murphy et al. 2004) . Consequently, there is no standard single -agent or 
combined -agent therapy in routine clinical use at the  current time.  
 
In contrast to the lack of effective systemic therapi[INVESTIGATOR_910300], our understanding of their molecular and genetic underpi[INVESTIGATOR_910301] #: 7627  
Local Protocol #: MC 057H  
NCI Version Date: April 15, [ADDRESS_1278222] decade. Identification of activating mutati ons 
of ras and B -Raf, and activating rearrangements of the RET proto -oncogene, 
implicate the ras/raf/MAP -kinase pathway in the pathogenesis of PTC (Salvatore, 
Giannini et al. 2004) . Animal models have confirmed the oncogenic potential of 
at least some of these identified mutations (Capen and Sagartz 1998) . There is 
also a recognized role  in PTC and FTC/HCC of the receptor protein -kinase 
systems (PKA and PKC) (Fagin 2004) , while between 30% and 50% of FTC 
express an oncoprotein that inhibits PPAR
  pathways, which has been implicated 
in oncogenesis (Sahin, Allard et al. 2005) . A number of growth factor receptors, 
including EGF -R, IGF -α, and IGF -1 are also expressed in thyroid cancers (Duh 
and Grossman 1995) , which also exhibit increased telomerase activity, and 
hTERT gene expression (Zeiger, Smallridge et al. 1999) . 
 
Development of novel targeted drugs affecting each of these pathways offers 
promise of new therapi[INVESTIGATOR_910302], which is 
currently otherwise untreatable.  
 
Medullary Thyroid Cancer (MTC)  
MTC arises from the C -cells of the thyroid gland, of neural crest lineage 
(Clayman and el -Baradie 2003) .  These tumors retain the capacity to secrete 
calcitonin, providing a reliable marker for disease recurrence, progression and 
response to treatment. MTC occ urs either sporadically (~80%) or as one 
manifestation of a familial cancer predisposition syndrome (~20%). In familial 
MTC (FMTC) the only phenotype is MTC arising typi[INVESTIGATOR_910303] -adult 
life (Quayle and Moley 2005) . Presentation of MTC typi[INVESTIGATOR_910304], and 
may be more aggressive, in the multiple endocrine neoplasia (MEN) syndromes. 
In MEN type 2A, MTC is accompanied by a high incidence of 
pheochromocytoma and hyperparathyroidism, while MEN -2B is associated also 
with developmental anomalies and multiple benig n neurofibromata (Quayle  and 
Moley 2005) . The penetrance of MTC in each of these familial syndromes 
approaches 100% and presentation is earlier and more aggressive in MEN2B than 
MEN2A, with nodal and distant metastatic spread being the rule, unless these 
patients are detected by [CONTACT_910350].  
 
Treatment of MTC consists of surgical resection of the disease and the disease -
bearing thyroid gland, with cervical lymph node dissection.  However, nodal 
metastatic spread affects up to 60% of cases, and the majority of these cases  
suffer either residual or recurrent disease, which may require further surgical 
debulking (Cohen and Moley 2003) .  
 
Because MTC arises from the C -cell lineage, these tumors do not express the 
sodium -iodide transporter and do not exhibit iodine -concentrating activity. 
Consequently, radioactive iodine is not effective in treating this disease.  
Similarly, the response of MTC to radiation therapy has proven disappointing, 
though it may prove useful to palliate symptomatic metastases.  
 
NCI Protocol #: 7627  
Local Protocol #: MC 057H  
NCI Version Date: April 15, [ADDRESS_1278223] on survival is 
marginal and unproven (Traugott and Moley 2005) . Chemotherapeutic 
combinations have had only limited success in a small number of case reports and 
consequently, there is no currently accepted systemic therapy for metastatic MTC.  
 
Activating mutations of the RET proto -oncogene, a receptor tyrosine kinase 
involved in signaling for cell growth and differentiation, are responsible for the 
familial MTC syndromes, and are also detectable in 50 – 80% of sporadic MTC 
(Jindrichova, Kodet et al. 2003) .  Novel agents directed at this and other 
intracellular signaling cascades offer hope for modulation of this disease.  
 
Anaplastic Thyroid Cancer (ATC)  
ATC is a highly aggressive and rapi[INVESTIGATOR_910305], 
accounting for half of all thyr oid cancer deaths despi[INVESTIGATOR_910306] 2% of all 
thyroid cancers (Jemal, Murray et al. 2005) .  Mortality from ATC exceeds 90% at 
1 year, and approaches 95% at 5 years, with a median life expectancy from the 
time of diagnosis of ~3 months (McIver, Hay et al. 2001) .  
 
Although ATC may arise spontaneously in some cases, a majority of cases exhibit 
co-existing differentiated thyroid cancer, suggesting that ATC ma y reflect “de -
differentiation” of a pre -existing differentiated thyroid cancer (McIver, Hay et al. 
2001) .  Mutations of the p53 tumor suppressor gene may play a role in the 
aggressive phenotype and chemoresistance of this tumor (Quiros, Ding et al. 
2005) . 
 
Initial treatment for loc alized ATC includes primary surgery and lymph node 
dissection, with consideration given to adjuvant radiotherapy and/or 
chemotherapy due to its highly aggressive nature.  Often, however, the disease 
presents at a locally advanced stage, precluding surgical  resection and requiring 
radiotherapy, with palliative tracheostomy and gastrostomy tube placement, 
because of rapi[INVESTIGATOR_910307]. Metastatic disease is present at 
the time of diagnosis in over 50% of all patients and becomes evident i n the 
majority of the remaining patients rapi[INVESTIGATOR_836638] (McIver, Hay et al. 2001) . 
 
Palliative therapi[INVESTIGATOR_910308], with transient responses to paclitaxel observed in up to 
50% of treated patients (Ain, Egorin et al. 2000) .  However, there is no evidence 
that such treatment alters the outcome of this near -universally fatal disease 
(McIver, Hay et al. 2001) , for which no effective therapy is currently available.  
 
NCI Protocol #: 7627  
Local Protocol #: MC 057H  
NCI Version Date: April 15, 201 8 11 
  
 
 2.2 GW786034 (pazopanib)  
 
GW786034 (pazopanib)  is a potent and selective , orally available,  small molecule 
inhibitor of VEGFR -1, -2, and -3, PDGF -α, PDGF -β, and c -kit tyrosine kinases  
(TKs)  [Pazopanib  (GW786034 ) Investigator’s Brochure , 200 5].  The agent  
selectively inhibits proliferation of endothelial cells stimulated with VEGF but not 
with basic fibroblast growth factor.  In non-clinical angiogenesis models, 
GW786034 (pazopan ib) inhibited VEGF -dependent angiogenesis in a dose -
dependent manner  and in  xenograft tumor models, twice -daily administration of 
GW786034 (pazopanib) significantly inhibited tumor growth in mice implanted 
with various human tumor cells .  Upon chronic oral  dosing, GW786034  
(pazopanib)  is expected to inhibit VEGF -driven angiogenesis and as a 
consequence, limit solid tumor growth.  Because angiogenesis is necessary for the 
growth and metastasis of solid tumors, and VEGF is believed to have a pi[INVESTIGATOR_910309] t his process, GW786034  (pazopanib)  treatment may have broad -spectrum 
clinical utility.   
 
Mechanism of Action  
Tumor VEGF expression has been associated clinically with disease prognosis in 
many differen t types of malignancies.  E xpression  of VEGF  is elevate d by [CONTACT_910351] , includ ing proto -oncogene activation and hypoxia, the latter effect 
frequently arising in solid tumors because of inadequate perfusion.  In addition to 
its angiogenic role, VEGF also profoundly increases the permeability of the 
vascula ture, an effect that can also contribute to tumor progression.  A leaky 
tumor endothelium enhances nutrient and catabolite exchange and represents less 
of a barrier to tumor cell intravasation during metastasis.  Two high -affinity 
receptors for VEGF with a ssociated TK activity have been identified on human 
vascular endothelium, VEGFR -1 (fms -like TK-1, or Flt -1) and VEGFR -2 (kinase 
insert domain -containing receptor, or KDR).  Although the relative contributions 
of VEGFR -[ADDRESS_1278224] that VEGFR -2 performs a 
predominant role.  
 
In addition to VEGF receptor signaling, increasing evidence implicates platelet -
derived growth factor receptor (PDGFR) signaling in tumor angi ogenesis.  PDGF 
is a critical regulator of pericyte recruitment to tumor vessels.  Pericytes surround 
the endothelial cells and play a key role in vascular development, stabilization, 
maturation, and remodeling.  Pericytes express PDGFR -, and pericyte 
abnormalities in tumors are consistent with alterations in PDGF signaling 
pathways.  Recent nonclinical evidence suggests that inhibition of PDGFR 
signaling augments the antitumor and antiangiogenic effects of VEGFR inhibitors 
by [CONTACT_910352].  In addition, PDGF signaling is implicated in the 
autocrine growth of tumor cells, and in the recruitment and regulation of tumor 
fibroblasts.  
 
In vitro  experiments have shown that GW786034 (pazopanib) inhibited the TK 
NCI Protocol #: 7627  
Local Protocol #: MC 057H  
NCI Version Date: April 15, 201 8 12 
  
 
 activity of human VEGFR -1, -2, and -3 with IC 50 values of 10, 30, and 47 nM, 
respectively.  The agent also potently inhibited mouse, rat, and dog VEGFR -2 
with IC 50 values of 42, 17, and 17 nM, respectively.  Compared to 23 other tested 
kinases, GW786034 (pazopanib) was 3 - to 400 -fold more selective for VEGF 
receptors.  Th ese studies also demonstrated that the agent inhibited PDGFR - and 
-, and c -kit TKs with IC 50 values of 71, 84, and 74 nM, respectively.  
 
In addition to its ability to inhibit TK activity, GW786034  (pazopanib) s electively 
inhibited proliferation of human umbilical vein endothelial cells (HUVEC) 
stimulated with VEGF (IC 50=21 nM) compared to its effect on HUVEC 
proliferation stimulated by [CONTACT_910353] (bFGF ; IC50=721 nM).  
Further evidence of the agent’s  potenti al effect on angiogenic activity is shown by 
[CONTACT_910354] -induced tyrosine phosphorylation of VEGFR -2 in HUVEC 
in a dose -dependent manner (IC 50=7 nM).  GW786034 (pazopanib) does not act 
directly on tumor cell proliferation as shown by [CONTACT_910355] -29 (colon), MDA -MB-468 (breast), PC3 
(prostate), or A375P (melanoma).  However, when the experiment evaluated the 
agent’s effect on angiogenic processes, GW786034 (pazopanib) was >[ADDRESS_1278225] (HFF) 
proliferation.  
 
Nonclinical Efficacy  
In contrast to in vitro  proliferation studies, in vivo  administration of GW786034 
(pazopanib) produced marked growth inhibition of a variety of human tumor 
xenografts in mice.  When GW786034 (pazopanib) was administered at 100 
mg/kg twice daily  for 21 days to mice bearing HT29 (colon) or HN5 (head and 
neck ca rcinoma) xenografts, tumor growth was inhibited by 82% and 101%, 
respectively.  A375P and PC3 xenografts were less sensitive to GW786034  
(pazopanib) . 
 
The inhibitory effect of GW786034 (pazopanib) on bFGF - and VEGF -induced 
angiogenesis has been demonstrate d in two different mouse models of 
angiogenesis, the Matrigel™ plug assay,  and the cornea micropocket model.  In 
the Matrigel™ plug assay, a Matrigel ™ plug containing bFGF is implanted 
subcutaneously in female Swiss nu/nu mice, resulting in new blood vesse l growth 
into the plug that is highly dependent on VEGFR -2 signaling.  When GW786034 
(pazopanib) was administered either once or twice daily for 5 days in this model 
system, a dose -dependent inhibition of angiogenesis resulted:  82 -86% (100 -200 
mg/kg  per d ay), 57-58% (30 -60 mg/kg  per day ), and 32% (10 mg/kg adm inistered 
twice daily).  A once -daily dose of 10 mg/kg was ineffective.  The ED 50 (dose 
producing 50% of the maximal effect) values were 29.4 mg/kg for once -daily 
dosing and 20.3 mg/kg for twice -daily  dosing.  In the cornea micropocket model, 
VEGF or bFGF is formulated into sucralsulfate micropellets, then implanted in 
the normally avascular cornea of female Swiss nu/nu mice.  Angiogenic endpoints 
are quantified by [CONTACT_910356] -limbus 
NCI Protocol #: 7627  
Local Protocol #: MC 057H  
NCI Version Date: April 15, 201 8 13 
  
 
 interface (clock hours) and maximum blood vessel length.  Using this model, 
administration of oral GW786034 (pazopanib) at 100 mg/kg twice daily for 5 
days inhibited vascul arization by 71% (bFGF) and 100 % (VEGF) , and the 
maximum blo od vessel length was reduced by 97% (bFGF) and 135% (VEGF).   
 
GW786034 (pazopanib) has been evaluated in combination with other TK 
inhibitors and with various chemotherapeutic agents.  The combined antitumor 
activity of GW786034 (pazopanib) and lapatanib (an EGFR/ErbB2 TK inhibitor) 
was examined in breast adenocarcinoma BT474 and  in nonsmall cell lung cancer 
NCI-H322 tumor xenografts in SCID mice.  GW786034 (pazopanib) administered 
alone at 30 or 100 mg/kg/day produced dose -dependent inhibition of both tumor 
xenografts.  When combined with lapatanib, there was a modest increase in 
antitumor activity against both tumor xenografts compared to either agent alone; 
however, t he differences were not statistically significant.  GW786034 
(pazopanib) has also been evaluated in combination with various other 
chemotherapeutic agents (topotecan, irinotecan, 5 -fluorouracil, oxaliplatin, or 
docetaxel ) against HT29 tumor xenografts.  Wh ile GW786034 (pazopanib) alone 
administered at 30 or 100 mg/kg/day produced dose -dependent inhibition of 
HT29 tumor growth and all of the chemotherapeutic agents  
alone have demonstrated activity against this xenograft model, the effect of any of 
the combi nations on tumor growth was not significantly different from that of 
either agent alone.    
 
Follow up studies were done with GW786034 (pazopanib) and docetaxel  with an 
endpoint of time to reach 2 tumor doublings.  GW786034 (pazopanib)  was 
administered orally (PO) at 100 mg/kg daily  and docetaxel  was administered 
intraperitoneally (IP) at 50 mg/kg once weekly (Q7D) for three weeks .  In two 
independent experiments, the median time to reach two tumor doublings was 
longest in mice treated with both GW786034 (pazopanib) and docetaxel 
concomitantly.  These results clearly show an advantage of combining 
GW786034 (pazopanib) with docetaxel  (and likely other chemotherapeutic 
agents) for better tumor control .   
 
Nonclinical Pharmacology and Toxicology  
In safety pharmacology studies , there were no GW876034  (pazopanib) -related 
central and peripheral nervous system, respi[INVESTIGATOR_696], or cardiovascular effects in 
rats or monkeys given single oral doses of up to 300 mg/kg and 500 mg/kg, 
respectively.  There were also no tr eatment -related effects on action -potential 
duration or other action -potential parameters when dog Purkinje fibers were 
incubated with up to 80 nM GW786034  (pazopanib) .  There was no detectable 
effect on -andrenergic control of the cardiovascular system i n the rat following 
IV treatment with up to 10 mg/kg GW786034  (pazopanib) .  In rats, drug -related 
effects after 1  mont h of dosing were limited to slight  liver enzyme increases and 
pharmacologically mediated  changes due to VEGFR -2 inhibition in bone and 
bone marrow (doses  ≥ 100 mg/kg/day ) and in teeth (incisors ; doses  ≥ 30 
mg/kg/day ).  All drug -related effects had reversed or were resolving by [CONTACT_910357] #: 7627  
Local Protocol #: MC 057H  
NCI Version Date: April 15, 201 8 14 
  
 
 a 10-week recovery period.  After 6 months of GW786034 (pazopanib) dosing at 
3 mg/kg/day in rats where sy stemic exposure (AUC) was approximately 90 
mcg•hour/mL, there were significant agent -related findings in the trachea, kidney, 
adrenals, and pi[INVESTIGATOR_160587].  Additional target organ effects occurred in the 
pancreas and nail and nail bed in rats given 30 m g/kg/day.  
 
Extended dosing in monkeys resulted in severe gastrointestinal signs in some 
animals, which may have been secondary to precipi[INVESTIGATOR_910310] .  These events  resulted in termination of the animals in 
the 500 mg/ kg/day dose group after [ADDRESS_1278226] level (NOAEL) in the monkey has not been determined; 
however, a dose of 50 mg/kg/day (AUC 100  mcg•hour/mL in the 1 -month study) 
was well tolerated.  
 
Nonclinical reproducti ve toxicology studies indicate reduced female fertility, fetal 
teratogenic effects, and reduced fetal body weight in pregnant rats  and/or rabbits 
given GW786034  (pazopanib) .  In rats, GW786034  (pazopanib)  caused a 
reduction in the number of stage I -V round  spermatids at ≥ 300 mg/kg/day, 
resulted in female reproductive tract target organs effects at 300 mg/kg/day, and 
caused early embryo resorptions.  The agent was found to be non -mutagenic and 
non-clastogenic in a range of genetic toxicity tests.  
 
Nonclinical Pharmacokinetics and Drug Metabolism  
GW786034 (pazopanib) has good oral bioavailability in both rodent and non -
rodent species.  Following oral administration of radiolabeled GW786034 
(pazopanib) to rats and monkeys, excretion of drug -related ma terial was rapid and 
essentially complete.  The majority of the dose was exc reted via feces in both 
species  with lesser amounts in the urine.  Biliary excretion accounted for a 
significant portion of the radioactivity ultimately found in the feces.  GW786034 
(pazopanib) i s highly (>99.9%) protein bound in mouse, rat, dog, monkey, and 
human plasma.  Preliminary in vitro  data indicate that GW786034  (pazopanib)  is 
highly permeable across membranes and is a substrate for the P -glycoprotein 
(Pgp) transport er.   
 
Clinical Experience  
The company -sponsored phase 1 dose -escalation study of orally administered 
GW786034  (pazopanib)  has completed enrollment of 63 patients with a variety of 
solid tumor types .  Doses administered ranged from 50 mg three times per we ek 
to 2000 mg once daily.  The maximally tolerated dose was not defined in this 
trial.  Tumor shrinkage (1 partial and 4 minimal response s) or stable disease (2 
cases) has been  observed in all seven  patients with renal cell carcinoma (RCC) 
treated at ≥ 800  mg onc e daily (n= 5) and 300 mg bid (n =2).  Tumor shrinkage 
was also seen in patient s with Hurthel cell  and neuroendocrine  tumors , as well as  
chondrosarcoma .  In all, [ADDRESS_1278227] remained on study for 6 months  or longer .   
NCI Protocol #: 7627  
Local Protocol #: MC 057H  
NCI Version Date: April 15, [ADDRESS_1278228] common adverse events (AEs) seen in this phase 1 trial regardless of 
causality were all grade 1 or 2 (except as noted).  These AEs (in decreasing order 
of frequency) include nausea (4 9%), diarrhea ( 45%), hypertension (35%), fatigue  
(33%), anorexia  (29%) and vomiting (2 7%).  One of three patients treated with 
2000 mg daily of GW786034  (pazopanib)  developed dose -limiting toxicity of 
grade 3 fatigue (Hurwitz et al., 2005).  Hair depi[INVESTIGATOR_371] (indicative of c -kit 
and, potentially, VEGFR modulation) w as seen in 12 patients , all of whom were  
treated at doses ≥ 800 mg.  One of three patients dosed at 2000 mg once daily 
experienced grade 3 fatigue that resolved upon dose reduction to 800 mg.   
 
As seen with many of the other agents that block VEGF signali ng, grade 1 -3 
hypertension that could be controlled with antihypertensive medication a s well as  
proteinuria ha ve been observed in this ongoing GW786034 (pazopanib) 
monotherapy phase [ADDRESS_1278229] of GW786034 (pazopanib) o n QTc has been seen.  Grade [ADDRESS_1278230] been reported with other 
angiogenesis inhibitors and could potentially occu r with GW786034  (pazopanib) .  
The use of GW786034  (pazopanib) in pediatric patients is contraindicated due to 
the potential effect on epi[INVESTIGATOR_33949].  
 
The pathogenesis of hypertension induced by [CONTACT_910358].  VEGF  and VEGFR -2 are involved in the proper maintenance, 
differentiation, and function of endothelial cells.  Arterial hypertension is 
characterized by [CONTACT_910359] (NO) biosynthesis, activation of the Renin -
Angiotensin -Aldosterone -System (RAAS), incre ased vasoconstriction, and 
microva scular rarefaction of arterioles and capi[INVESTIGATOR_11037].  Microvascular rarefaction 
in hypertension is partly due to impaired angiogenesis.   
 
Hyperte nsion observed with angiogenesis inhibitors is thought to be due to 
reduced end othelium -derived NO bioavailability.  This situation would effectively 
lead to NO deficiency, which would limit NO -dependent signal transduction 
pathways to the detriment of normal cellular function.  In addition to being a 
potent vasodilator, NO is requir ed for angiogenesis, although the cellular 
signaling mechanisms by [CONTACT_910360].  Angiogenic growth factors such as VEGF and FGF induce NO.  
NO upregulates VEGF leading to increased vascular permeability and 
angiogenesis. The RAAS also affects angiogenesis.  Angiotensin II (Ang II), a 
main effector molecule of the RAAS, acts as an angiogenic factor.  Ang II induces 
targeted migration of endothelial cells and pericytes.  However, the exact 
mechanisms by [CONTACT_9444] A ng II induces angiogenesis are not fully elucidated yet.  
 
Clinical Pharmacokinetics and Pharmacology  
Pharmacokinetic (PK) data have been collected  on 51 patients who received oral 
NCI Protocol #: 7627  
Local Protocol #: MC 057H  
NCI Version Date: April 15, 201 8 16 
  
 
 GW786034 (pazopanib) at doses ranging from 50 mg 3 times weekly to 2000 mg 
daily while enrolled in the company -sponsored phase 1 trial .  In a preliminary 
report on results from  43 patients , data showed a mean t 1/2 of 35 hours  (Hurwitz et 
al., 2005) .  Mean C max and AUC 0-24 values increased after single doses of 50 -800 
mg, but the increases in these parameters were neither consistent nor proportional 
to the increase in dose at all dose levels.  Maximal exposure (trough 
concentrations >18  mcg/mL) was observed at doses ≥ 800 mg daily .  Daily 
administrat ion resulted in an approximate  1.5- to 3-fold accumulation of 
GW786034  (pazopanib) in the plasma in most patients across all dose cohorts, 
and there were no obvious time -dependent changes in GW786034 (pazopanib) PK 
values .  Updated PK information from this trial indicates that t he greatest mean 
AUC 0-24 and mean C 24 (plasma concentration at 24 hr) values on Day 22 were 
observed in the 800 mg and 1000 mg /day cohort s (Company C ommunication) .  
Cohorts with daily  doses greater than 1000 mg had similar or l ower  mean Cmax , 
AUC 0-24, and C 24 values compared to th ose of the 800 mg cohort.    GW786034 
(pazopanib ) administered at 300 mg or 400 mg twice daily  (BID) resulted in an 
approximately 4 - to 7-fold accumulation in plasma [based on AUC 0-12] on Day [ADDRESS_1278231] patients .  Mean C max values on D ay 22 in the  300 mg BID and 400 mg 
BID dose groups were similar, and both values were  less than th e mean C max 
values in the  800 mg  and 1000 mg  once daily  cohorts .  However, mean C 24 values 
on Day 22 were similar all 4 dosing regimens.  There were no obviou s time -
dependent changes in GW786034 ( pazopanib ) PK after 22 days of 300 mg BID  or 
400 mg BID  dosing . 
 
Potential Drug Interactions  
In vitro  data indicate that GW786034 (pazopanib) cause s a marked to moderate 
inhibition of cytochrome P450 enzymes 1A2, 3A4, 2B6, 2C8, 2C9, 2C19, 2D6, 
and 2E1.  Due to the early phase of development, human experience with 
GW786034 (pazopanib) is limited , and definitive information on the metabolism 
and drug in teraction profile of GW786034 (pazopanib) is not available.  However, 
GW786034 (pazopanib) has the potential to alter the metabolism of medications 
which are substrates for cytochrome P450 enzymes.  GW786034 (pazopanib) 
should not be coadministered with me dications which are substrates for 
cytochrome P450 enzymes (i.e., CYP2C9) and which have the potential to cause 
serious and/or life -threatening adverse events.  Because the in vitro  data also 
suggest that GW786034 (pazopanib) is a substrate for CYP3A4, med ications that 
induce or inhibit CYP3A4 may alter the pharmacologic effects of GW786034  
(pazopanib) .  Due to the potential for drug interactions with certain anti -
hypertensive therapi[INVESTIGATOR_910311] , the prohibited and 
cautionary me dications list should be reviewed prior to initiating treatment (see 
Section 8).   
 
Dose Selection  
The 800 mg daily dose of oral GW786034 (p azopanib ) to be tested in this study is 
supported by [CONTACT_910361] .  Animal models (mice with 
human tumor xenografts and the Matrigel plug model of angiogenesis) using an 
NCI Protocol #: 7627  
Local Protocol #: MC 057H  
NCI Version Date: April 15, 201 8 17 
  
 
 osmotic pump to maintain a steady -state plasma concentration of GW786034 
(pazopanib ) suggest that a concentration of > 40 mcM (> 17,500 ng/mL) w as 
require d for optimal in vivo  activity.  These results were further supported by 
[CONTACT_910362] -stimulated receptor phosphorylation 
in mouse lungs also required similar plasma GW786034 ( pazopanib ) 
concentrations for reproducible activi ty.  The activity of GW786034 ( pazopanib ) 
against human and mouse VEGFR -2 kinase is similar (IC [ADDRESS_1278232] human and mouse VEGFR -2, respectively); therefore, similar effective 
concentrations are expected in humans.  In vitro  and in vivo  resul ts, taken 
together, su ggest that steady -state plasma GW786034 ( pazopanib ) concentrations 
of at least 17,500 – 22,000 ng/mL (40 to 50 mcM) were required to optimally 
inhibit VEGFR -2 activity.  
 
Doses ranging from 50 mg three times weekly to 2000 mg QD were e valuated 
clinically in the phase 1 dose-escalation study (VEG10003).  Mean plasma 
GW786034 ( pazopanib ) concentrations were maintained above 20,000 ng/mL (46 
mcM) over the entire dosing interval with 800 mg QD dosing (geometric mean 
C24 ~ 33,000 ng/mL [75 mcM]) or 300 mg BID dosing (geometric mean C 24 ~ 
27,000 ng/mL [62 mcM]). These results suggest  that GW786034 ( pazopanib ) 800 
mg QD or 300 mg BID dosing is  required to maintain  plasma GW786034 
(pazopanib ) concentrations at levels required for optimal activity in preclinical 
models  for the entire dosing interval . 
 
Evidence of biological activity associated with VEGFR inhibition was observed 
in cancer subjects  in study VEG10003 at plasma GW786034 ( pazopanib ) 
concentrations similar to those required for optimal biologic effect in preclinical 
models.  The probability of an increase in blood pressure requiring a modification 
of antihypertensive therapy increased markedly when plasma GW786034 
(pazopanib ) concentr ations were maintained above 20,000 ng/mL (46 mcM) over 
the entire dosing interval .  Preliminary DCE -MRI data indicate that doses of [ADDRESS_1278233] the IAUGC 60, which is consistent with a decrease in 
tumor perfusion.  In addition, prelimina ry data indicate inhibition of phospho -
VEGFR2 in the over -biopsy samples of the wound healing assay at doses  800 
mg QD. 
 
Evidence of clinical activity  after GW786034 ( pazopanib ) treatment has been 
observed in subjects with metastatic RCC.  In study VEG10 003, twelve  subjects 
with metastatic RCC  who had failed prior treatments were enrolled into the study.   
Tumor reductions, as assessed by [CONTACT_13407], were observed in all 7 subjects 
in whom the trough concentrations were  40 mcM (300mg BID, n=2;  800mg 
QD, n=5).   One of these seven subjects achieved a PR, and the other six had 
tumor reductions that were less than a PR.   In contrast, n o tumor re ductions  were 
observed in the 5 RCC subjects  dosed at 400 mg or less  (100mg three times a 
week, n=1; 50mg  QD, n=2; 400mg QD, n=2), and all of these 5 subjects had 
trough plasma GW786034 ( pazopanib ) concentrations of <40 mcM.  
 
NCI Protocol #: 7627  
Local Protocol #: MC 057H  
NCI Version Date: April 15, 201 8 18 
  
 
 In the phase 1 study (VEG10003 ), 800mg daily  dosing was relatively well 
tolerated and C [ADDRESS_1278234] 
dose selection in this trial.   Thus, a dose of GW786034 ( pazopanib ) of 800 mg 
daily  was selected as the dose to be tested in this trial.  
 
2.3 Background and  Rational e    
 
TUMOR  ANGIOGENESIS  
Tumor angiogenesis is the result of a complex sequence of events triggered by 
[CONTACT_910363].  Activation occurs via vascular endothelial 
growth factors (VEGFs), fibroblast growth factors (FGFs), and TGF  and –ß-- 
while in hibition is mediated via thrombospondins, angiostatins, endostatins, and 
others.  The VEGF gene family appears to play a fundamental role in 
neoangiogenesis (Leung 1989) by  [CONTACT_910364], 
stimulating angiogenesis, and increasing vascular permeability.  The expression of 
VEGF is controlled by [CONTACT_910365], transformation, and oxygen supply . 
 
ANGIOGENESIS IN THYROID CANCER  
In the thyroid gland,  neoangiogenesis occurs in hyperplastic goiters, Graves 
disease, thyroiditis, and cancer.  Further, Bunone et al.  (Bunone  1999) reported 
overexpression of VEGF in thyroid cancers, compared with normal tissue.  The 
authors suggested that factors inducing ne oangiogenesis are involved in the 
neoplastic growth and aggressiveness of thyroid cancers -- and that VEGF might 
be an initial angiogenic signal, inducing tumor growth and local invasiveness.  
Recently, it was shown that the intensity of VEGF expression is associated with 
an increased risk of recurrence and decreased disease -free survival in papi[INVESTIGATOR_910312] ( Lennard  2001).  Mounting evidence demonstrates that VEGF 
plays a role in thyroid cancer proliferation, as demonstrated by 1) increasing 
VEG F levels in differentiated thyroid cancer in comparison to control benign 
thyroid tissue, and 2) the fact that increased VEGF levels in sera/plasma from 
thyroid cancer patients is a negative prognostic indicator associated with 
increased risk of distant me tastases and disease recurrence (Lin 2003).  
Furthermore, increased VEGF immunohistochemical staining in tumor specimens 
is similarly associated with worse patient outcome (Klein 2001; Lennard 2001; 
Kilicarslan 2003), and interventions targeting VEGF atten uate tumor growth in 
xenograft models of both differentiated (Soh 2000; Bauer 2003) and anaplastic 
thyroid cancers (Bauer 2002; Schiff 2004).   Collectively, available data therefore 
implicate VEGF as a potentially important therapeutic molecular target in  thyroid 
cancer.  
 
GW786034  (Pazopanib)  

NCI Protocol #: 7627  
Local Protocol #: MC 057H  
NCI Version Date: April 15, 201 8 19 
  
 
 GW786034 (pazopanib) is a novel, orally active small molecule targeting multiple 
tyrosine kinases including VEGFR -1, VEGFR -2, VEGFR -3, PDGFR -alpha and –
beta, and c -kit.  An antitumor effect due to inhibiting of the VEGF driven 
angiogenic pathway is well established (package in sert).  In addition to its effects 
on VEGF receptors, GW786034 targets additional tyrosine kinases, including 
PDGF receptors and c -kit that also have established roles in tumorigenesis and 
oncogenic mutations (Shibuya 1990) .  Preliminary data from a phase I study of 
GW786034 in patients with solid tumors demonstrated early evidence of 
antitumor activity (Terman 1992) .  Among 43 patients enrolled, a minimal 
response occurred in 4 patients and stable disease > [ADDRESS_1278235] been tested with promising preclinical effects (Landriscina 2005).  
However, despi[INVESTIGATOR_910313] , retinoids, the most study agents in this 
group, did not show sufficient clinical activity in human trials (Cohelo 2005).  
 
TYROSINE KINASE INHIBITORS IN THYROID CANCER  
In xenograft models of several human carcinomas (pancreas, renal cell and colon 
cancer), VEGF receptor blockade with the tyro sine kinase inhibitor PTK/ZK 
induced significant inhibition of tumor growth (Drebs 2202; Baker 2002; Ellis 
2000; Wood 2000).  Similarly, blockade of VEGF receptors by [CONTACT_274179]/ZK inhibited 
growth of xenografts from human thyroid tumor cells of the ML -1 cell lin e 
implanted into nude mice, with mean xenograft tumor volume significantly 
reduced in PTK/ZK -treated mice, compared to control animals.  
 
Based upon these data, we hypothesized that blockade of VEGF function may be 
a promising target for the treatment of po orly or dedifferentiated thyroid 
carcinomas.  We also hypothesized that protein kinase inhibitor -mediated 
blockade of the VEGF/VEGF receptor system may result in re -differentiation of 
thyroid tissue, with re -expression of the NIS gene resulting in inductio n of iodine 
uptake ability in the tumor cells -- hopefully thereby [CONTACT_910366].  
 
NCI Protocol #: 7627  
Local Protocol #: MC 057H  
NCI Version Date: April 15, 201 8 20 
  
 
 Hypothesis 1 :GW786034 treatment of patients with thyroid cancers will lead to 
attenuated tumor growth or tumor regression, as we ll as to stabilization or 
reductions in patient tumor markers (e.g. thyroglobulin, calcitonin).   Tumor 
burden will be serially assessed via patient -appropriate imaging, and relevant 
tumor markers will be serially evaluated in plasma, to assess the effects of 
GW786034 on tumor extent and growth rate.  In particular, tumor extent will be 
formally evaluated using standard response criteria (RECIST) and changes in 
tumor status on treatment will be compared to tumor measurements prior to study 
entry to capture n ot only GW786034 -induced tumor regression, but also 
GW786034 -induced disease stability.  This will be accomplished by [CONTACT_910367] 6 month period 
prior to GW786034 initiation, making it poss ible to compare tumor growth pre - 
and on -study.  Similarly, rates of change of relevant tumor markers ( e.g. 
thyroglobulin, calcitonin, CEA) of patients will be evaluated pre - and on -study to 
determine whether GW786034 therapy may lead to either reductions,  or 
stabilizations, of these markers.  This will be critical, because substantial data 
suggest that VEGF -targeted agents will likely lead more to disease stabilization 
than regression.   
 
Hypothesis 2:  GW786034 will affect decreased levels of angiogenic markers 
(over time and in response to treatment), consequently impacting downstream 
targets of the pathway.  Levels of free VEGF and PDGF will be explored in a 
graphical manner in pre -treatment and mult iple on -treatment  samples.   Results of 
these assays  of circulating VEGF and PDGF, will be used to identify candidate 
markers of response to pazopanib . 
 
Hypothesis 3:  GW786034 -induced changes  in thyroglobulin levels in patients 
with advanced differentiated thyroid cancer s who are thyroglobulin antibody 
negative  will be predictive of patient objective response and disease progression.    
 
Rationale:  Anecdotal experience of investigators enrolling patients on the initial 
cohort of differentiated thyroid cancer patients  on MC057H  suggested that 
induced changes in thyroglobulin seen in thyroglobulin antibody negative patients 
might be predictive of patient response.  Formal retrospective analysis  indeed 
demonstrated that the proportion of patients with at least a 50% decrease in Tg 
values from pre -treatment levels was 0.[ADDRESS_1278236].  We therefore now propose to more rigorously and 
prospectively examine this association in an expanded DTC patient cohort.  This 
analysis will be important in the design of future pazopanib clinical trials in 
differentiated thyroid cancer, given its apparent promising clinical activity in 
DTC, so as to al low optimal use of tumor markers and imaging in  the evaluation 
of further patients receiving the agent.  
 
3. PATIENT SELECTION  
 
NCI Protocol #: 7627  
Local Protocol #: MC 057H  
NCI Version Date: April 15, 201 8 21 
  
 
 3.1 Inclusion  Criteria  
 
3.11 Histologically or cytologically confirmed  differentiated , medullary or 
anaplastic thyroid cancer  that is now advanced or met astatic .  NOTE: 
Patients with thyroid lymphomas or sarc omas are specifically excluded, as 
are patients with metastatic disease from other sites of origin to thyroid.  
 
3.111   As of P2C Addendum 6 , patients with confirmed differentiated 
thyroid cancer  to be enrolled in the expanded/additional DTC 
cohort  must be thyroglobulin antibody negative.  
 
3.11a  Zero , one or two prior therapeutic regimens ( this includes cytotoxic plus 
non-cytotoxic therapeutic regimens).  
 
3.12 Absence of sensitivity to therapeutic radioiodine ( differentiated only).  
 
3.[ADDRESS_1278237] one dimension (longest diameter to be recorded) as 
>20 mm with conventional techniques or as >[ADDRESS_1278238] scan.  
See section 11.2 for the evaluation of measurable disease.   NOTE: Disease 
that is  measurable by [CONTACT_131675] .  
 
3.14 Age >18 years .  NOTE: GW786034 (pazopanib) is contraindicated in the 
pediatric population due to the potential effect on the epi[INVESTIGATOR_170675].  
 
3.15 Life expectancy >3 months . 
 
3.16 ECOG performance status (PS) 0, 1 or 2 (Karnofsky ≥60%; see Appendix 
A). 
 
3.17 Normal /acceptable  organ and marrow function as defined below  and 
obtained ≤  7 days prior to registration : 
 
• Leukocytes > 3,000/mc L 
• Absolute neutrophil count  > 1,500/mc L 
• Platelets >1 00,000/mc L 
 
• Total  bilirubin  ≤ 1.5 X institutional upper limit of  normal (ULN)  
(If there is reason to believe that the patient has Gilbert’s 
Syndrome, the bilirubin can be fractionated.  If the fractionated 
bilirub in is consistent with Gilbert’s Syndrome and there is no 
other possible explanation for the elevated indirect bilirubin, 
the patient may be eligible for the study if and only if the direct 
bilirubin is  ≤ 1.[ADDRESS_1278239] )  
 
NCI Protocol #: 7627  
Local Protocol #: MC 057H  
NCI Version Date: April 15, 201 8 22 
  
 
 • AST(SGOT) < [ADDRESS_1278240]  
• Creatinine  ≤ 1.[ADDRESS_1278241]  
• Proteinuria  ≤ + on urinalysis  (may re -check per exclusion criteria 
3.25)  
• INR ≤ 1.[ADDRESS_1278242]  
 
3.18 Blood pressure (BP) <140 mmHg (systolic) and <90 mmHg (diastolic).  
Initiation or adjustment of BP medication is permitted prior to registration  
provided that the average of three BP readings at a visit prior to 
registration  is <140/90 mmHg.   
 
3.19a Objective evidence of tumor progression in the 6 mo nth period prior to 
GW786034 initiation  as assessed by [CONTACT_910368] (e.g. CT 
scan) .  In cases of uncertainty of tumor progression, the Principal 
Investigator [INVESTIGATOR_910314].  
 
3.19b Women of child -bearing potential must have a negative serum pregnancy 
test ≤7 days  prior to registration .  NOTE: The effects of GW786034 
(pazopanib) on the developi[INVESTIGATOR_19241].  However, 
teratogenic effects and reduced fetal body weight have been seen in 
pregnant rats and/or rabbits given GW786034  (pazopanib) .  For this 
reason and because antiangiogenic agents as well as other therapeutic 
agents used in this trial are known to be teratogenic, women of  child -
bearing potential and men must agree to use adequate contraception 
(hormonal or barrier method of birth control; abstinence) prior to study 
entry and for the duration of study participation.    Should a woman 
become pregnant or suspect she is pregna nt while participating in this 
study, she should inform her treating physician  immediately.   Effective 
contraception is required for all fertile participants in the trial.  
 
3.19c Ability to understand and the willingness to sign a written informed 
consent document.  
 
3.19d Willingness to comply with the requirement of the study.  
 
3.19e  Willingness to donate blood for correlative marker studies.  (Only 
applicable to sites within the [LOCATION_002])  
 
3.2 Exclusion Criteria  
 
3.21 Anaplastic , Differentiated, Medullary : a total of > 2 prior therapeutic 
regimens  (this total includes cytotoxic plus non -cytotoxic regimens) .  
Note: Enrollment of anaplastic , differentiated, and medullary  patients who 
have had  zero, one or  two prior therapeutic regimens  (cytotoxic plus non -
NCI Protocol #: 7627  
Local Protocol #: MC 057H  
NCI Version Date: April 15, 201 8 23 
  
 
 cytotoxic regimens)  is allowed  - provided therapy ceased > 21 days prior 
to registration.  
 
NOTE: The Principal Investigator [INVESTIGATOR_910315] y related patient eligibility based upon prior thera pi[INVESTIGATOR_014]. 
 
3.21b  Disease that is measurable by [CONTACT_339891].  
 
3.22    Any of the following:  
• Radiotherapy ≤ 4 weeks prior to registration . 
• Major surgery ≤4 weeks prior to registration  
• Radiotherapy to ≥25% of bone marrow   
• Concurrent therapy with octreotide  unless tumor progression on 
this therap y has been demonstrated.  
 
3.23 Any other  ongoing  investigational agents.  
 
3.24 History of allergic reactions attributed to compounds of similar chemical 
or biologic composition to GW786034 (pazopanib) or other agents used in 
the study.  
 
3.25 > +1 proteinuria  (<30 mg/dL)  on two consecutive dipstick  or other urine 
assessment s taken at least  1 week apart.   NOTE:  (In cases where questions 
arise related to disparate proteinuria measurements, the study PI [INVESTIGATOR_910316].)  
 
3.26 QTc prolongation (defined as a QTc inte rval ≥480 msecs) or other 
significant ECG abnormalities  (e.g. frequent ventricular ectopy, evidence 
of ongoing myocardial ischemia) .  NOTE : The Principal Investigator [INVESTIGATOR_910317] y related patient 
eligibility based upon ECG changes.    
 
3.[ADDRESS_1278243] through the CYP450 system are specifically 
prohibited in patients receiving GW786034 (pazopanib) because in vitro 
data indicate  that the agent has the potential to interact with the 
cytochrome P450 isoenzymes CYP2C9 and CYP3A4.   Certain other 
agents should be used with caution.  A list of medications that are 
specifically prohibited or that should be used with caution during this tri al 
of GW786034  (pazopanib)  can be found in Section [ADDRESS_1278244] GW786034  (pazopanib) through the 
cytochrome P450 system can be found in Appendix B.  
 
3.28 Any condition ( e.g., gastrointestinal tract disease resulting in an inability 
to take oral medication or a requirement for IV alimentation, prior surgical 
NCI Protocol #: 7627  
Local Protocol #: MC 057H  
NCI Version Date: April 15, 201 8 24 
  
 
 proce dures affecting absorption, or active peptic ulcer disease)  that 
impairs their ability to swallow and retain [COMPANY_004]786034  (pazopanib) . 
 
3.29a Any of the following conditions:  
• Serious or non -healing wound, ulcer, or bone fracture  
• History of abdominal fistula, gastrointestinal perforation, active 
diverticulitis,  intra-abdominal abscess  or gastrointestinal tract 
bleeding  ≤ 28 days of registration  
• Any histo ry of cerebrovascular accident ( CVA ) ≤6 months  
• Current use of therapeutic warfa rin.  Note : Low molecular weight 
heparin and prophylactic low -dose warfarin  (INR<1.[ADDRESS_1278245] ) are 
permitted.  PT/PTT must meet the inclusion criteria (Section 3. 17) 
• History of myocardial infarction, cardiac arrhythmia, admission for 
unstable angina, cardiac angioplasty or stenting within the last 12 
weeks  
• History of venous thrombosis in last 12 weeks  
• Class III or IV heart failure as defined by [CONTACT_301155]  (see Appendix C).   NOTE: A patien t who has 
a history of Class II heart fail ure and is asymptomatic on treatment 
may be considered eligible  
• History of bleeding disorder, including patients afflicted with 
hemophilia, disseminated intravascular coagulation, or any other 
abnormality of coagulation potentially predisposing patients to  
bleeding  
• Poorly controlled depression or anxiety disorder, or recent (≤6 
months) suicidal ideation  
 
3.29b Known  active and/or untreated brain metastases and/or brain metastases 
requiring ongoing  therapy (e.g. corticosteroids).   NOTE: (Because of the 
poor prognosis  often associated with brain metastases and because of the 
potential risk of bleeding in active brain metastases associated with multi -
targeted tyrosine kinase inhibitor therapy, patients with active and/or 
untreated  brain metastases and/or those  with brain metastases  requiring 
ongoing therapy - e.g. corticosteroids - are excluded from trial 
enrollment.   Enrollment  will, however, be  permitted in cases of patients 
with longstanding treated and inactive brain metastases not requiring 
ongoing therapy , providing that stability of brain metastases  has 
been  demonstrated for  a  period  of 3 months  or greater as assessed by 
[CONTACT_781963] - and providing  that there is no indication of 
increased vascularity of the treated metastases by  [CONTACT_910369] 
≤[ADDRESS_1278246]. Keith Bible, should be contact[CONTACT_910370].)  
 
NCI Protocol #: 7627  
Local Protocol #: MC 057H  
NCI Version Date: April 15, 201 8 25 
  
 
 3.29c Uncontrolled intercurrent illness including, but not limited to, ongoin g or 
active infection or psychiatric illness/social situations that would  or might 
reasonably be expected to  limit compliance with study requirements.  
 
3.29d Pregnant women .  NOTE: (Because GW786034 /pazopanib  is an 
antiangiogenic age nt which has produced  teratogenic effects and reduced 
fetal body weight in pregnant rats and/or rabbits, and therefore has the 
potential for teratogenic or abortifacient effects in humans.  Because there 
is an unknown but potential risk for adverse events in nursing infants 
secondary to treatment of the mother with GW786034 /pazopanib , 
breastfeeding should be discontinued if the mother is treated with 
GW786034 /pazopanib .  These potential risks may also apply to other 
agents used in this study. ) 
 
3.29e HIV-positive patients on combination antiretroviral therapy . NOTE: 
(Because of the potential for pharmacokinetic interactions with 
GW786034 /pazopanib .  In addition, these patients are at increased risk of 
lethal infections when treated with marrow -suppressive therapy.  
Appropriate  studies will be undertaken in patients receiving combination 
antiretroviral therapy when indicated. ) 
 
3.29f Receiving any medications or substances known to affect or with the 
potential to affect the activity or pharmacokinetics of GW786034  
(pazopanib).  NOTE : The eligibility of patients will be determined 
following review of their case by [CONTACT_079] (see Section 
3.27 for further information).  Efforts should be made to switch patients 
who are taking enzyme -inducing anticonvulsant agents to  other 
medications.  
 
3.29g  Receiving any concomitant medications that are associated with a risk of 
QTc prolongation and/or Torsades de Pointes.  (Appendix I)   NOTE:  
These medications should be discontinued or replaced with drugs that do 
not carry these r isks, if possible.  
 
 
4. REGISTRATION PROCEDURES  
 
4.1 Patient Registration  
To register a patient, access the Phase 2 Consortium (P2C) web page and enter the 
remote registration/randomization application.  The remote 
registration/randomization application i s available 24 hours a day, 7 days a week.  
Back up is available between 8 a.m. and 4:30 p.m. Central Time (Monday through 
Friday) by [CONTACT_1555] (507) 284 -2753 or by [CONTACT_60839] (507) 284 -0885.   
 
The instructions for remote registration are available on the P2C web page and 
detail the process for completing and confirming patient registration.  Prior to 
NCI Protocol #: 7627  
Local Protocol #: MC 057H  
NCI Version Date: April 15, [ADDRESS_1278247] be available as noted in the instructions.  It is the 
responsibility of the individual and institution registering the patient to confirm 
the process has been successfully completed prior to release of the study agent.  
Patient registrati on via the remote system can be confirmed in any of the 
following ways:  
 
• Contact [CONTACT_941] P2C Registration Office  (507) -284-2753.  If the patient was 
fully registered, the Registration  Office  staff can access the information 
from the centralized database and c onfirm the registration.  
• In the remote registration application, select the Show Subject  button to 
verify that the patient registration data is retrievable.  
• Enter the remote data entry system and, using the P2C subject ID, confirm 
the patient appears in t he data entry system.  
 
4.2 Required Reg ulatory  Documents  
A signed HHS 310 form, documenting current approval by [CONTACT_093]’s 
Institutional Review Board), must be on file in the P2C Registration  Office  before 
an investigator may register patients.  In  order to assure timely processing, this 
documentation must be faxed directly to the P2C Registration  Office  at 
(507)  284-0885.  
 
In addition to submitting initial IRB approval documents, ongoing approval 
documentation must be submitted (no less than annually) to the P2C Registration  
Office .  If the necessary documentation is not submitted in advance of attempting 
patient registratio n, the registration will not be accepted and the patient may not 
be enrolled in the protocol until the situation is resolved.  
 
4.3 Required Reg istration  Documents  
Prior to accepting the registration/randomization, the remote  
registration/randomization appl ication will verify the following:  
• IRB approval at the registering institution  
• Patient eligibility  
• Existence of a signed consent form  
• Existence of a signed authorization for use and disclosure of protected 
health information ([LOCATION_003] institutions only)  
 
4.4 Mandatory Translational Research  
A mandatory  translational research component  for blood  is part of this study,  the 
Randomization Center will automatically register patients separately to the 
mandatory transl ational component of this study  (see Section  9.0). (Only 
applicable to sites within the [LOCATION_002]).    
  
4.[ADDRESS_1278248], and/or medical 
NCI Protocol #: 7627  
Local Protocol #: MC 057H  
NCI Version Date: April 15, [ADDRESS_1278249] investigator registered with NCI Pharmaceutical Management Branch 
(PMB) and the P2C Coo rdinating Center.  
 
4.[ADDRESS_1278250] begin [ADDRESS_1278251] 
schedule.  
 
4.8 Baseline Symptoms  
All required baseline symptoms (see Section 7.34) must be documented and 
graded.  
 
5. TREATMENT PLAN  
 
5.1 GW786034 (Pazopanib) A dministration  
 
 5.11 Treatment Regimen  – One Cycle = 28 days  
 
Agent  Dose  Route  Schedule  Cycle Length  
GW786034  800 mg  PO (orally)  Once 
daily  28 days+ 
+Cycle length can be altered in the range of 21 to 35 days on an occasional basis 
with the specific approval of the study PI [INVESTIGATOR_910318], 
inclement weather, and other scheduling issues  if a particular patient is tolerating 
the study drug well .  Cycle length can also be extended to 56 +7 days (8 weeks + 1 
week) at treating MD discretion after a patient has been on study >12 cycle/1 
year.  
 
• Group ing Factor:  DTC, MTC, or ATC  
Patients  will be  divided into three cohorts based upon the nature of their 
thyroid cancer: Cohort 1, differentiated thyroid cancers; Cohort 2, 
medullary thyroid cancer; Cohort 3, anaplastic thyroid cancer.  These three 
cohorts will be evaluated independently for efficacy and toxicity end 
points.  
 
• Treatment will be administered on an outpatient basis.  Reported adverse 
events and potential risks are described in Section 7.  Appropriate dose 
modifications for GW786034 (pazopanib) are described in Section 6.  No 
investigational or commercial agents or therapi[INVESTIGATOR_278563]’s 
malignancy.  
 
• Patients receive GW786034 (pazopanib) on an outpatient basis at a dose 
NCI Protocol #: 7627  
Local Protocol #: MC 057H  
NCI Version Date: April 15, 201 8 28 
  
 
 of 800 mg/day (two 400 -mg tabl ets; dose modification will be 
accomplished by [CONTACT_106814] 400 -mg and 200 -mg tablets as necessary ).  
Patients are instructed to swallow tablets once a day (preferably in the 
morning)  on an empty stomach either 1 hour before or 2 hours after meals .  
Tablets s hould be swallowed whole ; they must not be chewed, broken, or 
crushed.  Treatment continues until one of the criteria in Section 5.[ADDRESS_1278252] been 
met.  Missed and/ or  withheld doses of pazopanib (whether intentional or 
unintended) are to be reported in the Medication Diary below, but not 
made up.   Patients will be provided with a Medication Diary for 
GW7 [ZIP_CODE] /pazopanib (Appendix D ), instructed in its use, and asked to 
bring the diary with them to each appointment.  A new copy of the 
Medication Diary will be given to patients whose dose is reduced due to 
adverse events.  
 
• TSH will be monitored each cycle, and if > 0.1  mIU/L , differentiated 
thyroid cancer patient’s dosage of levothyroxine ( S ynthroid  ) should be 
increased by 0.05 mg (50 micrograms) per day.  Dosage of l -thyroxine 
should not be increased more frequently than every 8 weeks.   
 
 
5.12 Precautions/Warnings  
 
Medical personnel must refer to the list of prohibited and “use with 
caution” agents in Section [ADDRESS_1278253] dose of GW786034  (pazopanib) until 1-2 weeks 
after discontinuation from the study .  The length of the pre -study 
prohibition will be at the discretion of the clinician based on the 
pharmacokinetic properties of the agents involved.    
 
Patients taking medications that are listed as “use with caution” should be 
closely monitored for advers e events.  In some instances  of treatment for 
hypertension , a lower dose of the medication may be sufficient to provide 
the required antihypertensive control.  In other instances, the standard dose 
of such a medication may be associated with adverse events  because of 
increased exposure.  Alternatively, the investigator may choose to replace 
the medication with another in the same pharmacologic class that is less 
likely to interact with GW786034  (pazopanib) .  If such a medication is 
discontinued and replaced , the transition period should occur no less than 
[ADDRESS_1278254] dose of GW786034  (pazopanib) .  Based on prior 
clinical experience with GW786034  (pazopanib) , the use of calcium 
channel blockers (dihydropyridine catego ry) and ACE inhibitors as fi rst-
line and second -line antihypertensive therapy is recommended.    
 
NCI Protocol #: 7627  
Local Protocol #: MC 057H  
NCI Version Date: April 15, 201 8 29 
  
 
 Frequent blood pressure (BP) monitoring  is important in patients 
receiving GW786034  (pazopanib) starting on day 8 and continuing until 
patient is off study .  Experience to date suggests that increases in BP may 
occur following dosing with GW786034 (pazopanib) for a number of 
weeks and that these increases may occur relatively quickly.  It is 
imperative that the investigator institute appropriate measures to co ntrol 
BP.  This may necessitate change s to existing antihypertensive 
medication, addition of new medication (s) and/or interruption/withdrawal 
of GW786034  (pazopanib) .  Section [ADDRESS_1278255] their twice -daily 
BP readings ( see Appendix E).  The two daily readings should be taken at 
least 1 to 4 hours apart.  If  two successive systolic read ings are >140 
mmHg OR two successive diastolic readings are >[ADDRESS_1278256] their physician as soon as possible.  Patients should 
seek medical advice if their B P exceeds 180 mmHg (systolic) or 105 
mmHg (diastolic) at any time and should also be encouraged to contact 
[CONTACT_910371] (e.g., headache).  Recommendations for the 
monitoring an d recording of BP readings as well as a flow chart for event 
management are presented in Appendix F.  Home blood pressure monitors 
can be obtained free of charge from GlaxoSmithKline ([COMPANY_004]) (See Section 
17.1) .   
 
Renal function  (creatinine and urinary protei n) should be frequently 
monitored as suggested by [CONTACT_675301].  Specific 
guidelines for management of proteinuria and elevated creatinine are 
presented in Section 6. 
 
The risk s of diverticular disease and/or intestinal perforation  and/or 
bleeding  appear to be increased in patients receiving pazopanib and 
related agents.  On this basis, patients with active diverticulitis, 
gastrointestinal tract bleeding and other po tentially serious underlying GI 
conditions within [ADDRESS_1278257] bleeding should be promptly 
evaluated with endoscopi[INVESTIGATOR_014], with strong consideration given to cessation 
NCI Protocol #: 7627  
Local Protocol #: MC 057H  
NCI Version Date: April 15, [ADDRESS_1278258] to prompt surgical evaluation, with cessation 
of pazopanib until perforation is absolutely excluded.  
 
5.13 Criteria for Continuing Treatment  
 
Patients will be evaluated at each clinic visit during the treatment period to 
determine if continued treatment is appropriate.  If, at any time during 
treatment the evaluation criteria are not met, GW786034 (pazopanib) will 
be held or the dose adjusted ac cording to the dose modification criteria 
stated in Section 6.  To continue therapy, subjects must meet the following 
criteria:  
 
o Absolute neutrophil count (ANC) ≥ 1,000/mm3 (1 X 109/L). 
o Platelet count ≥ 50,000/mm 3 (50 X 10 9/L). 
o Blood pressure, if elevated,  should be controlled with 
antihypertensive medication(s).  
o Urine protein < 1+ (30 mg/dL) . 
o No clinically signific ant non -hematologic toxicity ≥ g rade 2.  
o No indication of new or active gastrointestinal tract pathology (see 
section 5.12 above).  
 
Medical judgment should be exercised in deciding whether a n adverse 
event of greater than or equal to g rade 2 requires dose interruption or 
modification (see Section 6 for Dose Modification guidelines).  
 
5.2 General Concomitant Medication and Supportive Care Guidelines  
 
Because GW786034  (pazopanib) is known to interact with other concomitantly 
administered drugs through the cytochrome P450 (CYP450) system, the CRF  
must capture the concurrent use of all other drugs, over -the-counter medicati ons, 
or alternative therapi[INVESTIGATOR_014].  
 
Because of the risk of prolonged QTc, Caution should be exercised when 
administering pazopanib to patients with a history of QTc interval prolongation, 
in patients taking anti -arrhythmic s or other medications that may prolong the QTc 
interval, and those with relevant pre -existing cardiac disease.  
 
Section 8 provides lists of agents and substances specifically prohibited  during 
GW786034 (pazopanib) administration as well as those which are to be used with 
caution.  Appendix B provides comprehensive  lists of agents and substances that 
are known or which may have the potential to interact with GW786034 
(pazopanib) through CYP450 isoenzymes.   The Principal Investigator [INVESTIGATOR_910319].  
 
Patients should receive full supportive care during the study, including transfusion 
NCI Protocol #: 7627  
Local Protocol #: MC 057H  
NCI Version Date: April 15, [ADDRESS_1278259] pathology and/or symptoms should be 
managed in accord of the guideline provided above in section 5.12.  
 
Repeat EKG must be performed during the week 4, cycle 1 visit.  If the QTc 
interval at 4 weeks is > 500 msec, the EKG should be repeated within 7 days and, 
if the QTc interval remains ≥500 msec, the patient should be removed from the 
study.  Additionally, if the QTc interval is increased by 60 msec or more from 
baseline but the QTc interval remains at < 500 msec, an EKG should be r epeated 
within 7 days.  If the repeat EKG again shows a ≥ 60 msec increase in the QTc 
interval from baseline, consideration should be given to removing the patient from 
the study or increasing monitoring, after discussion with the principal 
investigator.  
 
 
5.3 Duration of Therapy  
 
In the absence of treatment delays due to adverse event(s), treatment may 
continue indefinitely or until one of the following criteria applies:  
 
• Disease progression,  
 
• Intercurrent illness that prevents further administration of treatment,  
 
• Unacceptable adverse event(s),  
 
• Patient goes on to alternate therapy,  
 
• Patient decides to withdraw from the study, or  
 
• General or specific changes in the patient’s condition render the patient 
unacceptable for further treatment in the judgment  of the investigator.  
 
5.4 Duration of Follow Up  
 
▪ If a patient discontinues treatment due to progression within [ADDRESS_1278260] -registration.   
 
▪ If a patient discontinues treatmen t due reasons other than progression or death within 
[ADDRESS_1278261] -registration.  
 
NCI Protocol #: 7627  
Local Protocol #: MC 057H  
NCI Version Date: April 15, 201 8 32 
  
 
 ▪ If a patient discontinues treatment more than 3 years after registration, 
submission of an event  monitoring report is required 6 months after 
treatment discontinuation.  
 
   
6. DOSING DELAYS/DOSE MODIFICATIONS  
 
Appropriate dose modifications for GW786034  (pazopa nib)-related adverse events are 
outlined in the following subsections.  If treatment has been held for more than [ADDRESS_1278262] the s ponsor 
(DCTD, NCI) to  review the subject’s condition prior to  resum ing the patien t’s treatment  
except for delays due to hypertension ( see Section 6.1 below ).  Dose level reductions 
follow:  
 
Dose level  GW786034  (pazopanib) * 
-3 200 mg daily  
-2 400 mg daily  
-1 600 mg daily  
1 800 mg daily  
   *If doses are held, do not make up doses.  
 
6.1 Management of Hypertension  
 
Increases in blood pressure (BP) and cases of hypertension have been associated 
with many drugs acting on the VEGF pathway.  The proposed mechanism for this 
increase is through inhibition of VEGF -induced peripheral vasodilation.  
Hypertension following GW7 [ZIP_CODE]  (pazopanib) treatment has been seen in 
animal studies as well as clinical trials.  Specific guid elines  for management of 
this adverse event are provided below; additional suggestions for BP management 
can be found in the flow chart in Appendix F. 
 
• While patients are receiving treatment with GW786034  (pazopanib),  the 
early initiation of antihypertensive treatment for grade 1 or 2 hypertension 
to minimize more severe or persistent hypertension is not considered a 
grade 3 adverse event.  
 
• Decisions  to hold or decrease the GW786034  (pazopanib) dose during 
treatment must be based on BP readings taken in the clinic by a medical 
professional.  
 
Hypertension Monitoring and Management*  
 
Systolic and Diastolic 
Categories  Antihypertensive  
Therapy  Blood Pressure 
Monitoring  GW786034  (pazopanib)  
Dose Modification  
Category A  
< 140 mmHg Systolic  
< 90   mmHg Diastolic  • None  
• Baseline  • Standard monitoring  
(BID)  
•  • No Change  
NCI Protocol #: 7627  
Local Protocol #: MC 057H  
NCI Version Date: April 15, 201 8 33 
  
 
 Category B  
140-159 mmHg Systolic  
90-94   mmHg Diastolic  
 • Initiate BB  or 
 Initiate DHP CCB  
 
• Increase doses of 
existing medications 
until BP controlled 
or at maximum dose  • Increased frequency 
of BP monitoring 
until stabilized  • No Change  
Category C  
160-179 mmHg Systolic  
95-104 mmHg Diastolic  
 • Initiate BB or 
preferably  
 DHP CCB  (may use  
 ACEI or 
 Vasodilator if DHP 
CCB ineffective)  
 
• Increase dos ages or 
number of 
medications until BP 
controlled or at 
maximum dos ages • Increased frequency 
of BP monitoring  
(e.g., every 4 -6 hours)  
until stabilized  
 
• Supervised by 
[CONTACT_59580]  • If partial or no control and 
BP still in a moderate range 
for 24 -48 hours, hold 
GW786034  (pazopanib) and 
add additional  
antihypertensive  drugs, 
increasing to a maximum 
dose until hypertension 
controll ed; monitor for 
hypotension.   
 
• Decrease GW786034  
(pazopanib)  by 1 dose level  
Category D  
> 180 mmHg Systolic  
> 105 mmHg Diastolic  • Start immediate 
therapy with [ADDRESS_1278263] a 
DHP CCB  
 
• Escalate dos ages to 
achieve optimal 
control of BP, up to 
the maximum dose  
 
• If partial or no BP 
control, add 
additional drugs up 
to 4; increase to 
optimal or maximum 
dosages of all drugs  
 • Increased frequency 
of BP monitoring  
(e.g., every 4 -6 hours)  
until stabilized  
 
• Supervised by 
[CONTACT_59580]  • Hold GW786034  
(pazopanib); if control of 
BP in  the Mild range, restart 
GW786034  (pazopanib) at 
the next lower dose level  
 
• If partial or no control, 
decrease GW786034  
(pazopanib) by [CONTACT_910372]  
 
• Stop GW786034  
(pazopanib) if hypertension 
is symptomatic, and 
hospi[INVESTIGATOR_910320] E  
Hypertensive Crisis  • Optimal 
management with 
intensive  IV support 
in ICU  • Hospi[INVESTIGATOR_910321]  • Off protocol therapy, 
discontinue GW786034  
(pazopanib) , and monitor 
closely for hypo tension  
Abbreviations : Dihydropyridine calcium -channel blockers (DHP -CCB), selective beta blockers (BB), Angiotensin 
Converting Enzyme Inhibitors (ACEI), Angiotensin II Receptor Blockers (ARB)  
 
• *See table below  for suggested antihypertensive medications by [CONTACT_71963]  
• If patients require a delay of > 2 weeks for management of hypertension, discontinue protocol therapy  
• If patients require > 2 dose reductions, discontinue protocol therapy  
• Patients may have up to 2 drugs for management of hypertension prior to any dose reduc tion in GW786034  
(pazopanib)  
• 24-48 hour s should elapse between modifications of antihypertensive therapy  
• Hypertension should be graded using the NCI CTCAEv4 .0 
                       
 Oral  Antihypertensive Medications  
Agents in bold characters are suggested as optimal choices to avoid or minimize 
potential drug -interactions with GW786034 (pazopanib) through CYP450.  
Agent   Initial  Intermediate Maximum  Hepatic  
NCI Protocol #: 7627  
Local Protocol #: MC 057H  
NCI Version Date: April 15, 201 8 34 
  
 
 class Agent  dose  dose  dose  metabolism  
Dihydro -
pyridine  
Calcium -
Channel 
Blockers  
(DHP CCB)  nifedipi[INVESTIGATOR_76361]  30 mg daily  60 mg daily  90 mg daily  CYP 3A4 
substrate  
amlodipi[INVESTIGATOR_050]  2.5 mg daily  5 mg daily  10 mg daily  CYP 3A4 
substrate  
felodipi[INVESTIGATOR_050]  2.5 mg daily  5 mg daily  10 mg daily  CYP 3A4 substrate 
and inhibitor  
Selective  
 Blockers  
(BB)  metoprolol  25 mg  
twice daily  50 mg  
twice daily  100 mg  
twice daily  CYP 2D6 substrate  
atenolol  25 mg daily  50 mg daily  100 mg daily  No 
acebutolol  100 mg  
twice daily  200-300 mg 
twice daily  400 mg  
twice daily  Yes (CYP450 
unknown)  
bisoprolol  2.5 mg daily  5-10 mg daily  20 mg daily  Yes (CYP450 
unknown)  
Angiotensin  
Converting  
Enzyme  
Inhibitors  
(ACEIs)  
 captopril  12.5 mg 3x 
daily  25 mg 3x daily  50 mg 3x daily  CYP 2D6 substrate  
enalapril  5 mg daily  10-20 mg daily  40 mg daily  CYP 3A4 substrate  
ramipril  2.5 mg daily  5 mg daily  10 mg daily  Yes (CYP450 
unknown)  
lisinopril  5 mg daily  10-20 mg daily  40 mg daily  No 
fosinopril  10 mg daily  20 mg daily  40 mg daily  Yes (CYP450 
unknown)  
Rarely used:       
perindopril   
4 mg daily   
none   
8 mg daily   
Yes, but not 
CYP450  
Rarely used:       
quinapril  10 mg daily  20 mg daily  40 mg daily  No 
Angiotensin II 
Receptor  
Blockers  
(ARBs)  losartan  25 mg daily  50 mg daily  100 mg daily  CYP 3A4 substrate  
candesartan  4 mg daily  8-16 mg daily  32 mg daily  CYP 2C9 substrate  
irbesartan  75 mg daily  150 mg daily  300 mg daily  CYP 2C9 substrate  
telmisartan  40 mg daily  none  80 mg daily  Yes, but not 
CYP450  
valsartan  80 mg daily  none  160 mg daily  Yes, but not 
CYP450  
 and   
Blocker  labetolol  100 mg twice 
daily  200 mg twice 
daily  400 mg twice 
daily  CYP 2D6 substrate 
and inhibitor  
 
 
NCI Protocol #: 7627  
Local Protocol #: MC 057H  
NCI Version Date: April 15, 201 8 35 
  
 
 6.2 Management of Proteinuria  
 
Although patients with  persistently  >1+ (30 mg/dL) proteinuria at entry are 
ineligible, increases in proteinuria may occur during treatment and should be 
managed as follows:  
  
NCI Protocol #: 7627  
Local Protocol #: MC 057H  
NCI Version Date: April 15, 201 8 36 
  
 
 Management of Proteinuria  
 
Proteinuria v alue Monitoring  Dose modification  
>1+ (30 mg/dL, dipstick 
or equivalent routine 
laboratory analysis)  Perform the following tests:  
• 24-hour urine collection for total protein 
and creatinine  
• microscopic examination of fresh urine  
• urine protein electrophoresis at first 
occurrence of >1+ (30 mg/dL) proteinuria 
only See below  
Based on results of the 24 -hour urine collection:  
<1g protein  
(24-hour collection)  Continue  dipstick or equivalent routine 
laboratory analysis  Continue planned dose  
>1 g but < 2g protein  
(24-hour collection)  Perform 24 -hour urine collection (total 
protein, creatinine) prior to day 1 of each 
subsequent cycle of therapy (q4w) until to tal 
protein is <500 mg/24 hours  Decrease one dose level; 
continue treatment  
>2 g protein  
(24-hour collection)  Perform 24 -hour urine collection (total 
protein, creatinine) weekly until proteinuria is 
<2 g  
 Hold GW786034  
(pazopanib)  
 
When protein is <2  g/24 
hours, resume tr eatment at 
one lower dose level  
Perform 24 -hour urine collection (total 
protein, creatinine) prior to day 1 of each 
subsequent cycle of therapy (q4w)  Continue until patient is off 
treatment  
 
 
6.3 Management of Other CTCAE Adverse Events  
 
Adverse E vent/ 
CTCAE v3.0 
Category   
Grade   
Treatment Modification   
Follow Up  
Gastrointestinal  
Perforation, GI  Grade > 1 Discontinue  treatment  and go to event 
monitoring  Monitor and treat as clinically 
indicated.  
Diverticulitis /colitis  
Typhlitis  Grade > 1 Hold Pazopanib therapy until resolved, 
resume at discretion of treating 
physician after complete resolution  Hold Pazopanib therapy until 
resolved, treat aggressively 
with antibiotics and supportive 
care; hospi[INVESTIGATOR_910322] >101 F 
or if otherwise clinical ly 
indicated.  
Hemorrhage/  
Bleeding/  
Coagulopathy  Grade 1  No interruption in treatment; maintain 
current dose.  Monitor as clinically indicated.  
 
 
 
Grade 2  Hold GW786034 (pazopanib) until 
resolved to < grade 1; reduce dose to 
next lower dose level, and continue 
treatment.  
 Monitor as clinically indicated.   
 
 
Follow up pe r protocol ( Section 
5.4) if patient is removed from 
NCI Protocol #: 7627  
Local Protocol #: MC 057H  
NCI Version Date: April 15, 201 8 37 
  
 
 If grade 2 or greater hemorrhage / 
bleeding recurs following dose 
reduction, stop GW786034 
(pazopanib) and remove patient from 
study. 1 the study.  
 
Grades  
3 or 4  Discontinue treatment go to event 
monitoring . 1 Follow up per protocol (see 
Section 5.4 ). 
Vascular/  
Thrombosis  Grade 2  No interruption in treatment; maintain 
current dose.  Monitor as clinically indicated.  
 
 
 
 
Grade 3 or  
asymp tomatic 
Grade 4  Hold GW786034  (pazopanib) until 
patien t is receiving a stable dose of 
Low Molecular Weight Heparin 
(LMWH). (Coumadin® is a prohibited 
medication.)  
Treatment  may resume during the 
period of full -dose anticoagulation if 
all of the following criteria are met:  
• The subject must be on a stable 
dose of LMWH for treatment.  
• The subject must not have had a    
>grade 2 hemorrhagic event while 
on anticoagulation.  Monitor as clinically indicated.  
Symptom atic 
Grade 4  Discontinue treatment and go to event 
monitoring . Follow up per protocol (see 
Section 5.4  
Thrombocytopenia/ 
Neutropenia/Anemia 2 Grades  
1 or 2  No interruption in treatment; maintain 
current dose.  Monitor as clinically indicated.  
Grade  
3 or 4  Interrupt treatment until toxicity is ≤ 
Grade 2; reduce dose to [ADDRESS_1278264] the sponsor (DCTD, NCI) to 
discuss course of action.  Monitor as clinically indicated.  
 
 
If subject is withdrawn from 
study, follow up per protocol  
(see Section 5.4) . 
1 If recurrent event has no clearly associated clinical consequences, consult with the sponsor (DCTD, NCI) about 
continued treatment at 200 mg per day for patients who are benefiting  from GW786034  (pazopanib) . 
2 Patients with anemia due to hemorrhage/bleeding should be managed according to 
Hemorrhage/Bleeding/Coagulopathy section of this table.  
 
 
6.4 Management of Other Clinically Significant Non -Hematologic Toxicities  (not 
specifically addressed above)  
 
Observation  Action  
AE resolves promptly with supportive care  Maintain dose level  
1. Grade 3 or higher (non -hematologic or grade 4 (he matologic) 
AE related to GW786034  (pazopanib) and lasting >5 days that 
does not resolve to grade 2 or below despi[INVESTIGATOR_910323]*  
NCI Protocol #: 7627  
Local Protocol #: MC 057H  
NCI Version Date: April 15, 201 8 38 
  
 
 supportive care for < 48 hour s. 
2. Lower grade but related AEs ( e.g., abdominal pain ) 
AE does not resolve to grade [ADDRESS_1278265] ( i.e., 200 mg daily ) reduced dose level.  In general, move patient to event 
monitoring ** 
* Alternatively and if medically appropriate, investigators may choose to hold dose for up to 21 days 
or withdraw patient from study.    
** After consultation with study PI, [CONTACT_910387] , a dose of 200 mg daily  may be considered for 
patients on study > 3 months who are benefiting from the agent.  
 
6.5 Management of Potassium, Calcium, Phosphorus and Magnesium.  
  
If, according to CTCAE version 4  criteria, the potassium level is grade 2 or greater and/or if 
the calcium, magnesium and/or phosphorous are grade [ADDRESS_1278266] be 
performed and appropriate action taken based on the results (see below).  
 
 
Adverse Event   
Grade   
Treatment Modification   
Follow Up  
Hypokalemia  (< LLN)  or  
Hyperkalemia  
(>5.5mmol/L)   
Grade ≥ [ADDRESS_1278267] the abnormal 
lab values to normal if possible.   
 Hypocalcemia  (<7.0 
mg/dL; <1.75 mmol/L; 
Ionized calcium 
<0.9mmol/L;)  
or  
Hypercalcemia  (>12.5  
mg/dL; > 3.1 mmol/L; 
Ionized calcium > 1.6  
mmol/L )  
 
 
Grade  ≥ 3 
  
 
 
Hold Pazopanib therapy until 
hypokalemia or hyperkalemia is grade 
2 
Hypophosphatemia  (<2.0  
mg/dL; <0.6  mmol/L)  
Hypomagnesemia  (<0.9 -
mg/dL; <0.4 mmol/L)   
or  
Hypermagnesemia  (>3.0 
mg/dL; >1.23 mmol/L)  
 
 
NCI Protocol #: 7627  
Local Protocol #: MC 057H  
NCI Version Date: April 15, 201 8 39 
  
 
 7. ADVERSE EVENTS:  LIST AND REPORTING REQUIREMENTS  
 
Adverse event (AE) monitoring and reporting is a routine part of every clinical trial.  The 
following list of AEs (Section 7.1) and the characteristics of an observed AE (Section 
7.2) will determine whether the event requires expedited (via AdEERS) reporti ng in 
addition  to routine (via CDUS) reporting .   
 
7.[ADDRESS_1278268] (CAEPR)  
For Pazopanib (GW786034, NSC 737754)  
The Comprehensive Adverse Event and Potential Risks list (CAEPR) provides a singl e list of reported 
and/or potential adverse events (AE) associated with an agent using a uniform presentation of events by 
[CONTACT_6764]. In addition to the comprehensive list, a subset, the Specific Protocol Exceptions to 
Expedited Reporting (SPEER), appear s in a separate column and is identified with bold and italicized 
text. This subset of AEs (SPEER) is a list of events that are protocol specific exceptions to expedited 
reporting to NCI via AdEERS (except as noted below).  Refer to the 'CTEP, NCI Guidelin es: Adverse 
Event Reporting Requirements' 
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/aeguidelines.pdf  for further 
clarification.  Frequency is provided based on 1568 patients. Below is the CAEPR for pazopanib 
(GW786034).  
NOTE :  Report AEs on the SPEER ONLY IF  they exceed the grade noted in parentheses next to the 
AE in the SPEER. If this CAEPR is part of a combination protocol using multiple investigational 
agents and has an AE listed on different SPEERs, use the lower of the grades to determine if 
expedited reporting is required.  
 
Version 2.4, April 11, [ZIP_CODE] 
 
 Adverse Events with Possible  
 Relationship to GW786034 (pazopanib)  
 (CTCAE 4.0 Term)  
[n= 1568]  
  
 
 Specific Protocol Exceptions to 
Expedited Reporting (SPEER)  
Likely (>20%)  Less Likely (<=20%)  Rare but Serious (<3%)    
BLOOD AND LYMPHATIC SYSTEM DISORDERS    
 Anemia    Anemia (Gr 3)  
CARDIAC DISORDERS    
  Left ventricular systolic 
dysfunction    
  Myocardial infarction    
  Sinus bradycardia     
ENDOCRINE DISORDERS    
  Hypothyroidism   L   
GASTROINTESTINAL DISORDERS    
 Abdominal pain    Abdominal pain (Gr 3)  
  Constipation     
Diarrhea     Diarrhea (Gr 3)  
  Gastrointestinal fistula2  Gastrointestinal fistula2 (Gr 1)  
  Gastrointestinal hemorrhage3   
 Gastrointestinal pain     
  Gastrointestinal perforation4  Gastrointestinal perforation4 (Gr 1)  
  Mucositis oral     
NCI Protocol #: 7627  
Local Protocol #: MC 057H  
NCI Version Date: April 15, 201 8 40 
  
 
 Nausea     Nausea (Gr 2)  
Vomiting     Vomiting (Gr 3)  
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS    
  Edema limbs     
Fatigue     Fatigue (Gr 3)  
  Fever     
  Non-cardiac chest pain     
INVESTIGATIONS    
 Activated partial 
thromboplastin time 
prolonged     
Alanine aminotransferase 
increased     Alanine aminotransferase increased 
(Gr 3)  
 Alkaline phosphatase 
increased    Alkaline phosphatase increased (Gr 3)  
Aspartate aminotransferase 
increased     Aspartate aminotransferase increased 
(Gr 3)  
Blood bilirubin increased     Blood bilirubin increased (Gr 3)  
 Creatinine increased    Creatinine increased (Gr 2)  
  Ejection fraction 
decreased     
  Electrocardiogram QT corrected 
interval prolonged (accompanied 
by [CONTACT_111809])    
 INR increased     
 Lipase increased     
Lymphocyte count 
decreased     Lymphocyte count decreased (Gr 3)  
Neutrophil count decreased     Neutrophil count decreased (Gr 3)  
 Platelet count decreased    Platelet count decreased (Gr 3)  
 Serum amylase 
increased     
  Weight loss    Weight  loss (Gr 2)  
White blood cell decreased     White blood cell decreased (Gr 3)  
METABOLISM AND NUTRITION DISORDERS    
 Anorexia    Anorexia (Gr 3)  
 Dehydration    Dehydration (Gr 3)  
 Hyperglycemia    Hyperglycemia (Gr 3)  
 Hyperkalemia    Hyperkalemia (Gr 2)  
 Hypernatremia     
 Hypoalbuminemia    Hypoalbuminemia (Gr 2)  
 Hypocalcemia    Hypocalcemia (Gr 3)  
 Hypoglycemia    Hypoglycemia (Gr 3)  
 Hypokalemia     
 Hypomagnesemia     
 Hyponatremia    Hyponatremia (Gr 3)  
 Hypophosphatemia    Hypophosphatemia (Gr 3)  
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS    
 Arthralgia    Arthralgia (Gr 3)  
 Back pain     
 Myalgia    Myalgia (Gr 2)  
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND 
POLYPS)    
 Tumor pain     
NERVOUS SYSTEM DISORDERS    
NCI Protocol #: 7627  
Local Protocol #: MC 057H  
NCI Version Date: April 15, 201 8 41 
  
 
  Dizziness    Dizziness (Gr 2)  
 Dysgeusia    Dysgeusia (Gr 2)  
 Headache    Headache (Gr 3)  
  Reversible posterior 
leukoencephalopathy syndrome    
RENAL AND URINARY DISORDERS    
 Proteinuria    Proteinuria (Gr 3)  
  Urinary fistula   Urinary fistula (Gr 1)  
REPRODUCTIVE SYSTEM AND BREAST DISORDERS    
  Female genital tract fistula   Female genital tract fistula (Gr 1)  
  Uterine fistula   Uterine fistula (Gr 1)  
  Vaginal fistula   Vaginal fistula (Gr 1)  
RESPI[INVESTIGATOR_6709], THORACIC AND MEDIASTINAL DISORDERS    
 Cough     
 Dyspnea     
 Respi[INVESTIGATOR_36393]5   Respi[INVESTIGATOR_36393]5 (Gr 1)  
SKIN AND SUBCUTANEOUS TISSUE DISORDERS    
 Alopecia    Alopecia (Gr 1)  
  Palmar -plantar 
erythrodysesthesia syndrome    
 Rash maculo -papular    Rash maculo -papular (Gr 3)  
Skin and subcutaneous 
tissue disorders - Other 
(hair color change/hair 
depi[INVESTIGATOR_371])     Skin and subcutaneous tissue 
disorders - Other (hair color 
change/hair depi[INVESTIGATOR_371]) (Gr 3)  
 Skin hypopi[INVESTIGATOR_453718] (Gr 1)  
VASCULAR DISORDERS    
Hypertension     Hypertension (Gr 3)  
  Thromboembolic event 
(venous)6   
  Vascular disorders - Other 
(arterial thromboembolic event)6   
1This table will be updated as the toxicity profile of the agent is revised. Updates will be distributed to all 
Principal Investigators at the time of revision. The current version can be obtained by [CONTACT_13172] 
[EMAIL_412] .  Your name, the name [CONTACT_6823], the protocol and the agent should 
be included in the e -mail.  
 
2Gastrointestinal fistula includes Anal fistula, Colonic fistula, Duodenal fistula, Enterovesical fistula, 
Esophageal fistula, Gastric fistula, Gastrointestinal fistula, Ileal fistula, Jejunal fistula, Oral cavity fistula, 
Pancreatic fistula, Rectal fistula, and Salivary gland fistula under the GASTROINTESTINAL DISORDERS 
SOC. 
 
3Gastrointestinal hemorrhage includes Anal hemorrhage, Cecal hemorrhage, Colonic hemorrhage, 
Duodenal h emorrhage, Esophageal hemorrhage, Esophageal varices hemorrhage, Gastric hemorrhage, 
Hemorrhoidal hemorrhage, Ileal hemorrhage, Intra -abdominal hemorrhage, Jejunal hemorrhage, Lower 
gastrointestinal hemorrhage, Oral hemorrhage, Pancreatic hemorrhage, Recta l hemorrhage, 
Retroperitoneal hemorrhage, and Upper gastrointestinal hemorrhage under the GASTROINTESTINAL 
DISORDERS SOC.  
 
4Gastrointestinal perforation includes Colonic perforation, Duodenal perforation, Esophageal perforation, 
Gastric perforation, Ileal perforation, Jejunal perforation, Rectal perforation, and Small intestinal 
perforation under the GASTROINTESTINAL DISORDERS SOC.  
 
NCI Protocol #: 7627  
Local Protocol #: MC 057H  
NCI Version Date: April 15, 201 8 42 
  
 
 5Respi[INVESTIGATOR_170678], Epi[INVESTIGATOR_3940], Laryngeal hemorrhage, 
Mediastinal hemorrhage, Pharyngeal hemorrhage, and Pleural hemorrhage under the RESPI[INVESTIGATOR_6709], 
THORACIC AND MEDIASTINAL DISORDERS SOC.  
 
6These events can result in life -threatening pulmonary, cardiac, cerebral, and other complications.  
 
7Infection includes all 75 sites of infection  under the INFECTIONS AND INFESTATIONS SOC.  
 
 
Also reported on pazopanib (GW786034) trials but with the relationship to pazopanib (GW786034) 
still undetermined:  
 
BLOOD AND LYMPHATIC SYSTEM DISORDERS  - Febrile neutropenia  
CARDIAC DISORDERS  - Acute coronary syndrome; Atrial fibrillation; Cardiac disorders - Other (sinus 
arrest); Cardiac disorders - Other (supraventricular extra systoles ); Pericardial effusion; Supraventricular 
tachycardia  
ENDOCRINE DISORDERS  - Adrenal insufficiency  
EYE DISORDERS  - Blurred vis ion; Eye disorders - Other (asthenopia); Eye disorders - Other (eye/retinal 
hemorrhage); Eye pain; Floaters; Glaucoma  
GASTROINTESTINAL DIS ORDERS  - Abdominal distension; Dry mouth; Dyspepsia; Dysphagia; 
Esophagitis; Flatulence; Gastrointestinal disorders - Other (pneumatosis intestinalis); Oral pain; 
Pancreatitis; Small intestinal obstruction  
GENERAL DISORDERS AN D ADMINISTRATION SIT E CONDITIONS  - Chills; Edema face; Malaise; 
Pain 
INFECTIONS AND INFES TATIONS  - Infection7 
INJURY, POISONING AN D PROCEDURAL COMPL ICATIONS  - Bruising  
INVESTIGATIONS  - Cholesterol high; GGT increased; Investigations - Other (blood TSH increased)  
METABOLISM AND NUTRI TION DISORDERS  - Hypercalcemia; Hypermagnesemia;  Hypertriglyceridemia  
MUSCULOSKELETAL AND CONNECTIVE TISSUE DI SORDERS  - Chest wall pain; Generalized muscle 
weakness; Musculoskeletal and connective tissue disorder -  Other (muscle spasms); Neck pain; Pain in 
extremity  
NERVOUS SYSTEM DISOR DERS  - Extrapyramidal disorder; Intracranial hemorrhage; Ischemia 
cerebrovascular; Pa resthesia; Peripheral sensory neuropathy; Stroke; Transient ischemic attacks  
PSYCHIATRIC DISORDER S - Confusion; Depression; Insomnia; Suicide attempt  
RENAL AND URINARY DI SORDERS  - Hematuria; Urinary frequency  
REPRODUCTIVE SYSTEM AND BREAST DISORDERS  - Vaginal hemorrhage  
RESPI[INVESTIGATOR_6709], THORACI C AND MEDIASTINAL DI SORDERS  - Pharyngolaryngeal pain; Pleuritic pain; 
Pneumonitis; Pneumothorax; Sore throat; Voice alteration  
SKIN AND SUBCUTANEOU S TISSUE DISORDERS  - Dry skin; Hyperhidrosis; Pruritus; Skin ulceration  
VASCULAR DISORDERS  - Flushing; Hot flashes  
Note : Pazopanib (GW786034) in combination with other agents could cause an exacerbation of any 
adverse event currently known to be caused by [CONTACT_6767], or the combination may result in events 
never previously associated with either agent.  
 
7.2 Adverse Event Characteristics   
 
CTCAE term (AE description) and grade:  CTCAE term (AE description) 
and grade:  The descriptions and grading scales found in the revised NCI 
Common Terminology Criteria for Adverse Events (CTCAE) version 3.[ADDRESS_1278269] access to a copy of the 
NCI Protocol #: 7627  
Local Protocol #: MC 057H  
NCI Version Date: April 15, 201 8 43 
  
 
 CTCAE ver sion 4.0.  A copy of the CTCAE version 4.0 can be downloaded 
from the CTEP web site ( http://ctep.cancer.gov ). 
 
“Expectedness” :  AEs can be ‘Unexpected’ or ‘Expected’ (see Section 7.1 
above) for expedited reporting purposes only.  ‘Expected’ AEs (the ASAEL) 
are bold and italicized  in the CAEPR (Section 7.1.1).  
 
Attribution  of the AE:  
- Definite – The AE is clearly related  to the st udy treatment.  
- Probable – The AE is likely related to the study treatment.  
- Possible – The AE may be related  to the study treatment.  
- Unlikely – The AE is doubtfully related to the study treatment.  
- Unrelated – The AE is clearly NOT related  to the study treatment.  
 
7.[ADDRESS_1278270] use AdEERS (Adverse Event 
Expedited Reporting System), accessed via the CTEP home page 
(http://ctep.canc er.gov ).  The reporting procedures to be followed are 
presented in the “CTEP, NCI Guidelines: Adverse Event Reporting 
Requirements” which can be downloaded from the CTEP home page 
(http://ctep.ca ncer.gov ).  These requirements are briefly outlined in the 
table below (Section 7.3.3).  
 
In the rare occurrence when Internet connectivity is lost, an AE report may 
be submitted using CTEP's Adverse Event Expedited Report -Single 
Agent.  A [ADDRESS_1278271] be entered electronically into 
AdEERS by [CONTACT_433].  
 
Effective with Addendum 12, and beginning October 1, 2010, expedited 
AdEERS reporting for this protocol has been updated by [CONTACT_6812]/CTEP to 
use CTCAE v4.0.  Therefore;  
 
1) Events requiring expedited reporting through AdEERS must be 
reported through the AdE ERS system in CTCAE v4.0.  
 
2) The events reported via AdEERS must ALSO be reported through 
routine reporting (i.e., Case Report Forms) using CTCAE v3.0.   
 
3) Routine data collection via Case Report Forms, including the 
"Notification Form: Grade 4 or 5 No n-AER Reportable 
Events/Hospi[INVESTIGATOR_331227]", will remain using CTCAE v3.0 for this 
study.  
 
NCI Protocol #: 7627  
Local Protocol #: MC 057H  
NCI Version Date: April 15, 201 8 44 
  
 
 7.32 AdEERS is programmed for automatic electronic distribution of reports to the 
following individuals:  Study Coordinator of the Lead Organization, Principal 
Investigator, and the local treating physician.  AdEERS provides a copy feature 
for other e -mail recipi[INVESTIGATOR_840].  
 
7.33 Expedited Reporting Guidelines  – AdEERS Reporting Requirements for 
Adverse Events that occur within [ADDRESS_1278272] Dose of the Investigational 
Agent on Phase 2 and 3 Trials  
 
Phase 2 and 3 Trials  
  
Grade 1   
Grade 2   
Grade 2   
Grade 3   
Grade 3  Grades  
4 & 52 Grades  
4 & 52 
Unexpected  
and 
Expected   
Unex -
pected   
 
Expected  Unexpected  Expected  
Unex - 
pected  Expected  with  
Hospi[INVESTIGATOR_36397] -
zation  without 
Hospi[INVESTIGATOR_36397] - 
zation  with  
Hospi[INVESTIGATOR_36397] - 
zation  without 
Hospi[INVESTIGATOR_36397] - 
zation  
Unrelated  
Unlikely  Not 
Required  Not 
Required  Not 
Required  10 
Calendar  
Days  Not 
Required  10 
Calendar  
Days  Not 
Required  10 
Calendar  
Days  10 
Calendar  
Days  
Possible  
Probable  
Definite  Not 
Required  10 
Calendar  
Days  Not 
Required  10 
Calendar  
Days  10 
Calendar  
Days  10 
Calendar  
Days  Not 
Required  24-Hour;  
[ADDRESS_1278273] 
dose of treatment with an agent under a CTEP IND require reporting as follows:  
AdEERS 24 -hour notification followed by [CONTACT_432] 5 calendar days for:  
• Grade 4 and Grade 5 unexpected events  
 AdEERS 10 calendar day r eport:  
• Grade 3 unexpected events with hospi[INVESTIGATOR_318]  
• Grade 5 expected events  
2 Although an AdEERS 24 -hour notification is not required for death clearly related to progressive disease, a full report is 
required as outlin ed in the table.  
December 15, 2004  
Note:  All deaths on study require both routine and expedited reporting regardless 
of causality.  Attribution to treatment or other cause must  be provided.  
 
Expedited AE reporting timelines defined:  
➢ “24 hours; 5 calendar days” – The investigator must initially report the AE via 
AdEERS within 24 hours  of learning of the event followed by a complete AdEERS 
report within 5 calendar days  of the initial 24 -hour report.  
➢ “10 calendar days” - A complete AdEER S report on the AE must be submitted within 
10 calendar days  of the investigator learning of the event.  
 
Any medical event equivalent to CTCAE v4.0 grade 3, 4, or 5 that precipi[INVESTIGATOR_6719] (or prolongation of existing hospi[INVESTIGATOR_059]) must be reported regardless of 
attribution and designation as expected or unexpected with the exception of any events 
identified as protocol -specific expedited  adverse event reporting exclusions.   
 
Any event that results in persistent or significant disabilities/incapacities, congenital 
anomalies, or birth defects must be reported via AdEERS if the event occurs following 
treatment with an agent under a CTEP IND . 
 
SECONDARY MALIGNANCIES (defined as “cancer caused by [CONTACT_910373],” e.g., treatment with radiation or chemotherapy) are to be reported through Addenda 12, 13  
NCI Protocol #: 7627  
Local Protocol #: MC 057H  
NCI Version Date: April 15, [ADDRESS_1278274] cancer 
that was treated, and may occur months or even years after initial treatment.  
 
Note:  Second Primary malignancy (malignancy not due prior to treatment) should not be 
reported t hrough AdEERS.  
 
Use the NCI protocol number and the protocol -specific patient ID assigned during trial 
registration on all reports.  
 
7.34 Adverse events to be graded at each evaluation and pretreatment 
symptoms/conditions to be evaluated at baseline per Common Terminology 
Criteria for Adverse Events (CTCAE) v3.0 grading unless otherwise stated in the 
table below:  
 
Category   
(CTCAE v3.0)  Adverse event/Symptoms  Baseline  Each 
evaluation  
Cardi ac General  Hypertension  X X 
Constitutional  
Symptoms  Fatigue  (lethargy, malaise, asthenia)  X X 
Dermatology/  
Skin  Hypopi[INVESTIGATOR_371] (Hair and or skin  
pi[INVESTIGATOR_592949] ) X X 
Neurology  Mood alteration – select  
- Agitation  
- Anxiety  
- Depression  
- Euphoria  X X 
Neuropathy, sensory  X X 
Gastrointestinal  Anorexia  X X 
(# of stools per day)  X  
Diarrhea   X 
Nausea  X X 
Vomiting  X X 
Blood/Bone Marrow  Hemoglobin  X X 
Leuko cytes (total WBC)  X X 
Platelets  X X 
Neutrophils/granulocytes 
(ANC/AGC)  X X 
Hemorrhage/  
Bleeding  Hemorrhage, GI (select)  
Abdomen NOS   X 
Lower GI NOS   X 
Oral Cavity   X 
Upper GI  NOS   X 
Metabolic/  
Laboratory  AST, SGOT (serum glutamic 
oxaloacetic transaminase)  X 
 X 
 
NCI Protocol #: 7627  
Local Protocol #: MC 057H  
NCI Version Date: April 15, [ADDRESS_1278275]  be reported in routine (CDUS) study data submissions.  
AEs reported through AdEERS must also be reported in routine study data 
submissions.  
 
7.41  Submit to the P2C Research Base via the Nadir/AE Log the following AEs 
experienced by a patient and not spec ified in Section 7.34: 
 
7.411  Grade 2 AEs deemed possibly, probably, or definitely related to 
the study treatment or procedure.  
 
7.412  Grade 3 and 4 AEs regardless of attribution to the study treatment 
or procedure.  
 
7.413  Grade 5 AEs (Deaths)  
 
7.4131 Any death within 30 days of the patient’s last study 
treatment or procedure regardless of attribution to the study 
treatment or procedure.  
 
7.4132 Any death more than 30 days after the patient’s last study 
treatment or procedure that is felt to be at least  possibly treatment 
related must also be submitted as a Grade 5 AE, with a CTCAE 
type and attribution assigned.  
 
7.42  Refer to the instructions in the Forms Packet (or electronic data entry 
screens, as applicable) regarding the submission of late occurrin g AEs 
following completion of the Active Monitoring Phase (i.e., compliance 
with Study Calendar in Section 10.0). 
 
7.5 Secondary AML/MDS  
 
Beginning October 1, 2010, AdEERS will only accept CTCAE v4.0 for this 
study:  Report these events using “Neoplasms benign, malignant and unspecified 
(incl. cysts and polyps) – Other (Specify, _____).”  
8. PHARMACEUTICAL INFORMATION  
 
A list of the adverse events and potential risks associated with the investigational agent 
administered in this study can be found in Secti on 7.1.   
 
8.1 GW786034  (NSC 737754 )   
 
NCI Protocol #: 7627  
Local Protocol #: MC 057H  
NCI Version Date: April 15, 201 8 47 
  
 
 Other Names:  Pazopanib HCl, GW786034B (the suffix B denotes the monohydrochloride 
salt).  
 
Classification:  VEGFR tyrosine  kinase inhibitor  
 
Mechanism of Action:  GW786034 is a highly potent inhibitor of vascular endothelial 
growth factor (VEGF) receptor tyrosine kinases (VEGFR1, VEGFR2, and VEGFR3). 
Vascular endothelial growth factor receptor inhibition may block VEGF driven angiogenesis 
and, as a consequence, cons train tumor growth.  
 
Molecular Formula:  C21H23N7O2S-HCl  
M.W.:  474.0 (monohydrate  salt) 437.5 (free base)  
 
Chemical Name:  5-[[4-[(2, 3-Dimethyl -2H-indazol -6-yl) methylamino] -2 pyrimidinyl]  
amino] -2-methylbenzenesulfonamide monohydrochloride  
 
Approximate Solubility:  The monohydrochloride salt is very slightly soluble in 0.1 M HCl 
(0.65 mg/mL), and is practically insoluble in pH 7.0 phosphate buffer (0.[ZIP_CODE] mg/mL), 
and in pH 11 pi[INVESTIGATOR_629473]  (0.0002 mg/mL).  
 
How Supplied:   
 
[COMPANY_001] supplies and the PMB, DCTD, NCI distributes  commercially -labeled 200 mg 
pazopanib tablets (as free base). Gray, film -coated tablets are debossed with “GS JT” on one 
side and packaged in bottles of 120 tablets.   
 
Tablet excipi[INVESTIGATOR_414549], povidone, sodium starch glycolate, and 
magnesium stearate. The film -coat consists of titanium dioxide, hypromellose, iron oxide 
black, macrogol/polyethylene glycol 400 and polysorbate 80.  
 
 
Storage:  The intact bottles should be stored at controlled room temperature [20°C - 25°C 
(68°F - 77°F) ].  Excursions are permitted between 15°C and  30°C.  
 
Stability:  Refer to package label for expi[INVESTIGATOR_910324] -labeled supplies.   
Repackaging  is not allowed  and tablets  must  be dispensed  in the original  container.   If 
exact  quantity must be dispensed, then extra tablets should be removed, documented as 
waste and destroyed immediately.  
 
Route  of Administration:  Oral.  GW786034 should be taken on an empty stomach either 1 
hour before or 2 hours after meals.  The tablets should be swallowed whole and cannot be 
crushed or broken.  
 
Potential Drug Interactions:   
 
In vitro  data indicate that GW786034 is an inhibitor for CYP2C9, CYP1A2, CYP2B6, 
NCI Protocol #: 7627  
Local Protocol #: MC 057H  
NCI Version Date: April 15, [ADDRESS_1278276] potent inhibition was seen for the isoenzyme CYP2C9.  Accordingly, 
the following med ications which are substrates for CYP2C9 are PROHIBITED  in 
subjects receiving GW786034 (the washout period is at the discretion of the clinician 
based on the pharmacokinetic properties of each individual agent):  
 
• Anticoagulants:  warfarin (therapeutic doses only)  
• Oral hypoglycemics:  glipi[INVESTIGATOR_7130], glyburide, tolbutamide , glimepi[INVESTIGATOR_14956], nate glinide  
• Ergot derivatives:  dihydroergotamine, ergonovine, ergotamine, 
methylergonovine  
• Neuroleptic:  pi[INVESTIGATOR_3924]  
• Erectile dysfunction agents:  sildenafil, tadalafil, vardena fil 
• Antiarrhythmics:  bepridil, flecainide, lidocaine, mexilitine, amiodarone, 
quinidine , propafenone  
• Immune modulators:  cyclosporine, tacrolimus, sirolimus  
• Miscellaneous:  theophylline, quetiapi[INVESTIGATOR_050], risperidone , tacrine, cloazapi[INVESTIGATOR_050], 
atomoxetine  
 
Certain medications should be used with CAUTION  due to the potential for alterations 
in the pharmacologic effects or increased adverse events secondary to the inhibition of 
multiple CYP enzymes by [CONTACT_31694]786034.  These medications include (but are not limited 
to): 
 
• Antidepressants: amitriptyline, buproprion, fluoxetine, fluvoxamine, imipramine  
• HMG co -reductase inhibitors:  atorvastatin, fluvastatin, lovastatin, simvastatin  
• Benzodiazepi[INVESTIGATOR_1651]:  alprazolam, midazolam, triazolam, clorazepate, diazepam, 
flurazepam  
• Calcium channel blockers:  diltiazem, felodipi[INVESTIGATOR_050], nifedipi[INVESTIGATOR_050], nicardipi[INVESTIGATOR_050], 
nimodipi[INVESTIGATOR_050], nitrendipi[INVESTIGATOR_050], verapamil, amlodipi[INVESTIGATOR_050], nisoldipi[INVESTIGATOR_050], isradipi[INVESTIGATOR_050]  
• Angiotensin II blockers:  losartan, irbesartan  
• Beta blockers:  carvedilol, metoprolol, propanolol, timolol  
• Anticonvulsants:  phenobarbital, phenytoin, primadone, carbamazepi[INVESTIGATOR_050]  
• Miscellaneous:  codeine, methadone, mifepristone, estrogens and progestins 
(including oral contraceptives)  
• Oral hypoglycemics: pi[INVESTIGATOR_051], rosiglitazone  
 
In vitro  data also suggest that GW786034 is a substrate for CYP3A4.  Therefore, 
substances that induce or inhibit CYP3A4 may alter the pharmacologic effects of 
GW786034 and should be used with CAUTION .  These medications include (but are 
not limited to):   
 
Inhibi tors of CYP3A4:  
NCI Protocol #: 7627  
Local Protocol #: MC 057H  
NCI Version Date: April 15, 201 8 49 
  
 
 • Antibiotics:  clarithromycin, erythromycin, troleandomycin  
• HIV:  anti -retrovirals (delaviridine),  protease inhibitors (ritonavir, indinavir, 
saquinavir, nelfinavir, amprenavir, lopi[INVESTIGATOR_054])  
• Antifungals:  itraconazole, ketoconazole, voriconaz ole, fluconazole  
• Antidepressants:  nefazodone, fluvoxaine  
• Calcium channel blockers:  verapamil, diltiazem  
• GI:  cimetidine, aprepi[INVESTIGATOR_910325]:  grapefruit  or its  juice  
 
Inducers of CYP3A4:  
•  Glucocorticoids :  cortisone (> 50 mg), hydrocortisone (> 40  mg), prednisone (> 
10 mg),, methylprednisolone (> 8 mg), dexamethasone (> 1.5 
mg)Anticonvulsants:  phenytoin, carbamazepi[INVESTIGATOR_050] , Phenobarbital, oxcarbazepi[INVESTIGATOR_050]  
• HIV:  efavirenz, nevirapi[INVESTIGATOR_050]  
• Antibiotics:  rifampin, rifabutin, rifapentine  
• Miscellaneous:  St. John’s  wort, modafinil  
 
 
Availability : Pazopanib is supplied by [CONTACT_910374] (DCTD), NCI.  
 
Agent Ordering : NCI-supplied agents may be requested by [CONTACT_079] (or 
their authorized designees) at each participating institution.  Pharmaceutical Management 
Branch (PMB) policy requires that the agent be shipped directly to the institution where 
the pa tient is to be treated.  PMB does not permit the transfer of agents between 
institutions (unless prior approval from PMB is obtained).  The CTEP -assigned protocol 
number must be used for ordering all CTEP -supplied investigational agents. The 
responsible in vestigator at each participating institution must be registered with 
CTEP, DCTD through an annual submission of FDA Form 1572 (Statement of 
Investigator), Curriculum Vitae, Supplemental Investigator Data Form  (IDF),  and 
Financial  Disclosure  Form  (FDF).   If there  are several  participating  investigators at 
one institution, CTEP -supplied investigational agents for the study should be ordered 
under the  name  [CONTACT_910385].  
 
Active CTEP -registered investigators and investigator -designated shippi[INVESTIGATOR_910326] (OAOP) application.  Access to OAOP requires the establishment 
of a CTEP Identity and Access Management (IAM) account and the maintenance of 
an “active” account status and a current” password.  For questions about drug orders, 
transfers, returns, or accountability, call or email PMB any time. Refer to the PMB’s 
website for specific policies and guidelines related to agent  management.  
 
Agent Accountability : The Investigator, or a responsible party designated by [CONTACT_1275], must maintain a careful record of the receipt, dispensing  and final 
NCI Protocol #: 7627  
Local Protocol #: MC 057H  
NCI Version Date: April 15, 201 8 50 
  
 
 disposition of all agents received from the PMB  using the NCI Investigational Agent 
(Drug ) Accountability Record Form  (DARF) available on the CTEP forms page .  Store 
and maintain separate NCI Investigational Agent Accountability Records for each 
agent, strength, formulation and ordering investigator on this protocol.  
   
Investigator  Brochure Availability:  The current versions of the IBs for the agents 
will be accessible to site investigators and research staff through the PMB Online 
Agent Order Processing (OAOP) application. Access to OAOP requires the 
establishment of a CTEP Identit y and Access Management (IAM) account and the 
maintenance of an “active” account status and a “current” password. Questions 
about IB access may be directed to the PMB IB coordinator via email.  
 
Useful Links and Contacts:  
• CTEP  Forms,  Templates,  Documents:  http://ctep.cancer.gov/forms/  
• NCI CTEP  Investigator  Registration:  [EMAIL_538]  
• PMB  policies  and guidelines: 
http://ctep.cancer.gov/branches/pmb/agent_management.htm  
• PMB  Online  Agent  Order  Processing  (OAOP)  application: 
https://eappsctep.nci.nih.gov/OAOP/pages/login.jspx  
• CTEP  Identity  and Access  Management  (IAM)  account:  
https://eappsctep.nci.nih.gov/iam/  
• CTEP  Associate  Registration  and IAM  account  help:  
[EMAIL_089]  
• PMB email:  [EMAIL_087]  
• PMB  phone  and hours  of service:  (240)  276-6575 Monday  through  Friday  
between  8:30 am and 4:30 pm  (ET)  
• IB Coordinator:  IBCoord [EMAIL_17366]  
 
 
Nursing Guidelines  
 
• Due to the early investigation nature of this drug, not all adverse effects can be 
known at this time.  Monitor patients closely and report side effects to the MD.  
 
• Hypertension is the most commonly reported side effect. Monitor blood pressure 
closely per study guidelines.  Administer antihypertensives as ordered by [CONTACT_28839].  
 
• Nausea and vomiting were also frequently reported in early studies.   Administer 
antiemetics as ord ered and assess for the effectiv eness.  
 
• Diarrhea was seen in all phase I dosing groups.  Assess hydration status, and 
administer antidiarrheals as ordered. Instruct patient to report an increase in the 
number of stools or nocturnal diarrhea to the study team.  
 
NCI Protocol #: 7627  
Local Protocol #: MC 057H  
NCI Version Date: April 15, 201 8 51 
  
 
 • Due to the similarity in nature of this agent to other VEGF inhibitors 
(bevacizumab, VEGF -trap, etc.) monitor for signs of th rombosis and PE.  Instruct 
patient to report any calf tenderness, shortness of breath or chest pain 
immediately.  
 
 
9. CORREL ATIVE/SPECIAL STUDIES   
(Mandatory  unless otherwise noted ) 
 Only applicable to sites within the [LOCATION_002]  
 
9.1 Hypothesis 1  
 GW786034 treatment of patients with thyroid cancers will lead to reductions in 
patient  blood  tumor markers (e.g. thyroglobulin, calcitonin , CEA ).  Rates of 
change of relevant  blood  tumor markers (thyroglobulin, calcitonin, CEA) of 
patients will be evaluated pre - and on -study to determine whether GW786034 
therapy may lead to either reductions, or stabilizations, of these markers.  This 
will be critical, because substantial data suggest that VEGF -targeted agents will 
likely lead more to disease stabilization than regression.  Relevant markers will be 
assessed as proscribed in the Section 10.  
 
9.2 Hypothesis 2:   
GW786034 will affect decreased levels of angiogenic markers (over time and in 
response to treatment),  consequently impacting downstream targets of the 
pathway.  Levels of free VEGF , free GW786034, and GW786034/VEGF  will be 
explored in a graphical manner in pre and post -treatment samples. Results of 
these assays, in addition to effects on circulating VEGF , PDGF and other 
angiogenic marker levels, will be used to identify markers of response in 
responders versus non -responders.   Times of collection of samples for 
VEGF/PDGF /angiogenic markers  assessment are indicated in Section 10.   
Weekly assessment of VEGF/PDGF / angiogenic markers  will be accomplished 
cycle 1 only to capture non -sustained/transient induced changes.  
 
9.3 Sample Instructions for Hypothesis 1 & 2: 
 
PLASMA PK SPECIMENS  
 
Blood should be drawn at the following timepoints:  
• Pretherapy  
• Cycle 1, Week 1  
• Cycle 1, Week 2  
• Cycle 1, Week 3  
• Cycle 1, Week 4  
• Retreatment Week 4  
• Retreatment Week 8  
• Retreatment Week 12  
• Retreatment Week 16  
NCI Protocol #: 7627  
Local Protocol #: MC 057H  
NCI Version Date: April 15, 201 8 52 
  
 
 • End of treatment  
------------------------------------------------------------------------------------------------------  
COLLECT:           (Lavender )EDTA 3.0 mL  
 
COAGULATE:   MIN. 30'/MAX. 60'  
 
PREPARE:  CENTRIFUGE AT 4°C MIN. 10' MAX. 15'AT 3000 RPM 
(approx.  1,000 x g)  
 
  TRANSFER WITH A PI[INVESTIGATOR_910327]:   PLASMA ( 1.8 NuncCryovial)  
  1.0 mL  
  PK STORAGE  
 
Do not fill tube completely as liquid will expand when frozen.  
 
STORE IN AN UPRIGHT POSITION AT –20°C ON SITE AND SEND ON 
DRY ICE ON THE DAY OF COLLECTION.  
 
Kit ordering:   Participating site Principal Investigators will be sent starter kits 
(after confirmation of local IRB approval) directly from Quest Diagnostics with 
complete instructions on how to order future kits (the protocol identification  for 
Quest  is listed under: ([CONTACT_910387] -NCI-7627).  Please use the patient 
number with the “PH” removed when identifying the patient study number.   
 
Shippi[INVESTIGATOR_22026] :  Quest Diagnostics Clinical Trials , Attn: Specimen  Processing 
for NCI Protocol #[ADDRESS_1278277] , Van Nuys, CA [ZIP_CODE]  
NCI Protocol #: 7627  
Local Protocol #: MC 057H  
NCI Version Date: April 15, 201 8 53 
  
 
 10. STUDY CALENDAR    
This schedule is based on currently available information regarding the study regimen and specifies the 
minimum  procedures, exams, testing, etc., necessary to determine eligibility (baseline) and to evaluate 
safety and plan dose adjustments at subsequent cycles.  The frequency of procedures may be increased or 
additional procedures performed as clinically indicated at physician discretion.  
    
 
 
Tests and procedures  7 days prior to 
registration  Prior to 
subsequent cycles   End of Treatment  
History10 and exam, wt, PS  or Karnofsky score , concomitant 
medications11 X X X 
Blood Pressure  X X6  
BP and Medication Diaries   X6  
Height  X   
Hematology group  
WBC, ANC, Hgb, PLT  X X3 X 
Chemistry group (fasting) 12: glucose, total and direct 
bilirubin, creatinine, alkaline phosphatase, AST (SGOT), 
ALT (SGPT), Na, K, Ca, Mg,  phosphorus ,  cholesterol, 
triglycerides, lactate, TSH  X X X 
Tumor Markers  (e.g. thyroglobulin, calcitonin, CEA) , TSH; 
as appropriate for involved cancer7 X X X 
INR X   
VEGF, PDGF , Angiogenic Markers 5, R  X9 X4 X 
Tumor Measurement/  
Evaluation of indicator lesion (CT, MRI, etc.)2,8,  X X2  
ECG  X X13  
Urinalysis  X X  
Serum pregnancy test1 X   
1. For women of childbearing potential only.  
2. Baseline assessment may be 21 days prior to registration.  Use the same method throughout the study.  Followup 
scans to be perfor med every other cycle (8 weeks) for differentiated  and medullary cancers, but every cycle (4 
weeks) for anaplastic thyroid cancer.  If tumor measurement made by [CONTACT_5292], must document prior 
to each cycle.  Repeat measurements are required [ADDRESS_1278278] criteria.  
3. To be performed weekly (+/ - 1 day).   Weekly CBC's are optional ( physician discretion) after cycle 2.  
4. To be performed w eekly (+/ - 1 day), cycle 1 weeks 1 -4, retreatment weeks 4, 8 , 12, 16 and End of Treatment . 
5. To be assayed off -site by [CONTACT_35316] .  
6. Twice daily blood pressure monitoring beginning Day 8 until off treatment (See Section 5.12 & Appendix E -1).  
Home Blood Pressure monitors can be obtained free of charge from GlaxoSmithKline  (See Section 17.1) . 
7. Papi[INVESTIGATOR_1396], follicular, Hurthle cell: TSH, anti -thyroglobulin antibody and thyroglobulin should be tested, with l -
thyroxin dosage adjusted to maintain TSH< 0.1 mIU/L; medullary: CEA and calcitonin should be tested; 
anaplastic: no spe cific tumor marker testing required . 
8. Baseline imaging of brain metast ases, if known, should be accomplish ed ≤14 days prior to registration  using MRI 
with gadolinium enhancement  (see Section 3.29b) . 
9. Plasma PK samples can be drawn after registration bu t prior to Day 1 therapy.    
10. To be performed ≤28 days prior to study drug administration, patient history  of heart disease, prolonged QTc, 
family history of prolonged QTc and medications associated with prolonged QTc (Appendix  I) must be obtain  
11 Any c oncomitant medications that are associated with a risk of QTc prolongation and/or Torsades de Pointes 
should be discontinued or replaced with drugs that do not carry these risks, if possible.  Patients who must take 
medications with a risk or possible risk  of Torsades de Pointes should be watched carefully for symptoms of QTc 
prolongation, such as syncope.  Performing additional EKGs on patients who must take one or more of these 
medications is not required; however, additional investigations, including EKG s, may be performed as per the 
treating physician’s judgment.  
12.  If, according to CTCAE version 4 criteria, the potassium level is grade 2 or greater and/or if the calcium, 
magnesium and/or phosphorous are grade [ADDRESS_1278279] be performed and appropriate action taken.  
(see section 16.5)  and footnote [ADDRESS_1278280] be performed during the week 4, cycle 1 visit.  If the QTc interval at 4 weeks is > 500 msec, the 
EKG should be repeated within 7 days and, if the QTc interval remains ≥500 msec, the patient should be removed 
from the study.  Additionally, if the QTc interval is increased by 60 msec or more from baseline but the QTc 
NCI Protocol #: 7627  
Local Protocol #: MC 057H  
NCI Version Date: April 15, 201 8 54 
  
 
 interval remains at <  500 msec, an EKG should be repeated within 7 days.  If the repeat EKG again shows a ≥ [ADDRESS_1278281]     
 
11.1 Schedule of Evaluations  
For the purposes of this study, patients should be reevaluated by [CONTACT_910375] (i.e. scan) every  2 cycles  (Differentiated, Medullary), versus every 
cycle (Anaplastic)  (see Section 10 .0 for more details).  
 
11.2 Treatment evaluation for patients (MTC or DTC) with measurable disease using 
RECIST1 Criteria  
 
11.[ADDRESS_1278282] diameter can be accurately measured as 2.0 cm with 
conventional techniques or as 1.[ADDRESS_1278283].  Clinical 
lesions will only be considered measurable when they are 
superfi cial (e.g., skin nodules, palpable lymph nodes).  Lesions 
on chest x -ray are acceptable as measurable lesions when they 
are clearly defined and surrounded by [CONTACT_6776].  However, 
CT is preferable.  
 
11.212  All other lesions  (or sites of disease), including smal l lesions 
(longest diameter <2.0 cm with conventional techniques or as 
1.[ADDRESS_1278284]) are considered non -measurable disease.  
Bone lesions leptomeningeal disease, ascites, pleural/pericardial 
effusions, lymphangitis cutis/pulmonis, inflammatory br east 
disease, abdominal masses (not followed by [CONTACT_177107]), and 
cystic lesions are all non -measurable.  
 
11.22  Guidelines for Evaluation of Measurable Disease  
 
11.221  Measurement Methods :  All measurements should be recorded in 
metric notation (i.e., decima l fractions of centimeters) using a 
ruler or calipers.  The same method of assessment and the same 
technique should be used to characterize each identified and 
reported lesion at baseline and during follow -up.  For patients 
having only lesions measuring at  least [ADDRESS_1278285] of a 
treatment.   
NCI Protocol #: 7627  
Local Protocol #: MC 057H  
NCI Version Date: April 15, 201 8 55 
  
 
  
11.222  Acceptable imaging modalities for measurable disease : CT scan 
(conventional and spi[INVESTIGATOR_23585]), MRI, chest x -ray.   
 
• Conventional CT and MRI should be performed with cuts of 
1.0 cm or less in slice thickness contiguously.  
 
• Spi[INVESTIGATOR_910328] a [ADDRESS_1278286], abdomen, and pelvis, while head and 
neck tumors and those of the extremities require specific 
procedures.   
 
• Ultrasound (US) : is not acceptable to measure tumor lesions 
that are clinically not easily accessible.  
 
• Color Photography: In the case of skin lesions, 
documentation by [CONTACT_3606] a ruler to 
estimate the size of the lesion is recommended.  
 
11.223  Measure ment at Follow -up Evaluation:    
 
• A subsequent scan must be obtained 4 weeks following 
initial documentation of an objective status of either 
complete response (CR) or partial response (PR).  
 
• In the case of stable disease (SD), follow -up measurements 
must h ave met the SD criteria at least once after study entry 
at a minimum interval of 6 weeks (see Section 11.44).  
 
• The cytological confirmation of the neoplastic origin of any 
effusion that appears or worsens during treatment when the 
measurable tumor has met criteria for response or stable 
disease is mandatory to differentiate between response or 
stable disease (an effusion may be a side effect of the 
treatment) and progressive disease.  
 
• Cytologic and histologic techniques can be used to 
differentiate between PR and CR in rare cases (e.g., residual 
lesions in tumor types such as germ cell tumors, where 
known residual benign tumors can remain.)  
 
11.[ADDRESS_1278287]  
 
11.31 Target Lesions  
 
NCI Protocol #: 7627  
Local Protocol #: MC 057H  
NCI Version Date: April 15, 201 8 56 
  
 
 All measurable lesions (as defined in Section 11.311) up to a maximum of 
10 lesions representative of all involved organs should be identified as 
target lesions and recorded and measured at baseline.  If the protocol 
specified studies are performed, and there are fewer than 10 lesions 
identified (as there often will be), there is no reason to perform additional 
studies beyond those specified in the protocol to discover new lesions.  For 
any one organ, no more than 5 lesions need to be measured.  Target lesions 
should be selected on the basis of their size (lesions with  the longest 
diameter) and their suitability for accurate repetitive measurements (either 
by [CONTACT_14217]).  
 
A sum of the longest diameter (LD) for all target lesions will be calculated 
and reported as the baseline sum LD.  The baseline  sum LD will be used as 
reference to further characterize the objective tumor response of the 
measurable dimension of the disease.  
 
11.32 Non-Target Lesions  
 
All other lesions (or sites of disease) should be identified as non -target 
lesions and should also  be recorded at baseline.  Measurements are not 
required, and these lesions should be followed in accord with 11.[ADDRESS_1278288] be followed on re -evaluation.  
Specifically, a change in objective status to  either a PR or CR cannot be 
done without rechecking all identified sites (i.e., target and non -target 
lesions) of pre -existing disease.  
 
Evaluation of Target Lesions  
 
• Complete Response (CR): Disappearance of all target lesions.   
• Partial Response (PR): At least a 30% decrease in the sum of the 
LD of target lesions taking as reference the baseline sum LD.  
 
• Progression (PD): At least a 20% increase in the sum of LD of 
target lesions taking as reference the smallest sum LD recorded 
since the treatment started or the appearance of one or more new 
lesions.  
 
• Stable Disease (SD):  Neither sufficient shrinkage to qualify for PR 
nor sufficient increase to qualify for PD taking as references the 
smallest sum LD.  
 
Evaluation of Non -Target Lesions  
NCI Protocol #: 7627  
Local Protocol #: MC 057H  
NCI Version Date: April 15, 201 8 57 
  
 
  
• Complete Response (CR ): Disappearance of all non -target lesions.  
 
• Stable Disease (SD): Persistence of one or more non -target lesions.  
 
• Progression (PD): Appearance of one or more new lesions.  
Unequivocal progression of existing non -target lesions.  
 
NOTE:  Although a clear progression of “non -target” lesions only is 
exceptional, in such circumstances, the opi[INVESTIGATOR_910329], and the progression status will be confirmed at a later time 
by [CONTACT_177108] a review panel.  
 
11.34 Overall objective status  
 
The overall objective status for an evaluation is determined by [CONTACT_177109]’s status on target lesions, non -target lesions, and new disease 
as defined in the following table.  
 
Target  
Lesions  Non-Target  
Lesions  New  
Lesions  Overall 
Objective Status  
CR CR No CR 
CR SD No PR 
PR Non-PD No PR 
SD Non-PD No SD 
PD Any Yes or No  PD 
Any PD Yes or No  PD 
Any Any Yes PD 
 
11.35  Residual Disease : In some circumstances it may be difficult to 
distinguish residual disease from normal tissue.  When the evaluation of 
complete response depends upon this determination, it is recommended 
that the residual lesion be investigated (fine needle aspi[INVESTIGATOR_337]/biopsy) 
before confirming the complete response status.  
 
11.36 Symptomatic Deterioration :  Patients with global deterioration of health 
status requiring discontinuation of treatment without objective evidence 
of disease progression at that time, and not either related to study 
treatment or other medical conditions, should be reported as PD due to 
“sympto matic deterioration.”  Every effort should be made to document 
the objective progression even after discontinuation of treatment due to 
symptomatic deterioration:  
• Weight loss >10% of body weight  
• Wors ening of tumor -related symptoms  
• Decline in performance s tatus of >1 level on ECOG scale  or > 
20% on the Karnofsky scale  
NCI Protocol #: 7627  
Local Protocol #: MC 057H  
NCI Version Date: April 15, 201 8 58 
  
 
  
11.4 Formal S tatistical Definitions of Analysis Variables  
Formal statistical definition of analysis variables involving response and disease 
progres sion are contained in Section 13 .0. 
 
12. DATA REPORTING / REGULATORY CONSIDERATIONS  
 
Adverse event lists, guidelines, and instructions for AE reporting can be found in Section 
7.0 (Adverse Events: List and Reporting Requirements).  
 
12.1 Data Reporting  
 
12.11 Method  
 
This study will be monitored by [CONTACT_470] (CDUS) 
version 3.0.  Cumulative CDUS data will be submitted quarterly to CTEP 
by [CONTACT_10075].  Reports are due January 31, April 30, July 31, and 
October 31.   Instructions for submitting data using the CDUS can be 
found  on the CTEP web site ( http://ctep.cancer.gov/reporting/cdus.html ). 
 
12.12  Responsibility for Submissions  
 
Study participants are responsible for submitting CDUS data and/or data 
forms to the C oordinating Center quarterly  to allow time for Coordinating 
Center compi[INVESTIGATOR_344], Principal Investigator [INVESTIGATOR_345], and timely submi ssion 
to CTEP (see Section 12.1 1.).  For trials monitored by [CONTACT_467], the monthly 
data submission to CTEP from Theradex should be co pi[INVESTIGATOR_910330].  
 
The Coordinating Center is responsible for compi[INVESTIGATOR_910331].   
 
12.2 CTEP Multicenter Guidelines  
 
This prot ocol will adhere to the policies and requirements of the CTEP 
Multicenter Guidelines.  The specific responsibilities of the Principal Investigator 
[INVESTIGATOR_131741] (Study Coordinator) and the procedures for auditing 
are presented in Appendix H. 
 
• The Principal Investigator/Coordinating Center is responsible for 
distributing all IND Action Letters or Safety Reports received from CTEP 
to all participating institutions for submission to their individual IRBs for 
action as required.  
 
NCI Protocol #: 7627  
Local Protocol #: MC 057H  
NCI Version Date: April 15, 201 8 59 
  
 
 • Except in very unusual circumstances, each participating institution will 
order DCTD -supplied agents directly from CTEP.  Agents may be ordered 
by a participating site only after the initial IRB approval for the site has 
been forwarded by [CONTACT_36477]  
([EMAIL_617] ) except for Group studies . 
 
12.3 Cooperative Research and Development Agreement (CRADA)/Clinical Trials 
Agreement (CTA)  
 
The agent(s), supplied by [CONTACT_472], DCTD, NCI, use d in this protocol is/are 
provided to the NCI under a Collaborative Agreement (CRADA, CTA) between 
the Pharmaceutical Company(ies) [hereinafter referred to as Collaborator(s)] and 
the NCI Division of Cancer Treatment and Diagnosis.  Therefore, the followin g 
obligations/guidelines, in addition to the provisions in the Intellectual Property 
Option to Collaborator @ (http://ctep.cancer.gov/industry ) contained within the 
terms  of award, apply to the use of Agent(s)  in this study:  
 
1. Agent(s) may not be used for any purpose outside the scope of this 
protocol, nor can Agent(s) be transferred or licensed to any party not 
participating in the clinical study.  Collaborator(s) data for Agent(s) are 
confidential and proprietary to Collaborat or(s) and shall be maintained as 
such by [CONTACT_473].  The protocol documents for studies utilizing 
investigational agents contain confidential information and should not be 
shared or distributed without the permission of the NCI.  If a copy of this 
protocol is requested by a patient participating on the study or patient’s 
family member, the individual should sign a confidentiality agreement.  A 
suitable model agreement can be downloaded from http://ctep.cancer.g ov. 
 
2. For a clinical protocol where there is an investigational Agent used in 
combination with (an)other investigational Agent(s), each the subject of 
different collaborative agreements, the access to and use of data by [CONTACT_910376] (data pertaining to such combination use 
shall hereinafter be referred to as "Multi -Party Data”.):  
 
a. NCI must provide all Collaborators with prior written notice 
regarding the existence and nature of any agreements governing 
their collaboration with NIH, the design of the proposed 
combination protocol, and the existence of any obligations that 
would tend to restrict NCI's participation in the proposed 
combination protocol.  
 
b. Each Collaborator shall agree to permit use of the Multi -Party Data 
from th e clinical trial by [CONTACT_910377], obtain 
regulatory approval, or commercialize its own investigational 
agent.  
NCI Protocol #: 7627  
Local Protocol #: MC 057H  
NCI Version Date: April 15, [ADDRESS_1278289] agree in writing prior to the commencement of the 
trials that it will use the Multi -Party Data solely for development, 
regulatory approval, and commercialization of its own 
investigational agent.  
 
3. Clinical Trial Data and Results and Raw Data developed under a 
collaborative agreement will be made available exclusively to 
Collaborator(s), the NCI, and the FDA, as appropriate  and unless 
additional disclosure is required by [CONTACT_47329].   Additionally, all 
Clinical Data and Results and Raw Data will be collected , used and 
disclosed consistent with all applicable federal statutes and regulations for 
the protection of human subjects, including, if applicable, the  Standards 
for Privacy of Individually Identifiable Health Inf ormation  set forth in [ADDRESS_1278290] be sent to the NCI, who will then notify the appropriate investigators 
(Group Chair for Cooperative Group studies, or PI [INVESTIGATOR_910332]) of 
Collaborator's wish to contact [CONTACT_476].  
 
5. Any data provided to Collaborator(s) for phase [ADDRESS_1278291] be in 
accordance with the guidelines and policies of the responsible Data 
Monitoring Committee (DMC), if there is a DMC for this clinical trial. 
 
6. Any manuscripts reporting the results of this clinical trial must be 
provided to CTEP for immediate delivery to Collaborator(s) for advisory 
review and comment prior to submission for publication.  Collaborator(s) 
will have [ADDRESS_1278292] that publication be delayed for up to an additional 
30 days in order to ensure that Collaborator’s confidential and proprietary 
data, in addition to Collaborator(s)’s intellectual proper ty rights, are 
protected.  Copi[INVESTIGATOR_910333](s) for courtesy review as soon as possible and preferably 
at least three (3) days prior to submission, but in any case, prior to 
presentation at the meet ing or publication in the proceedings.  Press 
releases and other media presentations must also be forwarded to CTEP 
prior to release.  Copi[INVESTIGATOR_352], abstract, and/or press release/ 
media presentation should be sent to:  
 
Regulatory Affairs Branc h, CTEP, DCTD, NCI  
    [ADDRESS_1278293]  
Rockville, MD   2089 2 
   FAX 301 -402-1584  
   E-mail: [EMAIL_5897]  
NCI Protocol #: 7627  
Local Protocol #: MC 057H  
NCI Version Date: April 15, 201 8 61 
  
 
  
The Regulatory Affairs Branch will then distribute them to 
Collaborator(s).  No publication, manuscript or other form of public 
disclosure shall contain any of Collaborator’s confidential/proprietary 
information.  
 
13. STATISTICAL CONSIDERATIONS   
 
13.1 Study Design/Endpoints  
 
13.11   Study Overview: The primary goal of this phase -II study is to evaluate the 
efficacy and biological effects of GW786034 treatment in patients with 
thyroid cancer.  Evaluating this treatment regimen in patients with 
differentiated thyroid carcinoma (DTC) is of primary interest; however , as 
noted above, we are also interested in evaluating this treatment in 
medullary thyroid carcinoma (MTC) and anaplastic thyroid carcinoma 
(ATC). Therefore, we propose to assess clinical and biologic responses as 
well as tolerability of GW786034 treatment  simultaneously and 
independently in each of these three patient cohorts.  Specifically, a one -
stage phase -II study design with an interim analysis based on the 
proportion of patients who have a clinical response (based on RECIST 
criteria) will be applied to the DTC, ATC, an d MTC group to assess 
efficacy.  This study will also assess toxicity, the proportion of patients 
who have not failed treatment by 6 months (3 months for ATC patients), 
survival, time to progression, and several biochemical and genetic 
correlates in each of the groups.   
 
An expanded/additional  cohort of 75 patients with confirmed 
differentiated thyroid cancer who are thyroglobulin antibody negative will 
be added to the original cohort of DTC patients enrolled on trial in order to 
prospectively examine a potential/hypothesized correlation between 
induced changes in thyroglobulin levels and patient response .  Rationale:  
Anecdotal experience of investigators enrolling patients on the initial 
cohort of differentiated thyroid cancer pat ients on MC057H suggested that 
induced changes in thyroglobulin seen in thyroglobulin antibody negative 
patients might be predictive of patient response.  Formal retrospective 
analysis undertaken in response indeed demonstrated that the proportion 
of patie nts with at least a 50% decrease in Tg values from pre -treatment 
levels was 0.[ADDRESS_1278294].  We therefore now propose to m ore rigorously and 
prospectively examine this association in an expanded DTC patient cohort.  
This analysis will be important in the design of future pazopanib clinical 
trials in differentiated thyroid cancer, given its apparent promising clinical 
activity  in DTC, so as to allow optimal use of tumor markers and imaging 
in the evaluation of further patients receiving the agent.  
NCI Protocol #: 7627  
Local Protocol #: MC 057H  
NCI Version Date: April 15, 201 8 62 
  
 
  
13.12    Primary Endpoint: The primary efficacy endpoint for each of the groups 
evaluated in this trial is the proportion of patient s who have achieved an 
objective response to the study agent (RECIST criteria).  
 
13.13   Secondary Endpoints: The secondary efficacy endpoints for each of the 
groups evaluated in this trial is the proportion of patients who have not 
failed treatment at 6 m onths (3 months for ATC), the proportion of 
patients in which the radioactive iodine scan have changed from “no 
uptake” to “any uptake”, and the proportion of patients achieving a 
biochemical response in appropriate tumor markers. Any patients who 
have pro gressive disease within 6/3 months of study entry will be 
considered treatment failures and will be included in the denominator of 
the proportion for efficacy analyses.  Note that each of the groups will be 
using radiographic (i.e. RECIST) criteria only to  document progression.  
In addition, radioactive iodine scan will be used to determine response to 
GW786034, as will tumor markers. Any patients who discontinue 
treatment due to adverse reactions, refusal, or who go on to receive 
alternate therapy within 6 /3 months of study entry will be considered 
treatment failures and will be analyzed in a similar manner.  For this 
measure we will evaluate those patients who are not treatment failures at 
6/3 months; i.e. those patients who are progression -free and have n ot gone 
off treatment due to adverse reactions, refusal, or have not gone on to 
receive further alternate therapy and those patients in which the 
radioactive iodine scan has changed from “negative” to “any uptake”.  
 
13.2 Sample Size/Accrual Rate  
  
13.21   Sample Size: The single arm, one stage design with an interim analysis to 
be used for each patient group (i.e. DTC, MTC, and ATC) is fully 
described below.  The efficacy decision rules require 33 evaluable patients 
for each patient group.  To accommodate p otential losses due to 
ineligibility, cancellation, or major violations, 3 additional patients will be 
accrued to each group.  Thus, a total of 36 patients will be accrued to each 
group for a maximum of 108 patients overall to this trial, unless undue 
toxicity is encountered or accrual is stopped early based on the results of 
the planned interim analysis.   An interim analysis will be performed in 
each patient group (as described below) after the first [ADDRESS_1278295] 6/3 months.  
Accrual will not be suspended prior to the interim analysis.  We recognize 
that additional patients will be accrued by [CONTACT_910378] s; however, given the paucity of treatments available for these 
patients as well as the relatively small overall sample size for each group, 
these analyses can be used for interim reporting of results as appropriate.  
 
NCI Protocol #: 7627  
Local Protocol #: MC 057H  
NCI Version Date: April 15, 201 8 63 
  
 
 13.22   Accrual Time and Study Durati on: Based upon ongoing accrual to the 
currently active Mayo P2C thyroid trial, the anticipated accrual rate for the 
proposed trial is about 1 to 2 patients per month in the cohort of patients 
with differentiated thyroid cancer (Cohort A).  At this accrual rate, it will 
take approximately 9 months to enroll the 14 patients needed for the 
interim analysis for Cohort A.   Overall accrual to Cohort A is expected to 
take 24 months.  Note that these accrual estimates also include the 
anticipated over accrual.  Ac crual to Cohorts B (medullary thyroid cancer) 
and C (anaplastic thyroid cancer) are expected to be somewhat slower.  If 
accrual is slower than expected, then the study can be opened to accrual at 
other Phase 2 Consortia.  
 
13.3   Statistical Design to be us ed for the ATC, DTC, and MTC Patient Groups  
 
13.31  Primary endpoint : This study is designed to also look at the proportion of 
patients who have a clinical response to treatment as defined by [CONTACT_131697]. Few prospective clinical studies have been done in these 
patient populations and little published data exist in these relatively rare 
patient groups for these kinds of trials, especially for the MTC and ATC 
groups.  Given that this study is focusing on (and hence requiring) patients 
who have docume nted disease progression within the [ADDRESS_1278296] more 
aggressive disease .  Therefore, we can assume that only 5% of patients 
will achieve a response if this therapeutic regimen is not effec tive in this 
patient population. If this single agent therapy of GW786034 is truly 
promising, we would expect that the true response rate would be at least 
20% for each of these patient population s.  In other words, the fact that we 
are requiring patients to have documentation of progressive disease within 
the 6 months prior to study entry (ATC patients excepted), we can assume 
that the same response rates would be of interest for all three thyroid 
carcinoma subtype populations.  
 
13.32   Definition of succ ess: As discussed above, a treatment success in this trial 
will be considered the event that a patient has a clinical response (i.e. a PR 
or CR by [CONTACT_773398]) .  This same definition for success will be 
used for all three patient groups.  
 
13.33   Decision rule:  This decision rule will be applied independently and 
individually for each of the patient cohorts. The largest success proportion 
where the proposed treatment regimen would be considered ineffective in 
this patient population is 5%, and the smallest success proportion that 
would warrant subsequent studies with the proposed regimen in this 
patient population is 20%.  The following Three -Outcome Phase II study 
design [ADDRESS_1278297] 5%. The following 
NCI Protocol #: 7627  
Local Protocol #: MC 057H  
NCI Version Date: April 15, 201 8 64 
  
 
 decision rule will be used for each patient cohor t: 
 
“Not promising”:  This regimen will be classified as not promising with 
respect to the success rate in this patient population if at most 1 
success is observed in a total of 33 evaluable patients.  
 
“Inconclusive” :  The results of this study will be classified as 
inconclusive with respect to this regimen demonstrating an improved 
success rate if [ADDRESS_1278298] not failed treatment at 6 
months (or 3 months for the ATC group), toxicity, and time to 
progression observed in this study will be used in addition to the rate 
of patients who responded to treatment in order to make the final 
determination as to whether or not this treatment is considered 
promising and worthy  of further study in this patient population.  
 
“Promising”:   This regimen will be classified as promising with 
respect to increasing the success rate in this patient population if at 
least 4 successes are observed in 33 evaluable patients.  Subsequent 
larger confirmatory studies may be recommended.  
 
13.34   Interim analyses:  
Efficacy: An interim analysis will be performed in each patient group after 
[ADDRESS_1278299]  responded to treatment, we 
will consider this regimen insufficiently active and accrual may be 
terminated in this group at this point.  It should be noted that unless 
we observe an unexpected toxicity rate or rapid accrual, we will 
not suspend accrual bet ween stages to wait to perform the interim 
analysis.   
 
Toxicity  Stoppi[INVESTIGATOR_10020] : The following toxicity stoppi[INVESTIGATOR_910334]. If 
at any time 30 %  or more patients in a patient group develop  
grade 4 non -hematologic toxicity (including febrile neutropenia), 
accrual to that patient group will be suspended to allow for 
investigation. After consideration by [CONTACT_3476] (study 
chair[s], statistician, P2C Operations Office, etc.) and consultati on 
with CTEP and the primary IRB affiliated with the P2C Operations 
Office, a decision will be made as to whether accrual can be 
resumed .  CTCAE v3.0 will be used to determine grading for these 
stoppi[INVESTIGATOR_004].  
 
13.35   Power and significance level:  Assumin g that the number of successes is 
binomially distributed, the significance level for this study design is 0.07.  
This decision rule has 90% power to detect an effective treatment given 
NCI Protocol #: 7627  
Local Protocol #: MC 057H  
NCI Version Date: April 15, [ADDRESS_1278300] 20% using this treatment.  
 
13.36   Other considerations : Toxicity, incidence and duration of response, and 
other considerations will be taken into account in any decision process at 
each step.  If more than [ADDRESS_1278301] 33 
will be used for decision purposes, but the additional patients will be 
included in the analyses described above.  
 
13.37   Statistical Design to be used for  the expanded cohort of  patient s with DTC 
who are thyroglobulin antibody negative :  
13.37 1    Primary endpoint:   The primary endpoint of this trial is a 
confirmed tumor response defined as a CR or PR (by [CONTACT_131697]) noted as the objective status on [ADDRESS_1278302] 8 weeks apart.  
13.37 2    Overview : The goal of this extended cohort of dif ferentiated 
thyroid carcinoma (DTC) patients is to examine whether the 
proportion of patients whose tumor size decreases (PR or CR by 
[CONTACT_773398]) tend in parallel to have greater decreases in 
serum thyroglobulin levels (Tg levels). This analysis w ill be 
important in the design of future pazopanib clinical trials, so as 
to allow optimal use of tumor markers and imaging in evaluation 
of patients receiving the agent.  Among the patients with DTC 
initially enrolled on MC057H, the proportion of patients  with at 
least a 50% decrease in Tg values from pre -treatment levels was 
0.[ADDRESS_1278303].  
 
13.37 3 Study design :  We expect a 2:[ADDRESS_1278304] a 50% 
decrease in Tg values from pre-treatment levels between patients 
who response to treatment and those who do not differs by [CONTACT_12697] 30%.  With [ADDRESS_1278305]  a significance level 0.05 and a 80% 
chance of detecting that difference in the proportion of patients 
with at least a 50% decrease in Tg values from pre -treatment 
levels between patients who respond  to treatment and those who 
do not is at least 0.30, when  the proportion of patients with at 
least a 50% decrease in Tg values from pre -treatment levels 
among patients with stable or progressive disease is 0.50.  
 
To account for ineligibility, cancellation, major treatment 
violation, or other reasons, we will additionally accrue 7 
NCI Protocol #: 7627  
Local Protocol #: MC 057H  
NCI Version Date: April 15, [ADDRESS_1278306] prior to 
this extended study, there will be no interim analysis for this 
cohort, but patients will be closely monitored for toxicity, AE, 
etc.  
 
Final analysis decision rule: after full accrual, we will c onduct a 
two-sample test for proportions as specified in the design.  
 
13.4 Analysis Plans  
The following analyses will be performed for each patient group.  All evaluable 
patients in that group will be used.  
 
13.41   Primary Efficacy Endpoint  
Patient evalua bility : All patients meeting the eligibility criteria who have 
signed a consent form and begun treatment will be considered evaluable 
for estimation of response to treatment  
 
Success probability : The proportion of successes will be estimated by (a) 
the sta ndard binomial estimator, i.e., the number of successes divided by 
[CONTACT_128773], and (b) 90% binomial confidence 
intervals.  
 
13.42  Analysis of Secondary Endpoints  for all 4 Patient Cohorts  
 
Definitions and Analyses of Secondary Endpoints:  
 
Toxicity : As per NCI CTCAE Version 3.0, the term toxicity is defined as 
adverse events that are classified as either possibly, probably, or definitely 
related to study treatment.  The maximum grade for each type of toxicity 
will be recorded for  each patient, and frequency tables will be reviewed to 
determine toxicity patterns.  In addition, we will review all adverse event 
data that is graded as 3, 4, or 5 and classified as either “unrelated or 
unlikely to be related” to study treatment in the e vent of an actual 
relationship developi[INVESTIGATOR_007].  
 
Proportion of patients who fail treatment at 6 months (3 months for ATC 
patients) : The proportion of patients who have not failed treatment due to 
disease progression, adverse reactions, refusal for further parti cipation, or 
who went on to alternate therapy at 6 months (3 months for ATC patients) 
will be calculated and summarized independently within each of the 
patient groups.  Assuming that the incidence of response is binomially 
distributed, 90% binomial confid ence intervals will also be calculated.  
 
Times to progression and death:   The overall survival time is defined as 
NCI Protocol #: 7627  
Local Protocol #: MC 057H  
NCI Version Date: April 15, [ADDRESS_1278307].  The distributions of overall survival time and time to progression 
will be estimated using the method of Kaplan -Meier. In addition, the 6 -
month progression -free rate will  be evaluated using the 6 -month rates and 
associated confidence intervals. In addition, competing risk analyses may 
be done to evaluate time to progression, allowing for going on to alternate 
treatment or death prior to progression as competing risks.  
 
Time to treatment failure and time to subsequent therapy : The time to 
treatment failure is defined as the time from registration to the date the 
patient discontinues treatment, and its distribution will be estimated using 
the method of Kaplan -Meier.  In addit ion, the time to subsequent therapy 
will also be evaluated using a similar approach.  
 
Duration of response : Duration of response will be calculated from the 
date of documentation of response (PR or CR) until the date of 
progression or last follow -up (whic hever comes first) in the subset of 
patients with confirmed response.  
 
Biomarker -based response and progression -free survival:  Response and 
progression -free rates based on biomarker -based definitions alone will 
also be evaluated in each of these patient gr oups and summarized 
independently.  Specifically, calcitonin -based progression alone will be 
evaluated for the MTC group and changes in thyroglobulin levels will be 
evaluated for the DTC group.  These rates will be summarized assuming 
they are binomially d istributed, and the biomarker levels themselves will 
be explored both quantitatively and graphically before and after treatment.  
 
Correlative assay analyses:  Given the limited sample sizes available for 
each of the patient cohorts evaluated in this trial, the following correlative 
endpoint analyses for each of the groups will be done in an exploratory 
manner.  In addition, we will also evaluate differences between groups and 
may analyze these endpoints across all three thyroid carcinoma subtypes.  
In this c ase, we may also be able to evaluate these relationships 
quantitatively in addition to the summarization and primary graphical 
analyses described below.  
 
Blood markers for angiogenesis including levels of free VEGF, free 
GW786034, and GW786034/VEGF comple xes will be evaluated before 
and during therapy.  Changes in these levels will largely be explored in a 
graphical manner as well as exploring any potential relationships between 
these levels and clinical outcome such as response or progression -free rate 
and toxicity incidence.  
 
NCI Protocol #: 7627  
Local Protocol #: MC 057H  
NCI Version Date: April 15, 201 8 68 
  
 
 13.5 Monitoring  
The principal investigator [INVESTIGATOR_910335], toxicity, and any endpoint problems that might be 
developi[INVESTIGATOR_007]. In addition, this study will be monitored ac cording to the Mayo Clinic 
Cancer Center ( MCCC ) Data Safety Monitoring Plan that is currently in place.   
The MCCC Data Safety Monitoring Board ( DSMB ) is responsible for reviewing 
safety data for this trial at least twice a year, based on reports provided by [CONTACT_890852].  
 
13.6 Data Reporting  
This study will be monitored by [CONTACT_470] (CDUS) version 
2.0.  The coordinating center will submit cumulative CDUS data quarterly to 
CTEP by [CONTACT_10075].  Reports are due January 31, April 30, July 31, and 
October 31.  
 
At the time CTCAE v4.[ADDRESS_1278308] all routine AE 
data using CTCAE v3.0; however, all adverse event data submitted via CDUS must 
use CTCAE v4.0 terminology.  CTEP provided mappi[INVESTIGATOR_910336] 
v3.0 data to v4.0 prior to submission to CTEP , as agreed upon by [CONTACT_910379].  
 
13.7 Subset Analyses for Minorities:  
This study will be available to all eligible patients, regardless of sex, race or 
ethnic origin.  The planned analyses will look for difference in treatment ef fect 
based on racial groupi[INVESTIGATOR_14839].  The current percentage of ethnic minorities accrued to 
studies at the P2C sites is approximately 7%.  Therefore, it is not expected that 
more than 5 ethnic minority patients will be accrued to this study.  Since there is 
no evidence currently available that suggests that the effects of therapi[INVESTIGATOR_910337], the sample sizes are not 
increased in order to provide additional power for subset analyses.  
 
Ethnic Category  Sex/G ender  
Females  Males  Unknown  Total  
Hispanic or Latino  2 2 0 4 
Not Hispanic or Latino  92 92 0 184 
Ethnic Category: Total of all subjects*  94 94 0 188* 
Racial Category   
American Indian or Alaskan Native  0 0 0 0 
Asian  1 1 0 2 
Black or African American  2 2 0 4 
Native Hawaiian or other Pacific Islander  0 0 0 0 
White  91 91 0 182 
Racial Category: Total of all subjects*  94 94 0 188 
*These totals must agree.   Enter actual estimates ( not percentages ) 
 
NCI Protocol #: 7627  
Local Protocol #: MC 057H  
NCI Version Date: April 15, 201 8 69 
  
 
 Ethnic 
Categories:  Hispanic or Latino – a person of Cuban, Mexican, Puerto Rico, South or Central American, or other 
Spanish culture or origin, regardless of race. The term “Spanish origin” can also be used in addition to 
“Hispanic or Latino.”  
Not Hispanic or Latino  
 
Racial 
Categories:  American  Indian or Alaskan Native – a person having origins in any of the original peoples of North, 
Central, or South America, and who maintains tribal affiliations or community attachment.  
Asian – a person having origins in any of the original peoples of the Far East, Southeast Asia, or the 
Indian subcontinent including, for example, Cambodia, China, India, Japan, Korea, Malaysia, Pakistan, 
the Philippi[INVESTIGATOR_31922], Thailand, and Vietnam. (Note: Indi viduals from the Philippi[INVESTIGATOR_362215].)  
Black or African American – a person having origins in any of the black racial groups of Africa. Terms 
such as “Haitian” or “Negro” can be  used in addition to “Black or African American.”  
Native Hawaiian or other Pacific Islander – a person having origins in any of the original peoples of 
Hawaii, Guam, Samoa, or other Pacific Islands.  
White – a person having origins in any of the original pe oples of Europe, the Middle East, or North 
Africa.  
 
14.0 DESCRIPTIVE FACTORS  
 
14.1    Baseline C alcitonin Levels  
 Baseline Thyroglobulin levels  
 
15.0 PATHOLOGY CONSIDERATIONS  
 
Histologic or cytologic confirmation of disease will be the responsibility of each center 
independently without central review.  A copy of the pathology reports is to be sent to the 
P2C Coordinating Center ≤2 weeks of study entry (see Section 16. 5).  NOTE: At Mayo 
enrollment sites, molecular markers of thyroid can cer will be assesse d to complete  
histological/cytological studies. (This is normal standard practice at Mayo Clinic).  
 
16. Data SUBMISSION To Coordinating Center  
 
16.1 Data Collection  
Data will be collected using protocol -specific forms and the P2C web -based 
remote data entry system.  Data is to be submitted ≤  2 weeks following each 
evaluation of the patient and according to the schedule in Section 16. 5.   
After the patient discontinues treatment, follow –up will continue as specified in 
the following section(s):  
 
16.[ADDRESS_1278309] 
provide On-study material and the End of Active Treatment /Cancel Notification  
Form must be submitted. No further follow -up is required.  
 
 16.3 Ineligible  
A patient is deemed ineligible  if at the time of registration, the patient did not 
satisfy each and every eligibility criteria for study entry.  
 
▪ If the patient received treatment, all data up until the point of confirmation 
NCI Protocol #: 7627  
Local Protocol #: MC 057H  
NCI Version Date: April 15, [ADDRESS_1278310] be submitted.  Event monitoring will be required per 
Section 16.5 of the protocol.  
 
▪ If the patient never received treatment, On -study materials and the End of 
Active Treatment /Cancel Notification  Form must be submitted. No further 
follow-up is required.  
 
16.4 Treatment Discontinuation  
After a patient discontinues treatment , follow -up data will be collected and 
entered via the remote data entry system according to schedule outlined below 
(also see Section 16.5).  
   
▪ If a patient discontinues treatment due to progression within [ADDRESS_1278311] -registration.   
 
▪ If a patient discontinues treatmen t due reasons other than progression or 
death within [ADDRESS_1278312] -registration.  
 
▪ If a patient discontinues treatment more than 3 years after registration, 
submission of an event  monitoring report is required 6 months after 
treatment discontinuation.  
 
Follow -up data will be collected and entered via the remote data entry system 
according  to the schedule in Section 16. 5.   
 
NCI Protocol #: 7627  
Local Protocol #: MC 057H  
NCI Version Date: April 21, 2017   71 
 
  16.5 Data Entry/Submission Timetable  
 
Forms/Other  Active -Monitoring Phase  
(Compliance with Test Schedule)  Event -Monitoring Phase2 
(Completion of Active -Monitoring Phase)  
PD = Progression (see Section 11.0)  At Each Occurrence  
Initial  Material  Subsequent material  
2 weeks after 
registration  At each 
evaluation  At end of 
treatment  q. 3 
months 
until PD2 At PD2 After PD q. 
6 mos.2 Death  All Grade 4/5 AEs  
All Hospi[INVESTIGATOR_910338]/MDS New 
Primary  Late 
Adverse 
Event  
On-Study Form  X          
Baseline Adverse Events  X          
Concomitant Medication 
Form  X X X        
Measurement Form4 X X4 X4        
Pathology Report 
 Submission1 X          
Event -Monitoring  
 Form     X X4 X X  X X 
Evaluation/Treatment  
 Form   X X        
Nadir/Adverse Event 
 Form   X X        
Endocrine Lab Form  X X         
Specimen Submission Form 
(Blood)  X X6         
End of Active 
Treatment /Cancel 
Notification  Form  X5  X        
AE Reporting per Section 7.0         X3 X3  
CTEP Report  
    Variables Form  X          
Notification Form, Grade 4/5         X   
1. Submit copy of pathology reports via fax or mail to the P2C Coordinating Center, (Attention: QCS for MC057H ), [ADDRESS_1278313] SW, [COMPANY_002]ster, MN [ZIP_CODE], Fax: (507) [ADDRESS_1278314] -registration.  If a patient discontinues treatment more than 3 years after 
registration, submission of  an event  monitoring report is required 6 months after treatment discontinuation.  
3. Reminder : Adverse events that necessitate expedited reporting are also to be reported via the routine clinical data (i.e. Nadir/Adver se Event Form, etc.) submitted with each evaluation.  
4. Submit copy of documentation of response, recurrence, or progression to the P2C Coordinating Center, Attention: QC S for MC057H , Fax (507) 266 -7240.  
5. Submit this form only if withdrawal/refusal prior to beginning protocol therapy occurs.  
6. To be performed (+/ -) 1 day.  Cycles 1 weeks 1 -4, retreatment weeks, 4, 8,  12, and 16 and End of Treatment.
NCI Protocol #: 7627  
Local Protocol #: MC 057H  
NCI Version Date: April 21, 2017  72 
  
   
17.   FUNDING CONSIDERATIONS  
 
 17.1 Costs Charged to Patient   
All routine clinical care.  GW786034  will be provided by [CONTACT_6812].  The patient or the 
patient’s health plan/insurer will be responsible for charges associated with supplies and 
procedures necessary for administration of the study drug(s), as well as all other drugs or 
treatment given to help  control adverse events as well as the cost of tests or exams to 
evaluate possible adverse events.   Blood pressure monitors will be provided free of 
charge and can be obtained by [CONTACT_910380]  (garnold@t heradex.com ), 
telephone 609 -799-7580 Ext 3001 .   
 
17.2 Other Budget C oncerns  
This study is supported by [CONTACT_165894] 2 Consortium (P2C) through its N01 contract with 
the National Cancer Institute.  
 
17.3 Manufacturer to Supply Drug  
The manufacturer of GW786034 will accomplish all VEGF and PDGF analyses at the 
site of their specification and at their expense.  
 
 
REFERENCES  
 
Ain, K. B., M. J. Egorin, et al. (2000). "Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 
2 trial using ninety -six-hour infusion. Collaborative Anaplastic Thyroid Cancer Health Intervention 
Trials (CATCHIT) Group." Thyroid  10(7): 587 -94. 
 
Alhamarneh, O., J. Murphy, et al.  (2004). "Somatostatin analogues have no role in the treatment of 
advanced differentiated thyroid cancer." J Laryngol Otol  118(8): 653 -4. 
Baker CH, Solorzano CC, Fidler IJ  2002 Blockade of vascular endothelial growth factor receptor 
signaling for therapy o f metastatic human pancreatic cancer. Cancer Res 62:1996 –2002 .  
Bauer AJ, Terrell R, Doniparthi NK, Patel A, Tuttle RM, Saji M, Ringel MD, Francis GL.     Vascular 
endothelial growth factor monoclonal antibody inhibits growth of anaplastic thyroid cancer xenografts in 
nude mice.  Thyroid. 2002 Nov ; 12(11):953 -61. 
Brink, J. S., J. A. van Heerden, et al. (2000). "Papi[INVESTIGATOR_368617] c ancer with pulmonary metastases in 
children: long -term prognosis." Surgery  128(6): 881 -6; discussion 886 -7. 
Bunone G , Vigneri P , Mariani L , Buto S , Collini P , Pi[INVESTIGATOR_068] S , Pi[INVESTIGATOR_1940] , Bongarzone I . Expression of 
angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical 
pathological features.  Am J Pathol. 1999;  155(6):1967 -76. 
 
Capen, C. and J. Sagartz (1998). "A ret transgenic mouse model of thyroid carcinogenesis ." Lab Anim 
Sci 48(6): 580 -3. 
 
NCI Protocol #: 7627  
Local Protocol #: MC 057H  
NCI Version Date: April 15, 2018  73   
 
   Caplan, R. H., G. G. Wickus, et al. (2005). "Long -term follow -up of a patient with papi[INVESTIGATOR_243713], elevated thyroglobulin levels, and negative imaging studies." Endocr Pract  11(1): 43 -8. 
 
Chow, S. M., S. C. Law, et al. (2003). "Changes in clinical presentation, management and outcome in 
1348 patients with differentiated thyroid carcinoma: experience in a single institute in Hong Kong, 
1960 -2000." Clin Oncol (R Coll Radiol)  15(6): 329 -36. 
 
Clayman, G. L. and T. S. el -Baradie (2003). "Medullary thyroid cancer." Otolaryngol Clin North Am  
36(1): [ADDRESS_1278315] of retinoic acid: a novel 
therapeutic approach for advanced thyroid cancer . Curr Pharm Des. 2005;  11(19):2525 -31. 
 
Cohen, M. S. and J. F. Moley (2003). "Surgical treatment of medullary thyroid carcinoma." J Intern Med  
253(6): 616 -26. 
 
Cooper, D. S., B. Specker, et al. (1998). "Thyrotropin suppression and disease progression in patients 
with differentiated thyroid cancer : results from the National Thyroid Cancer Treatment Cooperative 
Registry." Thyroid  8(9): 737 -44. 
 
D'Avanzo, A., P. Ituarte, et al. (2004). "Prognostic scoring systems in patients with follicular thyroid 
cancer: a comparison of different staging systems in predicting the patient outcome." Thyroid  14(6): 
453-8. 
Drevs J, Muller -Driver R, Wittig C, Fuxius S , Esser N, Hugenschmidt H, Konerding MA, Allegrini PR, 
Wood J, Hennig J, Unger C, Marme D  2002 PTK787/ZK222584, a specific vascular endothelial growth 
factor -receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the 
function al vascular properties as detected by [CONTACT_910381] i maging. Cancer 
Res 62:4015 –4022.  
Duh, Q. Y. and R. F. Grossman (1995). "Thyroid growth factors, signal transduction pathways, and 
oncogenes." Surg Clin North Am  75(3): 421 -37. 
Ellis LM, Takahashi Y, Liu W, Shaheen  RM 2000 Vascular endothelial growth factor in human colon 
cancer: biology and therapeutic implications. Oncologist 5(Suppl 1):11 –15. 
Fagin, J. A. (2004). "How thyroid tumors start and why it matters: kinase mutants as targe ts for solid 
cancer pharmacotherapy." J Endocrinol  183(2): 249 -56.  
Fernandes, J. K., T. A. Day, et al. (2005). "Overview of the management of differentiated thyroid 
cancer." Curr Treat Options Oncol  6(1): 47 -57. 
Gimm, O. (2001). "Thyroid cancer." Cancer Lett 163(2): 143 -56. 
Hay, I. D., E. J. Bergstralh, et al. (1993). "Predicting outcome in papi[INVESTIGATOR_243703]: 
development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one 
institution during 1940 through  1989." Surgery  114(6): 1050 -7; discussion 1057 -8. 
NCI Protocol #: 7627  
Local Protocol #: MC 057H  
NCI Version Date: April 15, 2018  74   
 
    
Hay, I. D., G. B. Thompson, et al. (2002). "Papi[INVESTIGATOR_910339] (1940 -1999): temporal trends in initial therapy and long -term outcome in 2444 
consecutively treated patients." World J Surg  26(8): 879 -85. 
 
Hurwitz, H., A. Dowlati, S. Savag e, et al.  (2005). Safety, tolerability and pharmacokinetics of oral 
administration of GW786034 in pts with solid tumors.  Proc Am Soc Clin Oncol.   23:A3012.  
 
Jemal, A., T. Murray, et al. (2005). "Cancer statistics, 2005." CA Cancer J Clin  55(1): 10 -30. 
 
Jindrichova, S., R. Kodet, et al. (2003). "The newly detected mutations in the RET proto -oncogene in 
exon 16 as a cause of sporadic medullary thyroid carcinoma." J Mol Med  81(12): 819 -23. 
 
Kilicarslan AB, Ogus M, Arici C, Pestereli HE, Cakir M, Karpuzoglu G.   Clinical importance of 
vascular endothelial growth factor  (VEGF) for papi[INVESTIGATOR_44330].  APMIS. 2003 
Mar;111(3):439 -43. 
 
Kim, T. H., D. S. Yang, et al. (2003). "Value of external irradiation for locally advanced papi[INVESTIGATOR_226796]." Int J Radiat Oncol Biol Phys  55(4): 1006 -12. 
 
Kinder, B. K. (2003). "Well differentiated thyroid cancer." Curr Opin Oncol  15(1): 71 -7. 
 
Klein M, Vignaud JM, Hennequin V, Tou ssaint B, Bresler L, Plenat F, Leclere J, Duprez A, Weryha G.   
Increased expression of the vascular endothelial growth factor is a pejorative prognosis marker in 
papi[INVESTIGATOR_243703].  J Clin Endocrinol Metab. 2001 Feb;86(2):656 -8. 
 
Landriscina M , Fabiano A , Altamura S , Bagala C , Pi[INVESTIGATOR_910340] A , Cassano A , Spadafora C , Giorgino F , 
Barone C , Cignarel li M. Reverse Transcriptase Inhibitors Downregulate Cell Proliferation in vitro and in 
vivo and Restore TSH Signaling and Iodine Uptake in Human Thyroid Anaplastic Carcinoma.   J Clin 
Endocrinol Metab. 2005 Jul 19(Epub ahead of print)  
 
Leaf, A. N., B. C. Wo lf, et al. (2000). "Phase II study of etoposide (VP -16) in patients with thyroid 
cancer with no prior chemotherapy: an Eastern Cooperative Oncology Group Study (E1385)." Med 
Oncol  17(1): [ADDRESS_1278316] CM, Patel A, Wilson J, Reinhardt B, Tuman C, Fenton C, Blair E, Francis GL, Tuttle RM.   
Intensity of vascular endothelia l growth factor expression is associated with increased risk of recurrence 
and decreased disease -free survival in papi[INVESTIGATOR_6686].  Surgery. 2001 May;129(5):[ADDRESS_1278317] CM, Patel A, Wilson J, Reinhardt B, Tuman C, Fenton C, Blair E, Francis GL , Tuttle RM  2001 
Intensity of vascular endothelial growth factor expression is associated with increased risk of recurrence 
and decreased disease -free survival in papi[INVESTIGATOR_6686]. Surgery 129:552 –558  
Leung DW, Cachianes G, Kuang WJ, Goeddel DV, F errara N  1989 Vascular endothelial growth factor 
is a secreted angiogenic mitogen. Science 246:1306 –1309  
Lin SY, Wang YY, Sheu  WH.   Preoperative plasma concentrations of vascular endothelial growth factor 
NCI Protocol #: 7627  
Local Protocol #: MC 057H  
NCI Version Date: April 15, 2018  75   
 
   and matrix metalloproteinase 9 are associated with stage progression in papi[INVESTIGATOR_6686].  Clin 
Endocrinol (Oxf). 2003 Apr;  58(4):[ADDRESS_1278318] SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, 
Stillman IE, Epstein FH, Sukhatme VP, Karumanchi SA.   Excess placen tal soluble fms -like tyrosine 
kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in 
preeclampsia.  J Clin Invest. 2003 Mar ; 111 (5):649 -58.  
 
McIver, B., I. D. Hay, et al. (2001). "Anaplastic thyroid carcinoma: a 50 -year experience at a single 
institution." Surgery  130(6): [ADDRESS_1278319]. 2003 Mar 5 ; 
95(5):[ADDRESS_1278320], Supko JG, He X, Bubley GJ, Sukhatme VP.   Increased endothelial uptake of 
paclitaxel as a potential mechanism for its antiangiogenic effects: potentiation by [CONTACT_44711] -2 inhibition.  Int J 
Cancer. 2005 Jan 20 ; 113 (3):490-8. 
 
Pazopanib (GW786034) Investigator’s Brochure, Version 3 (Decemb er 200 5).  Glaxo Smith  Kline, 
Collegeville, PA.  
 
Quayle, F. J. and J. F. Moley (2005). "Medullary thyroid carcinoma: including MEN 2A and MEN 2B 
syndromes." J Surg Oncol  89(3): 122 -9. 
 
Quiros, R. M., H. G. Ding, et al. (2005). "Evidence that one subset of anaplastic thyroid carcinomas are 
derived from papi[INVESTIGATOR_910341] p53 mutations." Cancer  103(11): [ADDRESS_1278321], et al. (2005). "PPARgamma staining as a surrogate for PAX8/PPARgamma 
fusion oncogene expression in follicular neoplasms: clinicopathological correlation and 
histopathological diagnostic value." J Clin Endocrinol Metab  90(1): 463 -8. 
 
Salvatore, G., R. Giannini, et al. (2004). "Analysis of BRAF point mutation and RET/PTC 
rearrangement refines the fine -needle aspi[INVESTIGATOR_910342]." J Clin 
Endocrinol Metab  89(10): 5175 -80. 
 
Sargent DJ, Chan  VC, Goldberg RM, A three outcome design for Phase II clinical trials, Controlled 
Clinical Trials 22: 117 -125, 2001.  
Shibuya M, Yamguchi S, Yamane A, Ikeda T, Tojo A, Matsushime H, Sato M  1990 Nucleotide 
sequence and expression of a novel human receptor -type tyrosine kinase gene (FLT) closely related to 
the fms family. Oncogene 5:519 –524.  
Schiff BA, McMurphy AB, Jasser SA, Younes MN, Doan D, Yigitbasi OG, Kim S, Zhou G, Mandal M, 
Bekele BN, Holsinger FC, Sherman SI, Yeung SC, El -Naggar AK, Myers JN.  Epi[INVESTIGATOR_13392] (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits 
the growth of anaplastic thyroid cancer.  Clin Cancer Res. 2004 Dec 15 ; 10(24):8594 -602.  
NCI Protocol #: 7627  
Local Protocol #: MC 057H  
NCI Version Date: April 15, 2018  76   
 
    
Soh EY, Eigelberger MS, Kim KJ, Wong MG, Young DM, Clark OH, Duh QY.   Neutralizing vascular 
endothelial growth factor activity inhibits thyroid cancer growth in vivo.  Surgery. 2000 Dec ; 
128(6):1059 -65; discussion [ADDRESS_1278322] tyrosine kinase as a receptor for vascular endothelial growth factor. Biochem 
Biophys Res Commun 187:1 579–1586 . 
Traugott, A. and J. F. Moley (2005). "Medullary thyroid cancer: medical management and follow -up." 
Curr Treat Options Oncol  6(4): 339 -46. 
Tseng, L. M., C. H. Lee, et al. (1996). "The surgical treatment and prognostic factors of well -
differentiated thyroid cancers in Chinese patients: a 20 -year experience." Zhonghua Yi Xue Za Zhi 
(Taipei)  58(2): 121 -31. 
Wood JM, Bold G, Buchdunger E, Cozens R,  Ferrari S, Frei J, Hofmann F, Mestan J, Mett H, O’Reilly 
T, Persohn E, Rosel J, Schnell C, Stover D, Theuer A, Towbin H, Wenger F, Woods -Cook K, Menrad 
A, Siemeister G, Schirner M, Thierauch KH, Schneider MR, Drevs J, Martiny -Baron G, Totzke F  2000 
PTK787 /ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine 
kinases, impairs vascular endothelial growth factor -induced responses and tumor growth after oral 
administration. Cancer Res 60:2178 –2189 . 
Zeiger, M. A., R. C. Smallridge, et al. (1999). "Human telomerase reverse transcriptase (hTERT) gene 
expression in FNA samples from thyroid neoplasms." Surgery  126(6): 1195 -8; discussion 1198 -9.
NCI Protocol #: 7627  
Local Protocol #: MC 057H  
NCI Version Date: April 15, 201 8 77 
 
    APPENDIX  A: Performance Status Criteria  
 
 
ECOG Performance Status Scale  
  
Karnofsky Performance Scale  
Grade  Descriptions  Percent  Description  
0 Normal activity.  Fully active, able 
to carry on all pre -disease 
performance without restriction.  100 Normal, no complaints, no evidence 
of disease.  
90 Able to carry on normal activity; 
minor signs or symptoms of disease.  
1 Symptoms, but ambulatory.  
Restricted in physically strenuous 
activity, but ambulatory and able 
to carry out work of a light or 
sedentary nature (e.g., light 
housework, office work).  80 Normal activity with effort; some 
signs or symptoms of disease.  
70 Cares for self, unable to carry on 
normal activity or to do active work.  
2 In bed <50% of the time.  
Ambulatory and capable of all 
self-care, but unable to carry out 
any work activities.  Up and about 
more than 50% of waking hours.  [ADDRESS_1278323] of his/her 
needs.  
50 Requires considerable assistance and 
frequent medical care.  
3 In bed >50% of the time.  Capable 
of only limited self -care, confined 
to bed or chair more than 50% of 
waking hours.  40 Disabled, requires special care and 
assistance.  
30 Severely disabled, hospi[INVESTIGATOR_373].  Death not imminent.  
4 100% bedridden.  Completely 
disabled.  Cannot carry on any 
self-care.  Totally confined to bed 
or chair.  20 Very sick, hospi[INVESTIGATOR_374]. 
Death not imminent.  
10 Moribund, fatal processes 
progressing rapi[INVESTIGATOR_375].  
5 Dead.  0 Dead.  
 
 
 
 
 
 
  
NCI Protocol #: 7627  
Local Protocol #: MC 057H  
NCI Version Date: April 15, 201 8 78 
 
   APPENDIX B : Drugs Known to be Metabolized by [CONTACT_177683]450 Isoenzymes  
 
Selected drugs known to be metabolized by [CONTACT_097]450 isoenzymes  
 
CYP2C8/9  
 
 
SUBSTRATES   
INHIBITORS   
INDUCERS  
Generic Name  [CONTACT_629572]: e.g. 
    Rifampin  
    Sulfadiazine   
Rifadin  
-- 
 Antifungals: e.g. 
    Fluconazole  
    Ketoconazole  
    Miconazole  
    Tioconazole   
Diflucan  
Nizoral  
Lotramin  
Monistat  Sedatives: e.g. 
    Phenobarbiatl  
    Primidone   
Luminal  
Mysoline  
Misc. CV agents: e.g. 
    Amiodarone  
    Carvedilol   
Cordarone  
Coreg  Antimalarials: e.g. 
    Pyrimethamine  
    Quinine      
Daraprim  
Legatrin  Anticonvulsants: e.g.  
    Carbamazapi[INVESTIGATOR_910343]-asthmatics: e.g. 
    Montelukast  
    Zafirlukast   
Singulair  
Accolate  Anti-hyperlipi[INVESTIGATOR_7509]: e.g. 
     Fluvastatin  
    Gemfibrozil   
Lescol  
Lopid  Antibiotics: e.g. 
    Rifapentine  
    Rifampin   
Priftin  
Rifadin  
Antidepressants: e.g. 
    Fluoxetine  
    Sertraline   
Prozac  
Zoloft  Antibiotics: e.g. 
    Isoniazid  
    Sulfadiazine  
    Sulfamethoxazole  
    Trimethoprim   
INH, Nydrazid  
-- 
Bactrim, Septra  
Primsol    
Anticonvulsants: e.g. 
    Fosphenytoin  
    Phenytoin   
Cerebyx  
Dilantin  Analgesics: e.g. 
    Flurbiprofen  
    Ibuprofen  
    Indomethacin  
    Mefenamic acid   
Ansaid  
Advil, Motrin  
Indocin  
Ponstel    
Anesthetics: e.g. 
    Ketamine  
    Propofol   
Ketalar  
Diprivan  Anti-ulceratives: e.g. 
    Omeprazole  
    Pantoprazole   
Prilosec  
Pantoloc    
Anti-diabetics: e.g. 
     Glimepi[INVESTIGATOR_629493]: e.g. 
    Irbesartan  
    Losartan  
    Nicardipi[INVESTIGATOR_629494]: e.g. 
    Losartan  
    Bosentan   
Cozaar  
Tracleer      
Paclitaxel  Taxol  Anti-diabetics: e.g. 
    Pi[INVESTIGATOR_910344] ‘substrates’ are co -administered with (Study Agent) , there is the potential for higher concentrations of the ‘substrate’. When  (Study Agent)   is 
co-administered with compounds classified as ‘inhibitors’, increased plasma concentrations of  (Study Agent)  is the potential outcome. The coadministration of 
‘inducers’ would potentially lower plasma   (Study Agent)  concentrations.  
 
NCI Protocol #: 7627  
Local Protocol #: MC 057H  
NCI Version Date: April 15, [ADDRESS_1278324] potential interactions  
CYP2C8/[ADDRESS_1278325]  
Zopi[INVESTIGATOR_910345] (Vitamin D 3) 
Cimetidine  
Clopi[INVESTIGATOR_910346]  
 
(Adapted from Cytochrome P -450 Enzymes and Drug metabolism. In: Lacy CF, Armstrong LL, Goldman MP, Lance LL eds. Drug Information Handbook 
12TH ed. Hudson, OH; LexiComp Inc. 2004: 1619 -1631.)  
 
 
 
  
NCI Protocol #: 7627  
Local Protocol #: MC 057H  
NCI Version Date: April 15, 201 8 80 
 
   Selected Potential Cytochrome P450 (CYP) Drug Interactions  
 
CYP3A4  
 
 
SUBSTRATES   
INHIBITORS   
INDUCERS  
Generic Name  [CONTACT_177738]-neoplastics: e.g. 
    Docetaxel  
    Gefitinib  
    Irinotecan   
Taxotere  
Iressa  
Camptosar  Anti-arrhythmics: e.g. 
    Amiodarone  
    Diltiazem  
    Quinidine   
Cordarone, Pacerone  
Cardizem, Dilacor XR  
Cardioquin  Aminoglutethimide  Cytadren  
Anti-virals: e.g. 
    Amprenivir  
    Rifampin   
Agenerase  
Rifadin  
 
 Anti-virals:  e.g. 
    Amprenavir  
    Indinavir  
    Nelfinavir  
    Ritonavir   
Agenerase  
Crixivan  
Viracept  
Norvir  Antibiotics: e.g. 
    Rifabutin  
    Rifampin   
Rifadin  
Mycobutin  
 
 
Anxiolytics: e.g. 
    Diazepam  
    Sertraline   
Valium  
Zoloft  Cimetadine  Tagamet  Anticonvulsants: e.g.   
    Carbamazapi[INVESTIGATOR_177668] (2) St. John’s Wort  
Anti-infectives: e.g. 
    Erythromycin  
    Tetracycline   
Erythrocin  
Sumycin  Antibiotics: e.g. 
    Ciprofloxacin  
    Clarithromycin  
    Doxycycline  
    Enoxacin  
    Isoniazid  
    Telithromycin   
Cipro, Ciloxan  
Biaxin  
Adoxa, Periostat  
Penetrex  
Nydrazid, INH  
Ketek    
Steroids: e.g. 
    Estrogens, conjugated  
    Estradiol  
    Progesterone   
Premarin  
Climara  
Crinone  Imatinib  Gleevec     
Haloperidol  Haldol  Haloperidol  Haldol    
Cardiovascular agents: e.g. 
    Digitoxin  
    Quinidine   
Crystodigin  
Cardioquin  Diclofenac  Cataflam, Voltaren    
Anti-hypertensives: e.g. 
    Nicardipi[INVESTIGATOR_177669], Chronovera  Vasodilators: e.g. 
    Nicardipi[INVESTIGATOR_177669], Chronovera    
Anesthetics: e.g. 
    Ketamine  
    Lidocaine   
Xylocaine  
Diprivan  Anesthetics: e.g. 
    Lidocaine  
    Propofol   
Xylocaine  
Diprivan    
Nefazodone  
     Serzone  Anti-depressants: e.g. 
    Nefazodone  
    Sertraline   
Serzone  
Zoloft    
Cocaine   Anti-fungals: e.g. 
    Itraconazole  
    Ketoconazole  
   Miconazole   
Sporanox  
Nizoral  
Lotrimin, Monistat    
Ketoconazole  Nizoral  Caffeine     
Sildenafil  Viagra  Grapefruit juice (1)     
Albuterol  Ventolin      
Carbamazapi[INVESTIGATOR_629499] ‘substrates’ are co -administered with (Study Agent) , there is the potential for higher concentrations of the ‘substrate’. When  (Study Agent)   
is co-administered with compounds classified as ‘inhibitors’, increased plasma concentrations of  (Study Agent)  is the potential outcome. The coadministration of 
‘inducers’ would potentially lower plasma   (Study Agent)  concentrations.  
 
  
NCI Protocol #: 7627  
Local Protocol #: MC 057H  
NCI Version Date: April 15, [ADDRESS_1278326]  
Moricizine  
Nateglinide  
Nefazodone  
Nelfinavir  
Nevirapi[INVESTIGATOR_910347] #: 7627  
Local Protocol #: MC 057H  
NCI Version Date: April 15, [ADDRESS_1278327]. John’s wort  Nevirapi[INVESTIGATOR_177673]  
 
(Adapted from Cytochrome P -450 Enzymes and Drug metabolism. In: Lacy CF, Armstrong LL, Goldman MP, Lance LL  eds. Drug Information Handbook 
12TH ed. Hudson, OH; LexiComp Inc. 2004: 1619 -1631.)  
 
(1)  Malhorta et al. (2000). Clin Pharmacol Ther. 69:14 -23 
 
(2)  Mathijssen et al. (2002). J Natl Cancer Inst. 94:1247 -1249  
      Frye et al. (2004). Clin Pharmacol Ther.  76:323 -329 
 
 
 
 
 
 
  
NCI Protocol #: 7627  
Local Protocol #: MC 057H  
NCI Version Date: April 15, 201 8 83 
 
   APPENDIX C : [LOCATION_001] Heart Association Classification of Cardiac Disease  
 
 
Class  Functional Capacity  Objective Assessment  
I Patients with cardiac disease but without resulting limitations of 
physical activity.  Ordinary physical activity does not cause undue 
fatigue, palpi[INVESTIGATOR_332], dyspnea, or anginal pain.  No objective evidence of 
cardiovascular disease.  
II Patients with cardiac disease resulting in slight limitation of physical 
activity.  They are comfortable at rest.  Ordinary physical activity 
results in fatigue, palpi[INVESTIGATOR_332], dyspnea, or anginal pain.  Objective evidence of 
minimal cardiovascular 
disease.  
III Patients with cardiac disease resulting in marked limitation of 
physical activity.  They are comfortable at rest.  Less than ordinary 
activity causes fatigue, palpi[INVESTIGATOR_332], dyspnea, or anginal pain.  Objective evidence of 
moderately severe 
cardiovascular disease.  
IV Patients with cardiac disease resulting in inability to carry on any 
physical activity without discomfort.  Sy mptoms of heart failure or 
the anginal syndrome may be present even at rest.  If any physical 
activity is undertaken, discomfort is increased.  Objective evidence of 
severe cardiovascular 
disease.  
 
 
 
 
 
  
NCI Protocol #: 7627  
Local Protocol #: MC 057H  
NCI Version Date: April 15, 201 8 84 
 
   APPENDIX D : Patient’s Medication Diary  
PATIENT’S MEDICATION DIARY  - GW786034  (pazopanib)  
 
     Today’s date  _______________________________  Agent  _________________ _GW786034  (pazopanib) ________  
     Patient Name _________________________ ( initials acceptable)  Patient Study ID  _____________________________________  
INSTRUCTIONS TO THE PATIENT:  
1. Complete one form for each month.  
2. Take your dose of GW786034 (pazopanib) each day.   You should take GW786034 on an empty stomach either 1 hour before or 2 hours 
after meals.  The tablets should be taken with about 1 cup (240mL) of water.   You will take ___ [ADDRESS_1278328] them in the Comments column.   
5. Please return the forms to your physician when you go for your next appointment.  
 
Day  
Date  What time was 
dose taken?  # of tablets taken  Comments  200 mg  400 mg 
1      
2      
3      
4      
5      
6      
7      
8      
9      
10      
11      
12      
13      
14      
15      
16      
17      
18      
19      
20      
21      
22      
23      
24      
25      
26      
27      
28      
29      
30      
31      
Physician’s Office will complete this section:  
1. Date patient started protocol treatment____________________________________________________________________  
2. Date patient was removed from study_____________________________________________________________________  
3. Patient’s p lanned total daily dose________________________________________________________________________  
4. Total number of pi[INVESTIGATOR_148372] (each size)___________________________________________________________  
5. Physician/Nurse/Data Manager’s Signature ___ _____________________________________________________________  
  
CTEP -assigned Protocol # ____ _______  
 
Local Protocol # ________________ ___ 
NCI Protocol #: 7627  
Local Protocol #: MC 057H  
NCI Version Date: April 15, 201 8 85 
 
       Patient’s signature:__________________________________________________________________________________________  
 
       
 
APPENDIX E: Patient’s Blood Pressure Diary  
Today’s date ________________________________  
Patient Name________________________________  Patient Study ID ________________________________  
(initials acceptable)  
INSTRUCTIONS TO THE PATIENT:  
1. Your blood pressure readings have two numbers.  The first number is the pressure in your blood vessels during a heart beat 
(systolic), and the second number is the pressure in the vessels when the heart rests in between beats (diastolic).  These 
numbers are usually written with a slash in between them (for example, 110/85).  
2. Record the date, then record your blood pressure twice each day using a home blood pressure monitor:  
• each morning while you are resting or reading (not while you are active:  dressing, making breakfast, etc.)  
• each evening at bedtime or while you are relaxing during the evening  
3. If you take your blood pressure at other times of the day, please record the numbers and time under “Other readings”.  
4. Normal blood pressur e is usually considered to be 120/[ADDRESS_1278329] your do ctor’s office at _______________________________ for instructions.  
5. Please bring this form to every clinic visit or appointment.  
Date  AM 
readings  PM 
readings  Other readings (include 
time of day)  Date  AM 
readings  PM 
readings  Other readings (include 
time of day)  
 / /   / /  
 / /   / /  
 / /   / /  
 / /   / /  
 / /   / /  
 / /   / /  
 / /   / /  
 / /   / /  
 / /   / /  
 / /   / /  
 / /   / /  
 / /   / /  
 / /   / /  
 / /   / /  
 / /   / /  
 / /   / /  
Patient’s Signature: _____________________________________________  Date: ____________________________________  
 CTEP -assigned Protocol # _____________  
 
Local Protocol # ______________________  
NCI Protocol #: 7627  
Local Protocol #: MC 057H  
NCI Version Date: April 15, 201 8 86 
 
   Physician’s Office will complete this section:  
 _________________________________  ____________________________________________________________  
 Date of this clinic visit Physician/Nurse/Data Manager’s Signature    
[INVESTIGATOR_182556] #: 7627  
Local Protocol #: MC 057H  
NCI Version Date: April 15, 201 8 87 
 
   APPENDIX F : Blood Pressure – Recommendations  for Data Collection/Recording  and Event Management  
 
Collection/Recording of Blood Pressure Information  
1.0 General Guidelines  
1.1 Frequency of monitoring.   Blood pressure (BP) should be monitored at least every [ADDRESS_1278330] two cycles of 
GW786034  (pazopanib) therapy.  
 
1.[ADDRESS_1278331] ing.  All required data should be recorded in the appropriate CRF or on the patient’s blood pressure monitoring 
diary, as appropriate.  The following data are required at baseline and at each subsequent assessment : 
• Assessment date and time  
• Pulse  
• Systolic a nd diastolic BP (2 readings/assessment taken 5 minutes apart while patient sitting)  
 
1.3 Risk factors  for hypertension (assess and record data in baseline history/physical CRF)  
• Diabetes (type 1 or type 2)  
• Renal disease (specify on CRF)  
• Endocrine condition associated with HTN (specify on CRF)  
• Use of steroids or NSAIDs (specify all concomitant meds)  
• Underlying cardiovascular condition – specify ( i.e., ischemic heart disease)  
 
2.0 Baseline data collection  (at study entry)  
2.1 All patients  
• Current BP  
• Proteinuria, if present  
 
2.2 Patients with preexisting hypertension  (i.e., those for whom “hypertension” is entered as a concomitant condition at study 
entry, or those who are currently receiving therapy with antihypertensive medication) – also record:  
• Date of HTN diag nosis (original)  
• Type HTN (essential or secondary)  
• CTCAE v3.0 grade of HTN (at time of study entry)  
• Trade name, drug class*, dose, dose frequency, start/stop dates/ongoing of the following:  
- Antihypertensive agents taken at study entry  
- Antihypertensive agents taken in past (e.g., discontinued for toxicity, lack of efficacy)  
 
3.0 Follow up BP data collection (during study)  
3.1 All patients  (at each clinic visit)  
• Current BP  
• Proteinuria, if present  
 
3.2 Patients with treatment -emergent hypertension  [defined as BP increase of >20 mmHg (diastolic) OR BP >150/100 (if 
previously within normal limits)] – record at time of hypertension diagnosis and at all subsequent clinic visits:  
• BP changes from baseline (or from previous assessment) (specify CTCAE v3.0 grade change s) 
• Hypertension -related symptoms as reported by [CONTACT_4676] ( e.g., headache)  
• Other relevant changes associated with development of hypertension ( e.g., ECG abnormalities)  
• Trade name, drug class*, dose, dose frequency, start/stop dates/ongoing of currently presc ribed antihypertensive 
agents  
 
3.3 Patients with preexisting hypertension  at study entry – record at each clinic visit  
• BP changes from previous clinic visit (specify CTCAE v3.0 grade changes)  
• Hypertension -related symptoms reported by [CONTACT_4676] ( e.g., headache)  
• Other relevant changes associated with development of hypertension ( e.g., ECG abnormalities)  
• Changes in antihypertensive medications since last assessment ( e.g., dose change, add/discontinue drug)  
 
Classes of antihypertensive drugs include ACE inhibitors, calcium channel blockers, alpha blockers, beta blockers, diuretics, angiotension 
II receptor antagonists.
NCI Protocol #: 7627  
Local Protocol #: MC 057H  
NCI Version Date: April 15, 201 8 88 
 
    APPENDIX G: Management of GW786034  (Pazopanib) -Induced Hypertension*  
 
 
Persistent Mild Hypertension  
140-149 / 90 -99   Persistent Moderate Hypertension  
150-179 / 100 -109 Persistent Severe Hypertension  
>180 / >110 
Consider long -acting DHP CCB at initial 
dose.  
→  partial or no control, ↑  dose in 
stepwise fashion until BP control  Start/add a long -acting DHP CCB at intermediate 
dose.  If partial or no control,, ↑ to maximum dose 
until BP control (at least down to mild 
hypertension)  
WORSENS  No Control  WORSENS  Asymptomatic  SYMPTOMATIC  
Add 2nd /additional drug (BB, ACEI, ARB, or ABB)  
→  partial  or no control, ↑  dose in stepwise fashion 
until BP control.  
No Con trol WORSENS  • Hold GW786034 (pazopanib)  
• Start / add 2 -drug combination (DHP CCB, 
BB, ACEI, or ARB)  
• ↑  dose(s) in stepwise fashion until BP control  
• When BP controlled, may start GW786034 
(pazopanib) per protocol  
No Control and 
Asymptomatic  No Control AND 
SYMPTOMATIC  
Add 3rd drug at initial dose  
↑ dose(s) in stepwise fashion 
until BP control  Add 3rd / additional drug (BB, ACEI, ARB, or ABB)  
→  partial or no control, ↑ dose in stepwise fashion until BP control  
OR 
Hold GW786034  (pazopanib)  and restart when BP controlled per 
protocol.  
No Control and 
Asymptomatic  No Control  WORSENS  
↓ GW786034 (pazopanib) by 
[CONTACT_910382]786034 (pazopanib)  ↓ GW786034 (pazopanib) by 
[CONTACT_910383]786034 (pazopanib)  • Stop GW786034 (pazopanib)  
• Consider hospi[INVESTIGATOR_910348]  
• Treat as hypertensive crisis.  PLEASE NOTE:  
• These are guidelines only  
• Investigators should use them  at their 
own discretion  
• 24-48 hrs are suggested as an elapsed 
time between decision steps unless 
persistent severe hypertension occurs.  
DHP CCB (Dihydropyridine Calcium -Channel Blockers); BB (selective Beta blockers); ACEIs (Angiotensin Converting Enzyme Inhibitors); ARBs (Angiotensin II Receptor Bloc kers);  ABB (alpha and beta blocker)  * Refer to Section 6.1for 
additional information on 
hypertension management and a 
list of oral antihypertensive 
medications  
NCI Protocol #: 7627  
Local Protocol #: MC 057H  
NCI Version Date: April 15, 201 8 89 
 
    APPENDIX H : CTEP Multicenter Guidelines  
 
 
If an institution wishes to collaborate with other participating institutions in performing a 
CTEP sponsored research protocol, the n the following guidelines must be followed.  
 
Responsibility of the Protocol Chair  
• The Protocol Chair will be the single liaison with the CTEP Protocol and Information 
Office (PIO).  The Protocol Chair is responsible for the coordination, development, 
submission, and approval of the protocol as well as its subsequent amendments.  The 
protocol must not be rewritten or modified by [CONTACT_36475].  
There will be only one version of the protocol, and each participating institution will us e 
that document.  The Protocol Chair is responsible for assuring that all participating 
institutions are using the correct version of the protocol.  
• The Protocol Chair is responsible for the overall conduct of the study at all participating 
institutions and  for monitoring its progress.  All reporting requirements to CTEP are the 
responsibility of the Protocol Chair.  
• The Protocol Chair is responsible for the timely review of Adverse Events (AE) to assure 
safety of the patients.  
• The Protocol Chair will be responsible for the review of and timely submission of data 
for study analysis.  
 
Responsibilities of the Coordinating Center  
• Each participating institution will have an appropriate assurance on file with the Office 
for Human Research Protection (OHRP), NIH .  The Coordinating Center is responsible 
for assuring that each participating institution has an OHRP assurance and must maintain 
copi[INVESTIGATOR_36419].  
•  Prior to the activation of the protocol at each participating institu tion, an OHRP form 
310 (documentation of IRB approval) must be submitted to the CTEP PIO.  
• The Coordinating Center is responsible for central patient registration.  The Coordinating 
Center is responsible for assuring that IRB approval has been obtained at e ach 
participating site prior to the first patient registration from that site.  
• The Coordinating Center is responsible for the preparation of all submitted data for 
review by [CONTACT_36476].  
• The Coordinating Center will maintain documentation of AE repo rts.  There are two 
options for AE reporting: (1) participating institutions may report directly to CTEP with a 
copy to the Coordinating Center, or (2) participating institutions report to the 
Coordinating Center who in turn report to CTEP.  The Coordinati ng Center will submit 
AE reports to the Protocol Chair for timely review.  
• Audits may be accomplished in one of two ways:  (1) source documents and research  
• G-2 
• records for selected patients are brought from participating sites to the Coordinating 
Center  for audit, or (2) selected patient records may be audited on -site at participating 
sites.  If the NCI chooses to have an audit at the Coordinating Center, then the 
Coordinating Center is responsible for having all source documents, research records, all 
NCI Protocol #: 7627  
Local Protocol #: MC 057H  
NCI Version Date: April 15, [ADDRESS_1278332] forms, patient registration 
lists, response assessments scans, x -rays, etc. available for the audit.  
 
Inclusion of Multicenter Guidelines in the Protocol  
• The protocol must include the following minimum information:  
➢ The title page must include the name [CONTACT_170740], telephone number and e -mail address of the responsible investigator at each 
participating institution.  
➢ The Coordinating Center  must be designated on the title page.  
➢ Central registration of patients is required.  The procedures for registration must be 
stated in the protocol.  
➢ Data collection forms should be of a common format.  Sample forms should be 
submitted with the protocol.  The frequency and timing of data submission forms to 
the Coordinating Center should be stated.  
➢ Describe how AEs will be reported from the participating institutions, either directly 
to CTEP or through the Coordinating Center.  
➢ Describe how Safety Reports an d Action Letters from CTEP will be distributed to 
participating institutions.   
 
Agent Ordering  
• Except in very unusual circumstances, each participating institution will order DCTD -
supplied agents directly from CTEP.  Agents may be ordered by a participatin g site only 
after the initial IRB approval for the site has been forwarded by [CONTACT_131815].  
 
 
 
  
NCI Protocol #: 7627  
Local Protocol #: MC 057H  
NCI Version Date: April 15, 201 8 91 
 
   APPENDIX I : Medications That May Cause QTc P rolongation  
 
The following table presents a list of drugs that prolong, may prolong or are unlikely to prolong the QTc.   
Please note that this list is frequently updated.  For the most current list of medications, users should be 
directed to the following website: http://www.azcert.org/medical -pros/drug -lists/drug -lists.cfm .   
 
Drugs that are generally 
accepted  to have a risk of 
causing Torsades de 
Pointes  Drugs that in some reports have been 
associated  with Torsades de Pointes 
and/or QT c prolongation but at this 
time lack substantial evidence for 
causing Torsades de Pointes  Drugs that, in some reports, 
have been weakly associated  
with Torsades de Pointes and/or 
QTc prolongation but that are 
unlikely to be a risk for Torsades 
de Pointes when used in usual 
recommended dosages and in 
patients without other risk 
factors (e.g., concomitant QT c 
prolonging drugs, bradycardia, 
electrolyte disturbances, 
congenital long QT c syndrome, 
concomitant drugs th at inhibit 
metabolism).  
      
Generic/Brand Name  [CONTACT_107518]/Brand Name  [CONTACT_107518]/Brand Name  
[CONTACT_107519] /Cordarone®  Alfuzosin /Uroxatral®  Amitriptyline /Elavil®  
Amiodarone /Pacerone®  Amantadine /Symmetrel®  Ciprofloxacin /Cipro®  
Arsenic trioxide 
/Trisenox®  Atazanavir /Reyataz®  Citalopram /Celexa®  
Astemizole /Hismanal®  Azithromycin /Zithromax®  Clomipramine /Anafranil®  
Bepridil /Vascor®  Chloral hydrate /Noctec®  Desipramine /Pertofrane®  
Chloroquine /Aralen®  Clozapi[INVESTIGATOR_050] /Clozaril®  Diphenhydramine /Benadryl®  
Chlorpromazine 
/Thorazine®  Dolasetron /Anzemet®  Diphenhydramine /Nytol®  
Cisapride /Propulsid®  Dronedarone /Multaq®  Doxepin /Sinequan®  
Clarithromycin /Biaxin®  Felbamate /Felbatrol®  Fluconazole /Diflucan®  
Disopyramide /Norpace®  Flecainide /Tambocor®  Fluoxetine /Sarafem®  
Dofetilide /Tikosyn®  Foscarnet /Foscavir®  Fluoxetine /Prozac®  
Domperidone /Motilium®  Fosphenytoin /Cerebyx®  Galantamine /Reminyl®  
Droperidol /Inapsine®  Gatifloxacin /Tequin®  Imipramine /Norfranil®  
Erythromycin 
/Erythrocin®  Gemifloxacin /Factive®  Itraconazole /Sporanox®  
Erythromycin /E.E.S.®  Granisetron /Kytril®  Ketoconazole /Nizoral®  
Halofantrine /Halfan®  Indapamide /Lozol®  Mexiletine /Mexitil®  
Haloperidol /Haldol®  Isradipi[INVESTIGATOR_050] /Dynacirc®  Nortriptyline /Pamelor®  
Ibutilide /Corvert®  Lapatinib /Tykerb®  Paroxetine /Paxil®  
Levomethadyl /Orlaam®  Lapatinib /Tyverb®  Protriptyline /Vivactil®  
Mesoridazine /Serentil®  Levofloxacin /Levaquin®  Sertraline /Zoloft®  
NCI Protocol #: 7627  
Local Protocol #: MC 057H  
NCI Version Date: April 15, [ADDRESS_1278333] been 
associated  with Torsades de Pointes 
and/or QT c prolongation but at this 
time lack substantial evidence for 
causing Torsades de Pointes   
Drugs that, in some reports, 
have been weakly associated  
with Torsades de Pointes and/or 
QTc prolongation but that are 
unlikely to be a risk for Torsades 
de Pointes when used in usual 
recommended dosages and in 
patients without other risk 
factors (e.g., co ncomitant QT c 
prolonging drugs, bradycardia, 
electrolyte disturbances, 
congenital long QT c syndrome, 
concomitant drugs that inhibit 
metabolism).  
      
Generic/Brand Name  [CONTACT_107518]/Brand Name  [CONTACT_107518]/Brand Name  
[CONTACT_675323] /Dolophine®  Lithium /Lithobid®  Solifenacin /VESIcare®  
Methadone /Methadose®  Lithium /Eskalith®  Trimethoprim -Sulfa /Sulfa®  
Pentamidine /Pentam®  Moexipril/HCTZ /Uniretic®  Trimethoprim -Sulfa /Bactrim®  
Pentamidine /NebuPent®  Moxifloxacin /Avelox®  Trimipramine /Surmontil®  
Pi[INVESTIGATOR_3924] /Orap®  Nicardipi[INVESTIGATOR_050] /Cardene®    
Probucol /Lorelco®  Nilotinib /Tasigna®    
Procainamide /Pronestyl®  Octreotide /Sandostatin®    
Procainamide /Procan®  Ofloxacin /Floxin®    
Quinidine /Cardioquin®  Ondansetron /Zofran®    
Quinidine /Quinaglute®  Oxytocin /Pi[INVESTIGATOR_31933]®    
Sotalol /Betapace®  Paliperidone /Invega®    
Sparfloxacin /Zagam®  Perflutren lipid microspheres 
/Definity®    
Terfenadine /Seldane®  Quetiapi[INVESTIGATOR_050] /Seroquel®    
Thioridazine /Mellaril®  Ranolazine /Ranexa®    
  Risperidone /Risperdal®    
  Roxithromycin* /Rulide®    
  Sertindole /Serlect®    
  Sertindole /Serdolect®    
  Sunitinib /Sutent®    
  Tacrolimus /Prograf®    
  Tamoxifen /Nolvadex®    
  Telithromycin /Ketek®    
  Tizanidine /Zanaflex®    
  Vardenafil /Levitra®    
  Venlafaxine /Effexor®    
  Voriconazole /VFend®    
NCI Protocol #: 7627  
Local Protocol #: MC 057H  
NCI Version Date: April 15, 201 8 93 
 
     Ziprasidone /Geodon®    
 